

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086446 A1

(51) International Patent Classification⁷: **A61K 38/00**,
G01N 21/64, 33/566, C07H 21/04, C12N 15/64, 15/65

(74) Agent: **DREGER, Ginger, R.**; Heller, Ehrman, White &
McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA
94025-3506 (US).

(21) International Application Number: PCT/US03/10879

(22) International Filing Date: 9 April 2003 (09.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/121,258 10 April 2002 (10.04.2002) US
10/209,208 29 July 2002 (29.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **TSIEN, Roger, Y.** [US/US]; 8535 Nottingham Place, La Jolla, CA 92037 (US). **CAMPBELL, Robert, E.** [CA/US]; 8090 Regents Road, #202, San Diego, CA 92122 (US). **BAIRD, Geoffrey, S.** [US/US]; 3627 Florida Street #5, San Diego, CA 92104 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MONOMERIC AND DIMERIC FLUORESCENT PROTEIN VARIANTS AND METHODS FOR MAKING SAME

(57) Abstract: The present invention relates generally to fluorescent proteins and fluorescent protein variants, and more specifically to monomeric and dimeric forms of Anthozoan fluorescent proteins. In one aspect, the present invention provides variants of fluorescent proteins, where the variants have a reduced propensity to tetramerize, and form dimeric or monomeric structures. In a further aspect, the present invention provides variants of fluorescent proteins, the variants being characterized by more efficient maturation than corresponding fluorescent proteins from which they are derived. The invention also relates to methods of making and using such fluorescent proteins and fluorescent protein variants, including fluorescent protein monomers and dimers.

WO 03/086446 A1

MONOMERIC AND DIMERIC FLUORESCENT PROTEIN VARIANTS AND METHODS FOR MAKING SAME

This application claims priority from U.S. Patent Application Serial No. 10/121,258 filed April 10, 2002, entitled Fluorescent Protein Variants and Methods for Making Same, and Serial No. 10/209,208 filed July 29, 2002, entitled Monomeric and Dimeric Fluorescent Protein Variants and Methods for Making Same, each of which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates generally to variant fluorescent proteins, and more specifically to Anthozoan fluorescent proteins that have a reduced propensity to oligomerize, where such proteins form monomeric and/or dimeric structures. The invention also relates to methods of making and using such fluorescent protein monomers and dimers. In particular, the present invention relates generally to variant red fluorescent proteins (RFPs), and more specifically to Anthozoan fluorescent proteins (AnFP), having at least one amino acid alteration that results in more efficient maturation than the corresponding wild-type protein or another variant RFP from which such variants derive. The invention further concerns RFP variants that additionally have reduced propensity tetramerize, and thus form predominantly monomeric and/or dimeric structures. The invention also relates to methods of making and using such RFP variants.

Description of the Related Art

The identification and isolation of fluorescent proteins in various organisms, including marine organisms, has provided a valuable tool to molecular biology. The green fluorescent protein (GFP) of the jellyfish *Aequorea victoria*, for example, has become a commonly used reporter molecule for examining various cellular processes, including the regulation of gene expression, the localization and interactions of cellular proteins, the pH of intracellular compartments, and the activities of enzymes.

The usefulness of *Aequorea* GFP has led to the identification of numerous other fluorescent proteins in an effort to obtain proteins having different useful fluorescence

characteristics. In addition, spectral variants of *Aequorea* GFP have been engineered, thus providing proteins that are excited or fluoresce at different wavelengths, for different periods of time, and under different conditions. The identification and cloning of a red fluorescent protein from *Discosoma* coral, termed DsRed or drFP583, has raised a great deal of interest due to its ability to fluoresce at red wavelengths.

The DsRed from *Discosoma* (Matz *et al.*, *Nature Biotechnology* 17:969-973 [1999]) holds great promise for biotechnology and cell biology as a spectrally distinct companion or substitute for the green fluorescent protein (GFP) from the *Aequorea* jellyfish (Tsien, *Ann. Rev. Biochem.*, 67:509-544[1998]). GFP and its blue, cyan, and yellow variants have found widespread use as genetically encoded indicators for tracking gene expression and protein localization and as donor/acceptor pairs for fluorescence resonance energy transfer (FRET). Extending the spectrum of available colors to red wavelengths would provide a distinct new label for multicolor tracking of fusion proteins and together with GFP (or a suitable variant) would provide a new FRET donor/acceptor pair that should be superior to the currently preferred cyan/yellow pair (Mizuno *et al.*, *Biochemistry* 40:2502-2510 [2001]).

One problem associated with the use of DsRed as a fluorescent report is its slow and inefficient chromophore maturation. Most previous attempts to improve the rate and/or extent of maturation of DsRed (Verkhusha *et al.*, *J. Biol. Chem.*, 276:29621-29624 [2001]; and Terskikh *et al.*, *J. Biol. Chem.*, 277:7633-7636 [2002]) including the commercially available DsRed2 (CLONTECH, Palo Alto, CA), have provided only modest improvements. Recently, an engineered variant of DsRed, known as T1 (shown in FIG. 1A), has become available and effectively solved the problem of the slow maturation (Bevis and Glick, *Nat. Biotechnol.*, 20:83-87 [2002]). However this variant appears to still suffer from an incomplete maturation and therefore like DsRed, a significant fraction of the protein remains as the green fluorescent intermediate in the aged tetramer.

All coelenterate fluorescent proteins cloned to date display some form of quaternary structure, including the weak tendency of *Aequorea* green fluorescent protein (GFP) to dimerize, the obligate dimerization of *Renilla* GFP, and the obligate tetramerization of the *Discosoma* DsRed (Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 97:11984-11989 [2000]; and Vrzheschch *et al.*, *FEBS Lett.*, 487:203-208 [2000]). While

the weak dimerization of *Aequorea* GFP has not impeded its acceptance as an indispensable tool of cell biology, the obligate tetramerization of DsRed has greatly hindered its development from a scientific curiosity to a generally applicable and robust tool, most notably as genetically encoded fusion tag.

5 DsRed tetramerization presents an obstacle for the researcher who wishes to image the subcellular localization of a red fluorescent chimera, as the question exists as to what extent will fusing tetrameric DsRed to the protein of interest affect the location and function of the latter. Furthermore, it can be difficult in some cases to confirm whether a result is due, for example, to a specific interaction of two proteins under
10 investigation, or whether a perceived interaction is an artifact caused by the oligomerization of fluorescent proteins linked to each of the two proteins under investigation. There have been several published reports (see, e.g., Mizuno *et al.*, *Biochemistry* 40:2502-2510 [2001]; and Lauf *et al.*, *FEBS Lett.*, 498:11-15 [2001]) and many unpublished anecdotal communications, in which DsRed chimeras have been
15 described as forming intracellular aggregates that have lost their biological activity. DsRed also suffers from slow and incomplete maturation (Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 97:11984-11989 [2000]).

One approach to overcome these shortcomings has been to continue the search for DsRed homologues in sea coral and anemone; an approach that has yielded several
20 red shifted proteins (Fradkov *et al.*, *FEBS Lett.*, 479:127-130 [2000]; and Lukyanov *et al.*, *J. Biol. Chem.*, 275:25879-25882 [2000]). However, the fundamental problem of tetramerization has yet to be overcome. The only published progress towards decreasing the oligomeric state of a red fluorescent protein involved an engineered DsRed homologue, commercially available as HcRed1 (CLONTECH), which was converted to
25 a dimer with a single interface mutation (Gurskaya *et al.*, *FEBS Lett.*, 507:16-20 [2001]). Although HcRed1 has the additional benefit of being 35 nm red-shifted from DsRed, it is limited by a low extinction coefficient (20,000 M⁻¹cm⁻¹) and quantum yield (0.015) (CLONTECH Laboratories Inc., (2002) Living Colors User Manual Vol. II: Red Fluorescent Protein [Becton, Dickinson and Company], p. 4) making the protein
30 problematic to use in experimental systems.

A methionine is found at position 66 of a tetrameric nonfluorescent chromoprotein from *Anemonia sulcata* which was converted to a fluorescent protein

through the introduction of two mutations (Lukyanov, K. A., Fradkov, A. F., Gurskaya, N. G., Matz, M. V., Labas, Y. A., Savitsky, A. P., Markelov, M. L., Zarausky, A. G., Zhao, X., Fang, Y. *et al.* (2000) *J. Biol. Chem.* **275**, 25879-25882). Introduction of a methionine at position 66 apparently improves the fluorescent properties of both a green (zFP506) and a cyan (amFP486) tetrameric fluorescent protein though no details have been published (Yanushevich, Y. G., Staroverov, D. B., Savitsky, A. P., Fradkov, A. F., Gurskaya, N. G., Bulina, M. E., Lukyanov, K. A. & Lukyanov, S. A. (2002) *FEBS Lett.* **511**, 11-14).

Similarly, most previous attempts to improve the rate and/or extent of maturation of DsRed (Verkhusha *et al.*, *J. Biol. Chem.*, 276:29621-29624 [2001]; and Terskikh *et al.*, *J. Biol. Chem.*, 277:7633-7636 [2002]) including the commercially available DsRed2 (CLONTECH, Palo Alto, CA), have provided only modest improvements. Recently, an engineered variant of DsRed, known as T1 (shown in FIG. 1A), has become available and effectively solved the problem of the slow maturation (Bevis and Glick, *Nat. Biotechnol.*, 20:83-87 [2002]). However this variant appears to still suffer from an incomplete maturation and therefore like DsRed, a significant fraction of the protein remains as the green fluorescent intermediate in the aged tetramer.

Thus, there exists a need in the art for the development of red fluorescent polypeptides that find use in scientific applications without technical limitations due to oligomerization, especially tetramerization, and due to inefficient and slow chromophore maturation. There exists a need for methods to produce fluorescent proteins having reduced propensity for oligomerization, especially tetramerization. There exists a need for methods to produce red fluorescent proteins (RFPs) exhibiting more efficient chromophore maturation than wild-type RFPs or other RFP variants. Furthermore, there exists a need for RFPs that additionally have reduced propensity for oligomerization, such as, tetramerization. Most significantly, there exists a need for RFP variants with improved efficiency of maturation that demonstrate useful fluorescence in a monomeric state in experimental systems. Most significantly, there exists a need for methods to produce fluorescent proteins that demonstrate useful fluorescence in a monomeric state in experimental systems. The present invention satisfies these needs and provides additional advantages.

SUMMARY OF THE INVENTION

The present invention concerns variants of red fluorescent proteins (RFPs) that have a reduced propensity to oligomerize. For example, the variant RFPs of the invention have a propensity to form monomers and dimers, where the native form of the RFP has a propensity to form tetrameric structures.

The present invention concerns variants of red fluorescent proteins (RFPs) comprising at least one amino acid alteration resulting in more efficient chromophore maturation than a corresponding wild-type or variant RFP. The present invention further concerns RFP variants that, in addition to showing more efficient maturation, have a reduced propensity to form tetramers. Thus, certain RFP variants of the invention have a propensity to form monomers and dimers, where the native form of the RFP has a propensity to form tetrameric structures.

In one aspect, the invention concerns an Anthozoan fluorescent protein (AnFP) having a reduced propensity to oligomerize, comprising at least one mutation within the wild-type AnFP amino acid sequence that reduces or eliminates the ability of the fluorescent protein to tetramerize and/or dimerize, as the case may be. The AnFP preferably is the red fluorescent protein of *Discosoma* (DsRed) of SEQ ID NO: 1, but is by no means so limited. In some embodiments, the invention concerns an Anthozoan fluorescent protein (AnFP), *e.g.*, DsRed, comprising at least one amino acid substitution within the AB and/or AC interface of said fluorescent protein (*e.g.*, DsRed) that reduces or eliminates the degree of oligomerization of said fluorescent protein.

In another embodiment, the variant AnFP (*e.g.*, DsRed) having a reduced propensity to oligomerize is a monomer in which the interfaces between the oligomeric subunits are disrupted by introducing mutations, *e.g.*, substitutions, which interfere with oligomerization (including dimerization), and, if necessary, introducing further mutations needed to restore or improve fluorescence which might have been partially or completely lost as a result of disrupting the interaction of the subunits.

The invention specifically includes dimeric and monomeric variants of other fluorescent proteins in addition to DsRed, such as fluorescent proteins from other species and fluorescent proteins that have fluorescence emission spectra in wavelengths other than red. For example, green fluorescent proteins and fluorescent proteins from *Renilla*

sp.find equal use with the invention. Furthermore, fluorescent proteins that normally have the propensity to form tetramers and/or dimers find equal use with the invention.

In a particular embodiment, the fluorescent protein is DsRed, and a DsRed variant having a reduced propensity to oligomerize (in this case, tetramerize) is prepared by first replacing at least one key residue in the AC and/or AB interface of the wild-type protein, thereby creating a dimer or monomer form, followed by the introduction of further mutation(s) to restore or improve red fluorescence properties.

The invention provides variant fluorescent proteins, including but not limited to DsRed, comprising amino acid substitutions relative to the respective wild-type sequences, where the substitutions impart the advantageous properties to the polypeptide variants. These amino acid substitutions can reside at any position within the polypeptide, and are not particularly limited to any type of substitution (conservative or non-conservative). In one embodiment, the mutations restoring or improving fluorescence are amino acid substitutions within the plane of the chromophore and/or just above the plane of the chromophore and/or just below the plane of the chromophore of the fluorescent protein.

In one aspect, the invention provides a polynucleotide sequence encoding a *Discosoma* red fluorescent protein (DsRed) variant having a reduced propensity to oligomerize, comprising one or more amino acid substitutions at the AB interface, at the AC interface, or at the AB and AC interfaces of the wild-type DsRed amino acid sequence of SEQ ID NO: 1, where the substitutions result in reduced propensity of the DsRed variant to form tetramers, wherein said variant displays detectable fluorescence of at least one red wavelength. In one embodiment, this protein sequence has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 1. In another embodiment, the fluorescent protein has detectable fluorescence that matures at a rate at least about 80% as fast as the rate of fluorescence maturation of wild-type DsRed of SEQ ID NO: 1, while in another embodiment the protein has improved fluorescence maturation relative to DsRed of SEQ ID NO: 1. In still another embodiment, the protein substantially retains the fluorescing properties of DsRed of SEQ ID NO: 1.

In some embodiments, the fluorescent protein variant has a propensity to form dimers. Some proteins contain substitutions in the AB interface and form an AC dimer.

In some embodiments, the fluorescent protein variant comprises at least nine amino acid substitutions that are at residues 2, 5, 6, 21, 41, 42, 44, 117, and 217, and additionally at least one more substitution including substitution at residue 125 of SEQ ID NO: 1. The protein can optionally further comprise at least one additional amino acid substitution that is at residue 71, 118, 163, 179, 197, 127, or 131 of SEQ ID NO: 1. In some embodiments, any one or more of said substitutions is optionally selected from R2A, K5E, N6D, T21S, H41T, N42Q, V44A, V71A, C117T, F118L, I125R, V127T, S131P, K163Q/M, S179T, S197T, and T217A/S.

The invention provides fluorescent protein variants that can be the proteins dimer1, dimer1.02, dimer1.25, dimer1.26, dimer 1.28, dimer1.34, dimer1.56, dimer1.61, or dimer1.76, as provided in FIGS. 20A-D. In one preferred embodiment, the protein variant is dimer2 (SEQ ID NO: 6).

In some embodiments, the fluorescent dimeric protein variant has at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 1, while in other embodiments, the protein has at least about 95% sequence identity with the amino acid sequence of SEQ ID NO: 1.

In still other embodiments, the fluorescent protein variant is a monomer. In this embodiment, the amino acid substitutions are in the AB interface and the AC interface.

In some embodiments, the monomeric protein variant comprises at least 14 amino acid substitutions that are at residues 2, 5, 6, 21, 41, 42, 44, 71, 117, 127, 163, 179, 197, and 217, and additionally at least one more substitution that is at residue 125 of SEQ ID NO: 1. In other embodiments, the monomeric protein optionally further comprises at least one additional amino acid substitution at residue 83, 124, 125, 150, 153, 156, 162, 164, 174, 175, 177, 180, 192, 194, 195, 222, 223, 224, and 225 of SEQ ID NO: 1. In still other embodiments, the substitutions in the monomeric protein is optionally selected from R2A, K5E, N6D, T21S, H41T, N42Q, V44A, V71A, K83L, C117E/T, F124L, I125R, V127T, L150M, R153E, V156A, H162K, K163Q/M, L174D, V175A, F177V, S179T, I180T, Y192A, Y194K, V195T, S197A/T/I, T217A/S, H222S, L223T, F224G, L225A.

In other embodiments, the monomeric protein variant is selected from mRFP0.1, mRFP0.2, mRFP0.3, mRFP0.4a, mRFP0.4b, mP11, mP17, m1.01, m1.02, mRFP0.5a, m1.12, mRFP0.5b, m1.15, m1.19, mRFP0.6, m124, m131, m141, m163, m173, m187,

m193, m200, m205 and m220, as provided in FIGS. 20A-20D. In a preferred embodiment, the monomeric variant is mRFP1 (SEQ ID NO: 8).

In some embodiments, the monomeric variant has at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 1, while in other embodiments, the protein has at least about 95% sequence identity with the amino acid sequence of SEQ ID NO: 1.

The present invention also provides tandem dimer forms of DsRed, comprising two DsRed protein variants operatively linked by a peptide linker. The peptide linker can be of variable length, where, for example, the peptide linker is about 10 to about 25 amino acids long, or about 12 to about 22 amino acids long. In some embodiments, the peptide linker is selected from GHGTGSTGSGSS (SEQ ID NO: 17), RMGSTSGSTKGQL (SEQ ID NO: 18), and RMGSTSGSGKPGSGEGSTKGQL (SEQ ID NO: 19).

In some embodiments, the tandem dimer subunit is selected from dimer1, dimer1.02, dimer1.25, dimer1.26, dimer 1.28, dimer1.34, dimer1.56, dimer1.61, dimer1.76, and dimer2, as provided in FIGS. 20A-20D. The tandem dimer can be a homodimer or a heterodimer. In one preferred embodiment, the tandem dimer comprises at least one copy of dimer2 (SEQ ID NO: 6).

The present invention also provides fusion proteins between any protein of interest operatively joined to at least one fluorescent protein variant of the invention. This fusion protein can optionally contain a peptide tag, and this tag can optionally be a polyhistidine peptide tag.

The present invention provides polynucleotides that encode each of the fluorescent protein variants described or taught herein. Furthermore, the present invention provides the fluorescent protein variants encoded by any corresponding polynucleotide described or taught herein. Such polypeptides can include dimeric variants, tandem dimer variants, or monomeric variants.

In other embodiments, the invention provides kits comprising at least one polynucleotide sequence encoding a fluorescent protein variant of the invention. Alternatively, or in addition, the kits can provide the fluorescent protein variant itself.

In other embodiments, the present invention provides vectors that encode the fluorescent protein variants described or taught herein. Such vectors can encode dimeric

variants, tandem dimer variants, or monomeric variants, or fusion proteins comprising these variants. The invention also provides suitable expression vectors. In other embodiments, the invention provides host cells comprising any of these vectors.

In another embodiment, the invention provides a method for the generation of a
5 dimeric or monomeric variant of a fluorescent protein which has propensity to tetramerize or dimerize, comprising the steps of mutagenizing at least one amino acid residue in the fluorescent protein to produce a dimeric variant, if the protein had the propensity to tetramerize, and a monomeric variant, if the protein had the propensity to dimerize; and mutagenizing at least one additional amino acid residue to yield a dimeric
10 or monomeric variant, which retains the qualitative ability to fluoresce in the same wavelength region as the non-mutagenized fluorescent protein.

In an optional variation of this method, an additional step can be added, essentially introducing a further mutation into a dimeric variant produced from a fluorescent protein that had the propensity to form tetramers to produce a monomeric
15 variant. In some embodiments, this additional step can come after the first mutagenizing step.

In some embodiments, this method can result in dimeric or monomeric variants having improved fluorescence intensity or fluorescence maturation relative to the non-mutagenized fluorescent protein.

20 The mutagenesis used in the present method can be by multiple overlap extension with semidegenerate primers, error-prone PCR, site directed mutagenesis, or by a combination of these. The results of this mutagenesis can produce protein variants that have a propensity to form dimers or monomers.

In some embodiments of this method, the fluorescent protein is an Anthozoan
25 fluorescent protein, and optionally, the Anthozoan fluorescent protein fluoresces at a red wavelength. The Anthozoan fluorescent protein can be *Discosoma* DsRed.

In other embodiments, the fluorescent protein variants of the invention can be used in various applications. In one embodiment, the invention provides a method for the detection transcriptional activity, where the method uses a host cell comprising a
30 vector encoding a variant DsRed fluorescent protein operably linked to at least one expression control sequence, and a means to assay said variant fluorescent protein

fluorescence. In this method, assaying the fluorescence of the variant fluorescent protein produced by the host cell is indicative of transcriptional activity.

In other embodiments the invention also provides a polypeptide probe suitable for use in fluorescence resonance energy transfer (FRET), comprising at least one fluorescent protein variant of the invention.

In still another embodiment, the invention provides a method for the analysis of *in vivo* localization or trafficking of a polypeptide of interest, where the method uses a fluorescent fusion protein of the invention in a host cell or tissue, and where the fusion protein can be visualized in the host cell or tissue.

In a further aspect, the invention concerns further improved variants of red fluorescent proteins (RFPs) that have reduced propensity to oligomerize. In particular, the invention concerns RFP variants that not only have a propensity to form monomers and dimers, where the native form of the RFP has a propensity to form tetrameric structures, but are additionally characterized by more efficient maturation than the corresponding non-oligomerizing variants from which they derive. Such variants are typically brighter than the corresponding non-oligomerizing variants, where brightness is typically expressed as the product of the extinction coefficient (EC) and the quantum yield (QY) at the desired red wavelength.

The invention further provides a polynucleotide encoding a variant of a red fluorescent protein (RFP) having a propensity to form tetrameric structures, comprising at least one amino acid alteration resulting in more efficient maturation into the desired red species from the immature green species, and at least one further amino acid alteration resulting in a reduced propensity to tetramerize. The amino acid alteration may be substitution, insertion and/or deletion, and preferably is substitution.

Thus, in one aspect the invention concerns polynucleotide encoding a variant of a red fluorescent protein (RFP) having a propensity to form tetrameric structures, comprising at least one amino acid alteration resulting in higher fluorescence intensity at red wavelength, and at least one further amino acid alteration resulting in a reduced propensity to tetramerize.

In a particular embodiment, the polynucleotide encodes a *Discosoma* red fluorescent protein (DsRed) variant.

In another embodiment, the polynucleotide encodes a DsRed variant, in which the amino acid substitution resulting in more efficient maturation is at position 66 of wild-type DsRed of SEQ ID NO: 1. A particular substitution is a Q66M substitution within SEQ ID NO: 1. In another embodiment, the polynucleotide encodes a DsRed variant, in which the amino acid substitution resulting in more efficient maturation is at position 147 of wild-type DsRed of SEQ ID NO: 1. The substitution at position 147 preferably is a T147S substitution, but other substitutions are also possible at this position and are specifically included within the scope of the present invention. In a further embodiment, the polynucleotide of the invention encodes a DsRed variant comprising a substitution at both position 66 and position 147 within SEQ ID NO: 1. In a preferred embodiment, the polynucleotide of the invention encodes a DsRed variant comprising a Q66M and a T147S substitution.

The polynucleotides of the invention encoding DsRed variants comprising at least one amino acid alteration resulting in improved efficiency of chromophore maturation into the desired red form, such as, for example, a Q66M substitution, may additionally contain codons for any of the other amino acid substitutions, alone or in any combination, discussed hereinabove and throughout the present disclosure, in connection with other embodiments. In particular, such polynucleotides (e.g. those encoding a DsRed variant with a Q66M mutation alone or in combination with a T147S substitution) may encode DsRed variants further comprising one or more substitutions at the AB interface, at the AC interface, or at the AB and AC interfaces of the wild-type DsRed amino acid sequence of SEQ ID NO: 1, where the substitutions result in reduced propensity of the DsRed variant to form tetramers.

In a particular embodiment, such polynucleotides encode DsRed variants additionally comprising one or more substitutions at an amino acid position selected from the group consisting of 42, 44, 71, 83, 124, 150, 163, 175, 177, 179, 195, 197, 217, 2, 5, 6, 125, 127, 180, 153, 162, 164, 174, 192, 194, 222, 223, 224, 225, 21, 41, 117, and 156 within the wild-type DsRed amino acid sequence of SEQ ID NO: 1. Possible substitutions at the indicated positions include, without limitation, one or more substitutions selected from the group consisting of N42Q, V44A, V71A, K83L, F124L, L150M, K163M, V175A, F177V, S179T, V195T, S197I, T217A, R2A, K5E, N6D, I125R, V127T, I180T, R153E, H162K, A164R, L174D, Y192A, Y194K, H222S,

L223T, F224G, L225A, T21S, H41T, C117E, and V156A within the wild-type DsRed amino acid sequence of SEQ ID NO: 1.

Thus, polynucleotides encoding DsRed variants comprising the following substitutions: N42Q, V44A, V71A, K83L, F124L, L150M, K163M, V175A, F177V,
5 S179T, V195T, S197I, T217A, R2A, K5E, N6D, I125R, V127T, I180T, R153E, H162K, A164R, L174D, Y192A, Y194K, H222S, L223T, F224G, L225A, T21S, H41T, C117E, and V156A within the wild-type DsRed amino acid sequence of SEQ ID NO: 1, are specifically within the scope of the invention. In a preferred embodiment, the invention concerns a polynucleotide encoding a mRFP1.1 shown in Figure 30 (SEQ ID NO: 79).

10 In another aspect, the invention concerns a polynucleotide encoding a fusion protein, comprising at least one DsRed protein variant encoded by the polynucleotides discussed above, operatively joined to at least one other polypeptide of interest. In particular embodiments, such fusion proteins may comprising either the Q66M or T147S substitution, or both, as a tandem dimer.

15 The invention further concerns polypeptides encoded by the polynucleotides discussed above, vectors containing such polynucleotides (including expression vectors), and recombinant host cells transformed with such polynucleotides or vectors.

The invention, in a different aspect, concerns a kit comprising at least one polynucleotide or polypeptide discussed above.

20 In yet another aspect, the invention concerns a method for the detection transcriptional activity, comprising

(a) providing a host cell comprising a vector, wherein said vector comprises nucleotide sequence encoding a DsRed fluorescent protein variant comprising at least one amino acid alteration resulting in higher fluorescence intensity at red
25 wavelength, and at least one further amino acid alteration resulting in a reduced propensity to tetramerize operably linked to at least one expression control sequence, and a means to assay said variant fluorescent protein fluorescence, and

(b) assaying fluorescence of said variant fluorescent protein produced by said host cell, where variant fluorescent protein fluorescence is indicative of
30 transcriptional activity.

In a further aspect, the invention concerns a method for the detection of protein-protein interactions, comprising detection of energy transfer from a fluorescent or bioluminescent protein fusion to a fusion protein as discussed above.

In a still further aspect, the invention concerns a method for the analysis of *in vivo* localization or trafficking of a polypeptide of interest, comprising the steps of:

(a) providing a polynucleotide encoding a fusion protein, comprising at least one DsRed protein variant encoded by the polynucleotides discussed above, operatively joined to at least one other polypeptide of interest and a host cell or tissue, and

(b) visualizing said fusion protein that is expressed in said host cell or tissue.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the tetrameric form of DsRed (PDB identification code 1G7K). The A-C and B-D interfaces are equivalent, as are the A-B and C-D interfaces.

FIGS. 2A-2C show graphical representations of the tetramer, dimer and monomer forms of DsRed, respectively, based on the x-ray crystal structure of DsRed. Residues 1-5 were not observed in the crystal structure but have been arbitrarily appended for the sake of completeness. The DsRed chromophore is represented in red and the four chains of the tetramer are labeled following the convention of Yarbrough *et al.* (Yarbrough *et al.*, *Proc. Natl. Acad. Sci. USA* 98:462-467 [2001]). FIG. 2A shows the tetramer of DsRed with the residues mutated in T1 indicated in blue for external residues and green for those internal to the β -barrel. FIG. 2B shows the AC dimer of DsRed with all mutations present in dimer2 represented as in FIG. 2A and the intersubunit linker present in tdimer2(12) shown as a dotted line. FIG. 2C shows the mRFP1 monomer of DsRed with all mutations present in mRFP1 represented as in FIG. 2A.

FIGS. 3A-3C show the results of an analytical ultracentrifugation analysis of DsRed, dimer2, and mRFP0.5a polypeptides, respectively. The equilibrium radial absorbance profiles at 20,000 rpm were modeled with a theoretical curve that allowed only the molecular weight to vary. The DsRed absorbance profile (FIG. 3A) was best fit with an apparent molecular weight of 120 kDa, consistent with a tetramer. The dimer2

absorbance profile (FIG. 3B) was best fit with an apparent molecular weight of 60 kDa, consistent with a dimer. The mRFP0.5a absorbance profile (FIG. 3C) was best fit with an apparent molecular weight of 32 kDa, consistent with a monomer containing an N-terminal polyhistidine affinity tag.

5 FIGS. 4A-4D show fluorescence and absorption spectra of DsRed, T1, dimer2 and tdimer2(12) and mRFP1, respectively. The absorbance spectrum is shown with a solid line, the excitation with a dotted line and the emission with a dashed line.

FIG. 5 shows a maturation time course of red fluorescence for DsRed, T1, dimer2, tdimer2(12) and mRFP1. The profiles are color coded, as indicated in the key.
10 Log phase cultures of *E. coli* expressing the construct of interest were rapidly purified at 4°C. Maturation at 37°C was monitored beginning at 2 hours post-harvest. The initial decrease in mRFP1 fluorescence is attributed to a slight quenching on warming from 4 to 37°C.

FIGs. 6A-6F show light and fluorescence microscopic images of HeLa cells
15 expressing Cx43 fused with T1, dimer2 or mRFP1. Images 6A, 6C and 6E were acquired with excitation at 568 nm (55 nm bandwidth) and emission at 653 nm (95 nm bandwidth) with additional transmitted light. Lucifer yellow fluorescence (images 6B, 6D and 6F) was acquired with excitation at 425 nm (45 nm bandpass) and emission at 535 nm (55 nm bandpass). FIG. 6A shows two contacting cells transfected with Cx43-
20 mRFP1 and connected by a single large gap junction. FIG. 6B shows one cell microinjected with lucifer yellow at the point indicated by an asterisk and the dye quickly passing (1-2 sec) to the adjacent cell. FIG. 6C shows four neighboring cells transfected with Cx43-dimer2. The bright line between the two right-most cells is the result of having two fluorescent membranes in contact and is not a gap junction. FIG.
25 6D shows microinjected dye slowly passing to an adjacent cell (observed approximately one third of the time). FIG. 6E shows two adjacent cells transfected with Cx43-T1 and displaying the typical perinuclear localized aggregation. FIG. 6F shows no dye passed between neighboring cells.

FIG. 7 shows a schematic representation of the directed evolution strategy of the
30 present invention. Randomization at two positions is shown but the technique has been used with up to five fragments.

FIGS. 8A and 8B show SDS-PAGE analysis of DsRed, T1, dimer2, tdimer2(12), and mRFP1 polypeptides. The oligomeric state of each protein is demonstrated by running each protein (20 µg) both not boiled and boiled on a 12% SDS-PAGE Tris-HCl precast gel (BioRad). FIG. 8A shows the gel prior to Coomassie staining, which was imaged with excitation at 560 nm and emission at 610 nm. The tandem dimer tdimer2(12) has a small tetrameric component due a fraction of the covalent tandem pairs participating in intermolecular dimer pairs. Fluorescent proteins that are not boiled do not necessarily migrate at their expected molecular weight. FIG. 8B shows the same gel as in FIG. 8A after Coomassie staining. The band at ~20 kDa results from partial hydrolysis of the mainchain acylimine linkage in protein containing a red chromophore.

FIGS. 9A-9D show fluorescent images of red fluorescent proteins expressed in *E. coli*. *E. coli* strain JM109(DE3) was transformed with either DsRed, T1, dimer2 or mRFP1, plated on LB/agar supplemented with ampicillin, and incubated 12 hours at 37°C then 8 hours at 20°C before the plate was imaged with a digital camera. In FIG. 9A, the quadrants corresponding to T1, dimer2, and mRFP1 all appear of similar brightness when excited at 540 nm and imaged with a 575 nm (long pass) emission filter. Almost no fluorescence is visible for identically treated *E. coli* transformed with DsRed. In FIG. 9B, when excited at 560 nm and imaged with a 610 (long pass) filter, mRFP1 appears brighter due to its 25 nm red shift. In FIG. 9C, the monomer mRFP1 does not contain a green fluorescent component and is thus very dim in comparison to T1 and dimer2 when excited at 470 nm, a wavelength suitable for excitation of EGFP. FIG. 9D shows a digital color photograph of the same plate taken after 5 days at room temperature reveals the orange and purple hues of T1 and mRFP1, respectively.

FIGS. 10A and 10B show a table describing the protocols and multiple libraries created during evolution of dimer1 and mRFP1, as well as other intermediate forms. The templates, method of mutagenesis, targeted positions within the DsRed polypeptide, and resulting clones are indicated.

FIGS. 11A – 11C show a table providing a key to the primer pairs used in the mutagenesis protocols, as well as the target codon positions.

FIGS. 12A and 12B provide the PCR primer sequences listed in FIGS. 11A-11C.

FIG. 13 shows a table describing the results of a series of experiments testing the functionality of various DsRed chimeric molecules. The chimeric molecules comprise a

DsRed sequence and the Cx43 polypeptide. The plasmids encoding the fusion polypeptides were transfected into HeLa cells, and the ability of the expressed fusion polypeptides to form functional gap junctions was assayed by the microinjection of lucifer yellow dye. Passage of the dye from one HeLa cell to an adjacent HeLa cell indicates the presence of a functional gap junction, and thus, a functional fusion polypeptide.

FIG. 14 shows various biophysical properties of wild-type DsRed, T1, dimer2, tdimer2(12), and mRFP1 polypeptides.

FIG. 15 shows a table providing excitation/emission wavelength values, relative maturation speed and red/green ratio values of red and green fluorescent protein species.

FIG. 16 provides the nucleotide sequence of the *Discosoma* sp. wild-type red fluorescent protein open reading frame (DsRed).

FIG. 17 provides the amino acid sequence of the *Discosoma* sp. wild-type red fluorescent protein (DsRed).

FIG. 18 provides the nucleotide sequence of the *Discosoma* sp. variant fast T1 red fluorescent protein.

FIG. 19 provides the amino acid sequence of the *Discosoma* sp. variant fast T1 red fluorescent protein.

FIGS. 20A – 20D provide a table showing the amino acid substitutions identified during the construction of variant DsRed proteins. Also shown are the substitutions originally contained in the fast T1 DsRed variant.

FIG. 21 provides the nucleotide sequence of the *Discosoma* variant red fluorescent protein dimer2 open reading frame.

FIG. 22 provides the amino acid sequence of the *Discosoma* variant red fluorescent protein dimer2.

FIG. 23 provides the nucleotide sequence of the *Discosoma* variant red fluorescent protein mRFP1 open reading frame.

FIG. 24 provides the amino acid sequence of the *Discosoma* variant red fluorescent protein mRFP1.

FIG. 25 provides the nucleotide sequence of a modified *Discosoma* wild-type red fluorescent protein open reading frame with humanized codon usage.

FIG. 26 illustrates the maturation of Q66M DsRed relative to the wild-type DsRed protein.

FIG. 27 shows the excitation and emission spectra of wild-type DsRed (dsRed w.t.) and Q66M DsRed (dsRED Q66M), plotting relative intensity as a function of wavelength.

FIG. 28 shows Coomassie-stained bands on SDS-polyacrylamide gel, representative of wild-type DsRed, Q66M DsRed and K83DsRed after hydrolysis at pH 1.

FIG. 29 shows the absorption spectrum of mRFP1, mRFP Q66M, and mRFP1.1. The absorption spectrum is normalized to the 280 nm peak which should approximate the total protein concentration. The emission spectrum (measured with excitation at 550 nm) is normalized to its respective absorption maximum for sake of representation.

FIG. 30 provides the amino acid sequence of mRFP1.1.

FIG. 31 provides the nucleotide sequence of mRFP1.1.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

Unless specifically indicated otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention belongs. In addition, any method or material similar or equivalent to a method or material described herein can be used in the practice the present invention. For purposes of the present invention, the following terms are defined.

The term "nucleic acid molecule" or "polynucleotide" refers to a deoxyribonucleotide or ribonucleotide polymer in either single-stranded or double-stranded form, and, unless specifically indicated otherwise, encompasses polynucleotides containing known analogs of naturally occurring nucleotides that can function in a similar manner as naturally occurring nucleotides. It will be understood that when a nucleic acid molecule is represented by a DNA sequence, this also includes RNA molecules having the corresponding RNA sequence in which "U" (uridine) replaces "T" (thymidine).

The term "recombinant nucleic acid molecule" refers to a non-naturally occurring nucleic acid molecule containing two or more linked polynucleotide sequences. A recombinant nucleic acid molecule can be produced by recombination methods, particularly genetic engineering techniques, or can be produced by a chemical synthesis method. A recombinant nucleic acid molecule can encode a fusion protein, for example, a fluorescent protein variant of the invention linked to a polypeptide of interest. The term "recombinant host cell" refers to a cell that contains a recombinant nucleic acid molecule. As such, a recombinant host cell can express a polypeptide from a "gene" that is not found within the native (non-recombinant) form of the cell.

Reference to a polynucleotide "encoding" a polypeptide means that, upon transcription of the polynucleotide and translation of the mRNA produced therefrom, a polypeptide is produced. The encoding polynucleotide is considered to include both the coding strand, whose nucleotide sequence is identical to an mRNA, as well as its complementary strand. It will be recognized that such an encoding polynucleotide is considered to include degenerate nucleotide sequences, which encode the same amino acid residues. Nucleotide sequences encoding a polypeptide can include polynucleotides containing introns as well as the encoding exons.

The term "expression control sequence" refers to a nucleotide sequence that regulates the transcription or translation of a polynucleotide or the localization of a polypeptide to which it is operatively linked. Expression control sequences are "operatively linked" when the expression control sequence controls or regulates the transcription and, as appropriate, translation of the nucleotide sequence (i.e., a transcription or translation regulatory element, respectively), or localization of an encoded polypeptide to a specific compartment of a cell. Thus, an expression control sequence can be a promoter, enhancer, transcription terminator, a start codon (ATG), a splicing signal for intron excision and maintenance of the correct reading frame, a STOP codon, a ribosome binding site, or a sequence that targets a polypeptide to a particular location, for example, a cell compartmentalization signal, which can target a polypeptide to the cytosol, nucleus, plasma membrane, endoplasmic reticulum, mitochondrial membrane or matrix, chloroplast membrane or lumen, medial trans-Golgi cisternae, or a lysosome or endosome. Cell compartmentalization domains are well known in the art and include, for example, a peptide containing amino acid residues 1 to 81 of human

type II membrane-anchored protein galactosyltransferase, or amino acid residues 1 to 12 of the presequence of subunit IV of cytochrome c oxidase (see, also, Hancock et al., EMBO J. 10:4033-4039, 1991; Buss et al., Mol. Cell. Biol. 8:3960-3963, 1988; U.S. Patent No. 5,776,689, each of which is incorporated herein by reference).

5 The term "operatively linked" or "operably linked" or "operatively joined" or the like, when used to describe chimeric proteins, refer to polypeptide sequences that are placed in a physical and functional relationship to each other. In a most preferred embodiment, the functions of the polypeptide components of the chimeric molecule are unchanged compared to the functional activities of the parts in isolation. For example, a
10 fluorescent protein of the present invention can be fused to a polypeptide of interest. In this case, it is preferable that the fusion molecule retains its fluorescence, and the polypeptide of interest retains its original biological activity. In some embodiments of the present invention, the activities of either the fluorescent protein or the protein of interest can be reduced relative to their activities in isolation. Such fusions can also find
15 use with the present invention. As used herein, the chimeric fusion molecules of the invention can be in a monomeric state, or in a multimeric state (*e.g.*, dimeric).

 In another example, the tandem dimer fluorescent protein variant of the invention comprises two "operatively linked" fluorescent protein units. The two units are linked in such a way that each maintains its fluorescence activity. The first and second units in the
20 tandem dimer need not be identical. In another embodiment of this example, a third polypeptide of interest can be operatively linked to the tandem dimer, thereby forming a three part fusion protein.

 The term "oligomer" refers to a complex formed by the specific interaction of two or more polypeptides. A "specific interaction" or "specific association" is one that is
25 relatively stable under specified conditions, for example, physiologic conditions. Reference to a "propensity" of proteins to oligomerize indicates that the proteins can form dimers, trimers, tetramers, or the like under specified conditions. Generally, fluorescent proteins such as GFPs and DsRed have a propensity to oligomerize under physiologic conditions although, as disclosed herein, fluorescent proteins also can
30 oligomerize, for example, under pH conditions other than physiologic conditions. The conditions under which fluorescent proteins oligomerize or have a propensity to

oligomerize can be determined using well known methods as disclosed herein or otherwise known in the art.

As used herein, a molecule that has a "reduced propensity to oligomerize" is a molecule that shows a reduced propensity to form structures with multiple subunits in favor of forming structures with fewer subunits. For example, a molecule that would normally form tetrameric structures under physiological conditions shows a reduced propensity to oligomerize if the molecule is changed in such a way that it now has a preference to form monomers, dimers or trimers. A molecule that would normally form dimeric structures under physiological conditions shows a reduced propensity to oligomerize if the molecule is changed in such a way that it now has a preference to form monomers. Thus, "reduced propensity to oligomerize" applies equally to proteins that are normally dimers and to proteins that are normally tetrameric.

As used herein, the term "non-tetramerizing" refers to protein forms that produce trimers, dimers and monomers, but not tetramers. Similarly, "non-dimerizing" refers to protein forms that remain monomeric.

As used herein, the term "efficiency of (chromophore) maturation" with reference to a red fluorescent protein (RFP) indicates the percentage of the protein that has matured from a species with a green fluorescent protein (GFP)-like absorbance spectrum to the final RFP absorbance spectrum. Accordingly, efficiency of maturation is determined after allowing sufficient time for the maturation process to be practically (e.g. >95%) complete. Preferably, the resultant RFP, e.g. DsRed, will contain at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, even more preferably at least about 95%, still more preferably at least about 98%, most preferably at least about 99% of the red fluorescent species.

As used herein, the term "brightness," with reference to a fluorescent protein, is measured as the product of the extinction coefficient (EC) at a given wavelength and the fluorescence quantum yield (QY).

The term "probe" refers to a substance that specifically binds to another substance (a "target"). Probes include, for example, antibodies, polynucleotides, receptors and their ligands, and generally can be labeled so as to provide a means to identify or isolate a molecule to which the probe has specifically bound. The term "label" refers to a composition that is detectable with or without the instrumentation, for example, by visual

inspection, spectroscopy, or a photochemical, biochemical, immunochemical or chemical reaction. Useful labels include, for example, phosphorus-32, a fluorescent dye, a fluorescent protein, an electron-dense reagent, an enzymes (such as is commonly used in an ELISA), a small molecule such as biotin, digoxigenin, or other haptens or peptide for which an antiserum or antibody, which can be a monoclonal antibody, is available. It will be recognized that a fluorescent protein variant of the invention, which is itself a detectable protein, can nevertheless be labeled so as to be detectable by a means other than its own fluorescence, for example, by incorporating a radionuclide label or a peptide tag into the protein so as to facilitate, for example, identification of the protein during its expression and isolation of the expressed protein, respectively. A label useful for purposes of the present invention generally generates a measurable signal such as a radioactive signal, fluorescent light, enzyme activity, and the like, either of which can be used, for example, to quantitate the amount of the fluorescent protein variant in a sample.

The term "nucleic acid probe" refers to a polynucleotide that binds to a specific nucleotide sequence or sub-sequence of a second (target) nucleic acid molecule. A nucleic acid probe generally is a polynucleotide that binds to the target nucleic acid molecule through complementary base pairing. It will be understood that a nucleic acid probe can specifically bind a target sequence that has less than complete complementarity with the probe sequence, and that the specificity of binding will depend, in part, upon the stringency of the hybridization conditions. A nucleic acid probes can be labeled as with a radionuclide, a chromophore, a lumiphore, a chromogen, a fluorescent protein, or a small molecule such as biotin, which itself can be bound, for example, by a streptavidin complex, thus providing a means to isolate the probe, including a target nucleic acid molecule specifically bound by the probe. By assaying for the presence or absence of the probe, one can detect the presence or absence of the target sequence or sub-sequence. The term "labeled nucleic acid probe" refers to a nucleic acid probe that is bound, either directly or through a linker molecule, and covalently or through a stable non-covalent bond such as an ionic, van der Waals or hydrogen bond, to a label such that the presence of the probe can be identified by detecting the presence of the label bound to the probe.

The term "polypeptide" or "protein" refers to a polymer of two or more amino acid residues. The terms apply to amino acid polymers in which one or more amino acid

residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The term "recombinant protein" refers to a protein that is produced by expression of a nucleotide sequence encoding the amino acid sequence of the protein from a recombinant DNA molecule.

5 The term "isolated" or "purified" refers to a material that is substantially or essentially free from components that normally accompany the material in its native state in nature. Purity or homogeneity generally are determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis, high performance liquid chromatography, and the like. A polynucleotide or a polypeptide is considered to be
10 isolated when it is the predominant species present in a preparation. Generally, an isolated protein or nucleic acid molecule represents greater than 80% of the macromolecular species present in a preparation, often represents greater than 90% of all macromolecular species present, usually represents greater than 95%, of the macromolecular species, and, in particular, is a polypeptide or polynucleotide that
15 purified to essential homogeneity such that it is the only species detected when examined using conventional methods for determining purity of such a molecule.

 The term "naturally-occurring" is used to refer to a protein, nucleic acid molecule, cell, or other material that occurs in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism, including in a virus. A naturally
20 occurring material can be in its form as it exists in nature, and can be modified by the hand of man such that, for example, is in an isolated form.

 The term "antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or antigen-binding fragments thereof, which specifically bind and recognize an analyte (antigen). The recognized
25 immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Antibodies exist as intact immunoglobulins and as well characterized antigen-binding fragments of an antibody, which can be produced by digestion with a peptidase or can using recombinant DNA methods. Such antigen-binding fragments of an antibody
30 include, for example, Fv, Fab' and F(ab')₂ fragments. The term "antibody," as used herein, includes antibody fragments either produced by the modification of whole antibodies or those synthesized *de novo* using recombinant DNA methodologies. The

term "immunoassay" refers to an assay that utilizes an antibody to specifically bind an analyte. An immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the analyte.

The term "identical," when used in reference to two or more polynucleotide
5 sequences or two or more polypeptide sequences, refers to the residues in the sequences that are the same when aligned for maximum correspondence. When percentage of sequence identity is used in reference to a polypeptide, it is recognized that one or more residue positions that are not otherwise identical can differ by a conservative amino acid substitution, in which a first amino acid residue is substituted for another amino acid
10 residue having similar chemical properties such as a similar charge or hydrophobic or hydrophilic character and, therefore, does not change the functional properties of the polypeptide. Where polypeptide sequences differ in conservative substitutions, the percent sequence identity can be adjusted upwards to correct for the conservative nature of the substitution. Such an adjustment can be made using well known methods, for
15 example, scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions can be calculated using any well known algorithm
20 (see, for example, Meyers and Miller, Comp. Appl. Biol. Sci. 4:11-17, 1988; Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; Pearson and Lipman, Proc. Natl. Acad. Sci., USA 85:2444 (1988); Higgins and Sharp, Gene 73:237-244, 1988; Higgins and Sharp, CABIOS 5:151-153; 1989; Corpet et al., Nucl. Acids Res. 16:10881-10890, 1988; Huang, et al., Comp. Appl. Biol.
25 Sci. 8:155-165, 1992; Pearson et al., Meth. Mol. Biol., 24:307-331, 1994). Alignment also can be performed by simple visual inspection and manual alignment of sequences.

The term "conservatively modified variation," when used in reference to a particular polynucleotide sequence, refers to different polynucleotide sequences that
30 encode identical or essentially identical amino acid sequences, or where the polynucleotide does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical polynucleotides encode any given polypeptide. For instance, the

codons CGU, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleotide sequence variations are "silent variations," which can be considered a species of "conservatively modified variations." As such, it will be recognized that each polynucleotide sequence disclosed herein as encoding a fluorescent protein variant also describes every possible silent variation. It will also be recognized that each codon in a polynucleotide, except AUG, which is ordinarily the only codon for methionine, and UUG, which is ordinarily the only codon for tryptophan, can be modified to yield a functionally identical molecule by standard techniques. Accordingly, each silent variation of a polynucleotide that does not change the sequence of the encoded polypeptide is implicitly described herein. Furthermore, it will be recognized that individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, and generally less than 1%) in an encoded sequence can be considered conservatively modified variations, provided alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative amino acid substitutions providing functionally similar amino acids are well known in the art, including the following six groups, each of which contains amino acids that are considered conservative substitutes for each another:

- 1) Alanine (Ala, A), Serine (Ser, S), Threonine (Thr, T);
- 2) Aspartic acid (Asp, D), Glutamic acid (Glu, E);
- 3) Asparagine (Asn, N), Glutamine (Gln, Q);
- 4) Arginine (Arg, R), Lysine (Lys, K);
- 5) Isoleucine (Ile, I), Leucine (Leu, L), Methionine (Met, M), Valine (Val, V); and
- 6) Phenylalanine (Phe, F), Tyrosine (Tyr, Y), Tryptophan (Trp, W).

Two or more amino acid sequences or two or more nucleotide sequences are considered to be "substantially identical" or "substantially similar" if the amino acid sequences or the nucleotide sequences share at least 80% sequence identity with each other, or with a reference sequence over a given comparison window. Thus, substantially similar sequences include those having, for example, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity, or at least 99% sequence identity.

A subject nucleotide sequence is considered "substantially complementary" to a reference nucleotide sequence if the complement of the subject nucleotide sequence is substantially identical to the reference nucleotide sequence. The term "stringent conditions" refers to a temperature and ionic conditions used in a nucleic acid hybridization reaction. Stringent conditions are sequence dependent and are different under different environmental parameters. Generally, stringent conditions are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature, under defined ionic strength and pH, at which 50% of the target sequence hybridizes to a perfectly matched probe.

The term "allelic variants" refers to polymorphic forms of a gene at a particular genetic locus, as well as cDNAs derived from mRNA transcripts of the genes, and the polypeptides encoded by them. The term "preferred mammalian codon" refers to the subset of codons from among the set of codons encoding an amino acid that are most frequently used in proteins expressed in mammalian cells as chosen from the following list: Gly (GGC, GGG); Glu (GAG); Asp (GAC); Val (GUG, GUC); Ala (GCC, GCU); Ser (AGC, UCC); Lys (AAG); Asn (AAC); Met (AUG); Ile (AUC); Thr (ACC); Trp (UGG); Cys (UGC); Tyr (UAU, UAC); Leu (CUG); Phe (UUC); Arg (CGC, AGG, AGA); Gln (CAG); His (CAC); and Pro (CCC).

Fluorescent molecules are useful in fluorescence resonance energy transfer, FRET, which involves a donor molecule and an acceptor molecule. To optimize the efficiency and detectability of FRET between a donor and acceptor molecule, several factors need to be balanced. The emission spectrum of the donor should overlap as much as possible with the excitation spectrum of the acceptor to maximize the overlap integral. Also, the quantum yield of the donor moiety and the extinction coefficient of the acceptor should be as high as possible to maximize R_0 , which represents the distance at which energy transfer efficiency is 50%. However, the excitation spectra of the donor and acceptor should overlap as little as possible so that a wavelength region can be found at which the donor can be excited efficiently without directly exciting the acceptor because fluorescence arising from direct excitation of the acceptor can be difficult to distinguish from fluorescence arising from FRET. Similarly, the emission spectra of the donor and acceptor should overlap as little as possible so that the two emissions can be

clearly distinguished. High fluorescence quantum yield of the acceptor moiety is desirable if the emission from the acceptor is to be measured either as the sole readout or as part of an emission ratio. One factor to be considered in choosing the donor and acceptor pair is the efficiency of fluorescence resonance energy transfer between them.

- 5 Preferably, the efficiency of FRET between the donor and acceptor is at least 10%, more preferably at least 50% and even more preferably at least 80%.

The term "fluorescent property" refers to the molar extinction coefficient at an appropriate excitation wavelength, the fluorescence quantum efficiency, the shape of the excitation spectrum or emission spectrum, the excitation wavelength maximum and
10 emission wavelength maximum, the ratio of excitation amplitudes at two different wavelengths, the ratio of emission amplitudes at two different wavelengths, the excited state lifetime, or the fluorescence anisotropy. A measurable difference in any one of these properties between wild type *Aequorea* GFP and a spectral variant, or a mutant thereof, is useful. A measurable difference can be determined by determining the
15 amount of any quantitative fluorescent property, e.g., the amount of fluorescence at a particular wavelength, or the integral of fluorescence over the emission spectrum. Determining ratios of excitation amplitude or emission amplitude at two different wavelengths ("excitation amplitude ratioing" and "emission amplitude ratioing", respectively) are particularly advantageous because the ratioing process provides an
20 internal reference and cancels out variations in the absolute brightness of the excitation source, the sensitivity of the detector, and light scattering or quenching by the sample.

As used herein, the term "fluorescent protein" refers to any protein that can fluoresce when excited with an appropriate electromagnetic radiation, except that chemically tagged proteins, wherein the fluorescence is due to the chemical tag, and
25 polypeptides that fluoresce only due to the presence of certain amino acids such as tryptophan or tyrosine, whose emission peaks at ultraviolet wavelengths (*i.e.*, less than about 400 nm) are not considered fluorescent proteins for purposes of the present invention. In general, a fluorescent protein useful for preparing a composition of the invention or for use in a method of the invention is a protein that derives its fluorescence
30 from autocatalytically forming a chromophore. A fluorescent protein can contain amino acid sequences that are naturally occurring or that have been engineered (*i.e.*, variants or mutants). When used in reference to a fluorescent protein, the term "mutant" or "variant"

refers to a protein that is different from a reference protein. For example, a spectral variant of *Aequorea* GFP can be derived from the naturally occurring GFP by engineering mutations such as amino acid substitutions into the reference GFP protein. For example ECFP is a spectral variant of GFP that contains substitutions with respect to GFP (compare SEQ ID NOS: 10 and 11).

Many cnidarians use green fluorescent proteins as energy transfer acceptors in bioluminescence. The term "green fluorescent protein" is used broadly herein to refer to a protein that fluoresces green light, for example, *Aequorea* GFP (SEQ ID NO: 10). GFPs have been isolated from the Pacific Northwest jellyfish, *Aequorea victoria*, the sea pansy, *Renilla reniformis*, and *Phialidium gregarium* (Ward et al., Photochem. Photobiol. 35:803-808, 1982; Levine et al., Comp. Biochem. Physiol. 72B:77-85, 1982, each of which is incorporated herein by reference). Similarly, reference is made herein to "red fluorescent proteins", which fluoresce red, "cyan fluorescent proteins," which fluoresce cyan, and the like. RFPs, for example, have been isolated from the corallimorph *Discosoma* (Matz et al., *Nature Biotechnology* 17:969-973 [1999]). The term "red fluorescent protein," or "RFP" is used in the broadest sense and specifically covers the *Discosoma* RFP (DsRed), and red fluorescent proteins from any other species, such as coral and sea anemone, as well as variants thereof as long as they retain the ability to fluoresce red light.

The term "coral" as used herein encompasses species within the class Anthozoa, and includes specifically both corals and corallimorphs.

A variety of *Aequorea* GFP-related fluorescent proteins having useful excitation and emission spectra have been engineered by modifying the amino acid sequence of a naturally occurring GFP from *A. victoria* (see Prasher et al., *Gene* 111:229-233, 1992; Heim et al., *Proc. Natl. Acad. Sci. USA* 91:12501-12504, 1994; U.S. Patent No. 5,625,048; International application PCT/US95/14692, now published as PCT WO96/23810, each of which is incorporated herein by reference). As used herein, reference to a "related fluorescent protein" refers to a fluorescent protein that has a substantially identical amino acid sequence when compared to a reference fluorescent protein. In general, a related fluorescent protein, when compared to the reference fluorescent protein sequence, has a contiguous sequence of at least about 150 amino acids that shares at least about 85% sequence identity with the reference fluorescent

protein, and particularly has a contiguous sequence of at least about 200 amino acids that shares at least about 95% sequence identity with the reference fluorescent protein. Thus, reference is made herein to an "*Aequorea*-related fluorescent protein" or to a "GFP-related fluorescent protein," which is exemplified by the various spectral variants and GFP mutants that have amino acid sequences that are substantially identical to *A. victoria* GFP (SEQ ID NO: 10), to a "*Discosoma*-related fluorescent protein" or a "DsRed-related fluorescent related protein," which is exemplified by the various mutants that have amino acid sequences substantially identical to that of DsRed (SEQ ID NO: 1), and the like, for example, a Renilla-related fluorescent protein or a Phialidium-related fluorescent protein.

The term "mutant" or "variant" also is used herein in reference to a fluorescent protein that contains a mutation with respect to a corresponding wild type fluorescent protein. In addition, reference is made herein to a "spectral variant" or "spectral mutant" of a fluorescent protein to indicate a mutant fluorescent protein that has a different fluorescence characteristic with respect to the corresponding wild type fluorescent protein. For example, CFP, YFP, ECFP (SEQ ID NO: 11), EYFP-V68L/Q69K (SEQ ID NO: 12), and the like are GFP spectral variants.

Aequorea GFP-related fluorescent proteins include, for example, wild type (native) *Aequorea victoria* GFP (Prasher et al., *supra*, 1992; see, also, SEQ ID NO: 10), allelic variants of SEQ ID NO: 10, for example, a variant having a Q80R substitution (Chalfie et al., Science 263:802-805, 1994, which is incorporated herein by reference); and spectral variants of GFP such as CFP, YFP, and enhanced and otherwise modified forms thereof (U.S. Pat. Nos. 6,150,176; 6,124,128; 6,077,707; 6,066,476; 5,998,204; and 5,777,079, each of which is incorporated herein by reference), including GFP-related fluorescent proteins having one or more folding mutations, and fragments of the proteins that are fluorescent, for example, an *A. victoria* GFP from which the two N-terminal amino acid residues have been removed. Several of these fluorescent proteins contain different aromatic amino acids within the central chromophore and fluoresce at a distinctly shorter wavelength than the wild type GFP species. For example, the engineered GFP proteins designated P4 and P4-3 contain, in addition to other mutations, the substitution Y66H; and the engineered GFP proteins designated W2 and W7 contain, in addition to other mutations, Y66W.

The term "non-tetramerizing fluorescent protein" is used broadly herein to refer to normally tetrameric fluorescent proteins that have been modified such that they have a reduced propensity to tetramerize as compared to a corresponding unmodified fluorescent protein. As such, unless specifically indicated otherwise, the term "non-tetramerizing fluorescent protein" encompasses dimeric fluorescent proteins, tandem dimer fluorescent proteins, as well as fluorescent proteins that remain monomeric.

As used herein, the term "aggregation" refers to the tendency of an expressed protein to form insoluble precipitates or visible punctae and is to be distinguished from "oligomerization". In particular, mutations that reduce aggregation, *e.g.*, increase the solubility of the protein, do not necessarily reduce oligomerization, *i.e.*, convert tetramers to dimers or monomers.

Description of the Preferred Embodiments

The present invention provides fluorescent protein variants that can be derived from fluorescent proteins that have a propensity to dimerize or tetramerize. As disclosed herein, in one embodiment of the invention, a fluorescent protein variant of the invention can be derived from a naturally occurring fluorescent protein or from a spectral variant or mutant thereof, and contains at least one mutation that reduces or eliminates the propensity of the fluorescent protein to oligomerize. In particular, the present invention provides dimeric and monomeric red fluorescent proteins (RFP) and RFP variants with reduced propensity to oligomerize. As disclosed herein, in a further embodiment of the invention, a fluorescent protein is provided having improved efficacy of maturation. In particular, the present invention provides dimeric and monomeric red fluorescent proteins (RFP) and RFP variants with improved efficacy of maturation. In embodiments of the invention, fluorescent protein variants are provided which contain at least one mutation that reduces or eliminates the propensity of the fluorescent protein to oligomerize and which contain at least one mutation that improves the efficacy of maturation of fluorescence in the protein variant as compared to other variants including the parent protein.

The cloning of a red fluorescent protein from *Discosoma* (DsRed) raised a great deal of interest due to its tremendous potential as a tool for the advancement of cell biology. However, a careful investigation of the properties of this protein revealed

several problems that would preclude DsRed from being as widely accepted as the *Aequorea* GFP and its blue, cyan, and yellow variants, which have found widespread use as both genetically encoded indicators for tracking gene expression and as donor/acceptor pairs for fluorescence resonance energy transfer (FRET). Extending the spectrum of available colors to red wavelengths would provide a distinct new label for multicolor tracking of fusion proteins and together with GFP would provide a new FRET donor/acceptor pair that would be superior to the currently preferred cyan/yellow pair.

The three most pressing problems with the 28 kDa DsRed are its strong tendency to oligomerize, its slow maturation, and its inefficient maturation from a species with a GFP-like spectrum to the ultimate RFP spectrum.

A variety of techniques have been used to determine that DsRed is an obligate tetramer both *in vitro* and *in vivo*. For numerous reasons, the oligomeric state of DsRed is problematic for applications in which it is fused to a protein of interest in order to monitor trafficking or interactions of the latter. Using purified protein, it was shown that DsRed requires greater than 48 hours to reach >90 % of its maximal red fluorescence (see below). During the maturation process, a green intermediate initially accumulates and is slowly converted to the final red form. However, the conversion of the green component does not proceed to completion and thus a fraction of aged DsRed remains green. The primary disadvantage of the incomplete maturation is an excitation spectrum that extends well into the green wavelengths due to energy transfer between the green and red species within the tetramer. This is a particularly serious problem due to overlap with the excitation spectra of potential FRET partners such as GFP.

The original report of the cloning of DsRed provided an *in vivo* application marking the fates of *Xenopus* blastomeres after 1 week of development (Matz *et al.*, *Nature Biotechnology* 17:969-973 [1999]). As disclosed herein, DsRed has been characterized with respect to the time the red fluorescence takes to appear, the pH sensitivity of the chromophore, how strongly the chromophore absorbs light and fluoresces, how readily the protein photobleaches, and whether the protein normally exists as a monomer or an oligomer in solution. The results demonstrate that DsRed provides a useful complement to or alternative for GFP and its spectral mutants. In addition, DsRed mutants that are non-fluorescent or that are blocked or slowed in converting from green to red emission were characterized, including mutants in which

the eventual fluorescence is substantially red-shifted from wild type DsRed (see, Baird et al., Proc. Natl. Acad. Sci., USA 97:11984-11989, 2000; Gross et al., Proc. Natl. Acad. Sci., USA 97:11990-11995, 2000, each of which is incorporated herein by reference).

5 Red Fluorescent Protein Variants with Improved Efficacy of Maturation

The present invention provides RFP variants that show more efficient chromophore maturation than a reference wild-type or variant RFP, as a result of at least one amino acid alteration within the reference (wild-type or variant) sequence.

10 The wild-type RFP protein typically consists of about 70% red protein with about 30% contamination by the green, immature form of the protein. Through careful mass spectrometric and biochemical investigations, it has been determined that the C α -N bond of Q66 in DsRed is oxidized as the protein matures into its red form, which, in turn, led to a further investigation of the role of the amino acid at position 66 as it relates to chromophore maturation. By site-directed mutagenesis, it was determined that the
15 substitution of methionine (M) for the native glutamine (Q) at amino acid position 66 yielded a protein that showed a deeper pink color than the wild-type protein, and contained less of the immature green form than wild-type DsRed. In addition, the Q66M DsRed variant was found to mature more quickly than wild-type DsRed. Additional experiments have shown that the Q66M mutation retained its advantageous properties
20 also when introduced into non-tetramerizing, i.e. dimeric or monomeric DsRed variants, which contained additional mutations. Further details of these findings are set forth in the Examples below. Thus, an RFP variant of the invention can be derived from a naturally occurring (wild-type) RFP or from a spectral variant or mutant thereof, and contains at least one mutation that makes chromophore maturation more efficient.

25 While the invention is illustrated with reference to the Q66M mutation in DsRed, it will be understood that it is not so limited. Mutations of other amino acids within the wild-type DsRed sequence that play a role in chromophore structure, orientation and/or maturation can also yield DsRed variants with improved maturation efficiency. Similarly, amino acid alterations (e.g. substitutions) at corresponding (homologous)
30 positions or regions in other RFPs can produce RFP variants showing an improvement in maturation efficiency. All of such variants, alone or in combination with other mutations (substitutions, insertions and/or deletions) within the wild-type RFP sequence, are

specifically within the scope of the invention. Thus an additional exemplary amino acid alteration that is believed to improve maturation of both the wild-type DsRed protein and DsRed variants, including Q66M DsRed is a substitution at amino acid position 147 of wild-type DsRed. A preferred substitution at this position is T147S, but
5 other substitutions resulting in similar improvements in spectral properties and, in particular, in the efficiency and potentially speed of maturation, are also possible. Especially, substitution of amino acids with similar properties of threonine (T) are expected to yield such variants.

In a specific embodiment, the invention concerns RFP variants with improved
10 maturation efficiency that have a reduced propensity to tetramerize, as a result of one or more further mutations within the RFP molecule. In particular, in this embodiment, the invention concerns non-tetramerizing, such as dimeric or monomeric, DsRed variants that show enhanced maturation efficiency relative to the corresponding non-tetramerizing DsRed variant. Further details about the design and preparation of such
15 variants are provided below.

In brief, the RFP variants of the invention can be derived from RFPs that have a propensity to dimerize or tetramerize. As disclosed herein, an RFP variant of the invention can be derived from a naturally occurring RFP or from a spectral variant or mutant thereof, and contains at least one mutation that enhances maturation efficiency,
20 and optionally at least one additional mutation that reduces or eliminates the propensity of the RFP to oligomerize.

A fluorescent protein variant of the invention can be derived from any fluorescent protein that is known to oligomerize, including, for example, a green fluorescent protein (GFP) such as an *Aequorea victoria* GFP (SEQ ID NO: 10), a *Renilla reniformis* GFP, a
25 *Phialidium gregarium* GFP; a red fluorescent protein (RFP) such as a *Discosoma* RFP (SEQ ID NO: 1); or a fluorescent protein related to a GFP or an RFP. Thus, the fluorescent protein can be a cyan fluorescent protein (CFP), a yellow fluorescent protein (YFP), an enhanced GFP (EGFP; SEQ ID NO: 13), an enhanced CFP (ECFP; SEQ ID NO: 14), an enhanced YFP (EYFP; SEQ ID NO: 15), a DsRed fluorescent protein (SEQ
30 ID NO: 1), a homologue in any other species, or a mutant or variant of such fluorescent proteins.

As disclosed herein, the propensity of the fluorescent protein variant of the invention to oligomerize is reduced or eliminated. There are two basic approaches to reduce the propensity of the fluorescent protein, *e.g.*, RFP such as DsRed, to form intermolecular oligomers, (1) oligomerization can be reduced or eliminated by
5 introducing mutations into appropriate regions of the fluorescent protein, *e.g.*, an RFP molecule, and (2) two subunits of the fluorescent protein can operatively link, *e.g.*, link RFP to each other by a linker, such as a peptide linker. If oligomerization is reduced or eliminated by following approach (1), it is usually necessary to introduce additional mutations into the molecule, in order to restore fluorescence, which is typically lost or
10 greatly impaired as a result of introducing mutations at the oligomer interfaces.

Red Fluorescent Protein Variants with Reduced Propensity to Oligomerize

The present invention provides fluorescent protein variants where the degree of oligomerization of the fluorescent protein is reduced or eliminated by the introduction of
15 amino acid substitutions to reduce or abolish the propensity of the constituent monomers to tetramerize. In one embodiment, the resulting structures have a propensity to dimerize. In other embodiments, the resulting structures have a propensity to remain monomeric.

Various dimer forms can be created. For example, an AB orientation dimer can
20 be formed, or alternatively, an AC orientation dimer can be formed. However, with the creation of dimeric forms, fluorescence or the rate of maturation of fluorescence, can be lost. The present invention provides methods for the generation of dimeric forms that display detectable fluorescence, and furthermore, fluorescence that has advantageous rates of maturation.

25 In one embodiment, the dimer is an intermolecular dimer. Furthermore, the dimer can be a homodimer (comprising two molecules of the identical species) or a heterodimer (comprising two molecules of different species). In a preferred embodiment, dimers will spontaneously form in physiological conditions. As used herein, the molecules that form such types of structures are said to have a reduced
30 tendency to oligomerize, as the monomeric units have reduced or non-existent ability to form tetrameric intermolecular oligomers.

A non-limiting, illustrative example of such a dimeric red fluorescent protein variant is described herein, and is termed "dimer2." The dimer2 nucleotide sequence is provided in SEQ ID NO: 7 and FIG. 21. The dimer2 polypeptide is provided in SEQ ID NO: 6 and FIG. 22.

5 In an attempt to produce a still further advantageous form of the DsRed variant dimer, a novel strategy to synthesize a "tandem" DsRed variant dimer was devised. This approach utilized covalent tethering of two engineered monomeric DsRed units to yield a dimeric form of DsRed with advantageous properties. The basic strategy was to fuse two copies of an AC dimer with a polypeptide linker such that the critical dimer interactions
10 could be satisfied through intramolecular contacts with the tandem partner encoded within the same polypeptide. Such operably linked homodimers or heterodimers are referred to herein as "tandem dimers," and have a substantially reduced propensity to form tetrameric structures.

Illustrative examples of such tandem red fluorescent protein variant dimers
15 include, without limitation, two monomeric units of the dimer2 species (SEQ ID NO: 6) operably covalently linked by a peptide linker, preferably about 9 to about 25, more preferably about 9 to 20 amino acid residues in length. Such linkers finding use with the invention include, but are not limited to, for example, the 9 residue linker RMGTGSGQL (SEQ ID NO: 16), the 12 residue linker GHGTGSTGSGSS (SEQ ID NO: 17), the 13
20 residue linker RMGSTSGSTKGQL (SEQ ID NO: 18), or the 22 residue linker RMGSTSGSGKPGSGEGSTKGQL (SEQ ID NO: 19). As noted above, the subunits of such tandem dimers preferably contain mutations relative to the wild-type DsRed sequence of SEQ ID NO: 1, in order to preserve/restore fluorescent properties. An illustrative example of the tandem red fluorescent protein dimers herein is a dimer
25 composed of two monomers, wherein at least one of the monomers is a variant DsRed, which has an amino acid sequence of SEQ ID NO: 6, operatively linked by a peptide linker, preferably about 9 to about 25, more preferably about 10 to about 20 amino acid residues in length, including any of the 9, 12, 13, and 22 residue linkers above. Yet another illustrative example of a tandem red fluorescent protein dimer herein is a tandem
30 dimer composed of two identical or different DsRed variant monomeric subunits at least one of which contains the following substitutions within the DsRed polypeptide of SEQ ID NO: 1: N42Q, V44A, V71A, F118L, K163Q, S179T, S197T, T217S (mutations

internal to the β -barrel); R2A, K5E and N6D (aggregation reducing mutations); I125R and V127T (AB interface mutations); and T21S, H41T, C117T and S131P (miscellaneous surface mutations). Just as in the other illustrative dimers, the two monomeric subunits may be fused by a peptide linker, preferably about 9 to about 25, more preferably about 10 to about 25 amino acid residues in length, such as any of the 9, 12, 13, and 22 residue linkers above. Shorter linkers are generally preferable to longer linkers, as long as they do not significantly slow affinity maturation or otherwise interfere with the fluorescent and spectral properties of the dimer. As noted above, the two monomeric subunits within a dimer may be identical or different. Thus, for example, one subunit may be the wild-type DsRed monomer of SEQ ID NO: 1 operatively linked to a variant DsRed polypeptide, such as any of the DsRed variants listed above or otherwise disclosed herein. The monomers should be linked such that the critical dimer interactions are satisfied through intramolecular contacts with the tandem partner. The peptide linkers are preferably protease resistant. The peptide linkers specifically disclosed herein are only illustrative. One skilled in the art will understand that other peptide linkers, preferably protease resistant linkers, are also suitable for the purpose of the present invention. See, e.g., Whitlow *et al.*, *Protein Eng* 6:989-995 (1993).

In one embodiment, disclosed in more detail in the examples below, a novel approach was used to overcome the intermolecular oligomerization propensity of wild-type DsRed by linking the C-terminus of the A subunit to the N-terminus of the B subunit through a flexible linker to produce tandem dimers. Based on the crystal structure of DsRed tetramer, a 10 to 20 residue linkers, such as an 18 residue linker (Whitlow *et al.*, *Prot. Eng.* 6:989-995, 1993, *supra*, which is incorporated herein by reference) was predicted to be long enough to extend from the C-terminus of the A subunit to the N-terminus of the C subunit (about 30 Å), but not to the N-terminus of the B subunit (greater than 70 Å). As such, 'oligomerization' in the tandem dimers is intramolecular, *i.e.*, the tandem dimer of DsRed (tDsRed), for example, is encoded by a single polypeptide chain. Furthermore, a combination of tDsRed with the I125R mutant (tDsRed-I125R) resulted in another dimeric red fluorescent protein. It should be recognized that this strategy can be generally applied to any protein system in which the distance between the N-terminus of one protein and the C-terminus of a dimer partner is

known, such that a linker having the appropriate length can be used to operatively link the monomers. In particular, this strategy can be useful for other modifying other fluorescent proteins that have interesting spectral properties, but form obligate dimers that are difficult to disrupt using the targeted mutagenesis method disclosed herein.

5

Mutagenesis Strategy to Produce Dimeric and Monomeric Red Fluorescent Proteins

The present invention provides variant fluorescent proteins that have a reduced propensity to form tetrameric oligomers (*i.e.*, the propensity to form tetramers is reduced or eliminated) due to the presence of one or more mutations in the fluorescent protein.

10 As disclosed herein, mutations were introduced into DsRed, and DsRed mutants having reduced oligomerization activity were identified, including, for example, a DsRed-I125R mutant of DsRed of SEQ ID NO: 20. The strategy for producing the DsRed mutants involved introducing mutations in DsRed that were predicted to interfere with the dimer interfaces (A-B or A-C, see FIGS. 1 and 2) and thus prevent formation of the tetramer.

15 This strategy resulted in the production of DsRed mutants that had a reduced propensity to form tetramers by disrupting the A-B interface, for example, using the single replacement of isoleucine 125 with an arginine (I125R).

The basic strategy for decreasing the oligomeric state of DsRed was to replace key dimer interface residues with charged amino acids, preferably arginine. It is

20 contemplated that dimer formation would require the targeted residue to interact with the identical residue of the dimer partner through symmetry. The resulting high energetic cost of placing two positive charges in close proximity should disrupt the interaction. Initial attempts to break apart the DsRed AC interface (see FIG. 2A) with the single mutations T147R, H162R, and F224R, consistently gave non-fluorescent proteins. The

25 AB interface however, proved somewhat less resilient and could be broken with the single mutation I125R to give a poorly red fluorescent dimer that suffered from an increased green component and required more than 10 days to fully mature.

Illustrative examples of mutations (amino acid substitutions) which can further improve the fluorescent properties of I125R include mutations in at least one of amino

30 acid positions 163, 179 and 217 within SEQ ID NO: 1. In a preferred embodiment, the I125R variant comprises at least one of the K163Q/M, S179T and T217S substitutions. Further illustrative variants may contain additional mutations at position N42 and/or C44

within SEQ ID NO: 1. Yet another group of illustrative DsRed dimers comprise additional mutations at at least one of residues I161 and S197 within SEQ ID NO: 1. Specific examples of DsRed variants obtained by this mutagenesis approach include DsRed-I125R, S179T, T217A, and DsRed-I125R, K163Q, T217A.

5 It is noted that there exists an inconsistency in the naming convention of the DsRed subunits in the prior art. As shown in FIG. 1, one convention assigns the A-B-C-D subunits as shown. However, a different convention is also recognized, which is shown in FIG. 2. When viewing the model of FIG. 1, the AC interface of that figure is equivalent to the AB interface shown in FIG. 2A. With the exception of FIG. 1,
10 reference to subunit interfaces in the present application is according to the convention used in FIG. 2.

A similar directed mutagenesis strategy starting from T1-I125R (see FIG. 10A, library D1) was undertaken and eventually identified dimer1. Dimer1 was somewhat better than wt DsRed both in terms of brightness and rate of maturation but had a
15 substantial green peak equivalent to that of T1. Dimer1 was also somewhat blue-shifted with an excitation maximum at 551 nm and an emission maximum at 579 nm. Error prone PCR on dimer1 (FIG. 10A, library D2) resulted in the discovery of dimer1.02 containing the mutation V71A in the hydrophobic core of the protein and effectively no green component in the excitation spectra. A second round of random mutagenesis (FIG.
20 10A, library D3) identified the mutations K70R which further decreased the green excitation, S197A which red-shifted the dimer back to DsRed wavelengths and T217S which greatly improved the rate of maturation. Unfortunately, K70R and S197A matured relatively slowly and T217S had a green excitation peak equivalent to DsRed. Using dimer1.02 as the template, two more rounds of directed mutagenesis were
25 performed; the first focusing on the three positions identified above (FIG. 11A, library D3) and the second on C117, F118, F124, and V127 (FIG. 10A, library D4).

Continuing with the directed evolution strategy for a total of 4 generations, an optimal dimeric variant was produced, which was designated dimer2 (illustrated in FIG. 2B). This variant contains 17 mutations, of which eight are internal to the β -barrel
30 (N42Q, V44A, V71A, F118L, K163Q, S179T, S197T and T217S), three are the aggregation reducing mutations found in T1 (R2A, K5E and N6D and see Bevis and Glick, *Nat. Biotechnol.*, 20:83-87 [2002]; and Yanushevich *et al.*, *FEBS Lett.*, 511:11-14

[2002]), two are AB interface mutations (I125R and V127T), and 4 are miscellaneous surface mutations (T21S, H41T, C117T and S131P). The dimer2 nucleotide sequence is provided in SEQ ID NO: 7 and FIG. 21. The dimer2 polypeptide is provided in SEQ ID NO: 6 and FIG. 22.

5 The ultimate product of the mutagenesis approach described herein is a monomeric red fluorescent protein, designated mRFP1, which contains the following mutations within the wild-type DsRed sequence of SEQ ID NO: 1: N42Q, V44A, V71A, K83L, F124L, L150M, K163M, V175A, F177V, S179T, V195T, S197I, T217A, R2A, K5E, N6D, I125R, V127T, I180T, R153E, H162K, A164R, L174D, Y192A, Y194K,
10 H222S, L223T, F224G, L225A, T21S, H41T, C117E, and V156A. Of these, the first 13 mutations are internal to the β -barrel. Of the remaining 20 external mutations, 3 are aggregation reducing mutations (R2A, K5E, and N6D), 3 are AB interface mutations (I125R, V127T, and I180T), 10 are AC interface mutations (R153E, H162K, A164R, L174D, Y192A, Y194K, H222S, L223T, F224G, and L225A), and 4 are additional
15 beneficial mutations (T21S, H41T, C117E, and V156A). The mRFP1 nucleotide sequence is provided in SEQ ID NO: 9 and FIG. 23. The mRFP1 polypeptide is provided in SEQ ID NO: 8 and FIG. 24.

Although mRFP1 is believed to be optimized in many aspects, a person skilled in the art will appreciate that other mutations within these and other regions of the wild-type DsRed amino acid sequence (SEQ ID NO: 1) may also yield monomeric DsRed
20 variants retaining the qualitative red fluorescing properties of the wild-type DsRed protein. Accordingly, mRFP1 serves merely as an illustration, and embodiments of the invention are by no means intended to be limited to this particular monomer.

Specifically, the monomeric DsRed variants herein, e.g. mRFP1, can be further
25 modified to alter the spectral and/or fluorescent properties of DsRed. For example, based upon experience with GFP, it is known that in the excited state, electron density tends to shift from the phenolate towards the carbonyl end of the chromophore. Therefore, placement of increasing positive charge near the carbonyl end of the chromophore tends to decrease the energy of the excited state and cause a red-shift in the
30 absorbance and emission wavelength maximum of the protein. Decreasing a positive charge near the carbonyl end of the chromophore tends to have the opposite effect,

causing a blue-shift in the protein's wavelengths. Similarly, mutations have been introduced into DsRed to produce mutants having altered fluorescence characteristics.

Amino acids with charged (ionized D, E, K, and R), dipolar (H, N, Q, S, T, and uncharged D, E and K), and polarizable side groups (e.g., C, F, H, M, W and Y) are
5 useful for altering the ability of fluorescent proteins to oligomerize, especially when they substitute an amino acid with an uncharged, nonpolar or non-polarizable side chain.

Similarly, monomers of other oligomerizing fluorescent proteins can also be prepared following a similar mutagenesis strategy, and are intended to be within the scope of the present invention.

10

Variant Anthozoan Fluorescent Proteins

It is contemplated that the mutagenesis methods provided by the present invention can be used to generate advantageous fluorescent protein variants that have reduced ability to oligomerize (*i.e.*, tetramerize), and also find uses analogous to the uses
15 of the *Discosoma* DsRed variant proteins. It is known in the art that the DsRed protein is a member of a family of highly related homologous proteins sharing high degrees of amino acid identity and protein structure (see, *e.g.*, Labas *et al.*, *Proc. Natl. Acad. Sci. USA* 99:4256-4261 [2002]; and Yanushevich *et al.*, *FEBS Letters* 511:11-14 [2002]). These alternative fluorescent proteins are additionally advantageous since they have the
20 ability to fluoresce at different wavelengths than does *Discosoma* DsRed. If dimeric or monomeric forms of these proteins can be produced, they will have great experimental potential as fluorescent markers.

Anthozoan species from which related fluorescent proteins have been identified include, but are not limited to, *Anemonia* sp., *Clavularia* sp., *Condylactis* sp., *Heteractis*
25 sp., *Renilla* sp., *Ptilosarcus* sp., *Zoonthus* sp., *Scolymia* sp., *Montastraea* sp., *Ricordea* sp., *Goniopara* sp., and others.

Fusion Proteins Comprising the Tandem Dimers and Monomers

Fluorescent proteins fused to target proteins can be prepared, for example using
30 recombinant DNA methods, and used as markers to identify the location and amount of the target protein produced. Accordingly, the present invention provides fusion proteins comprising a fluorescent protein variant moiety and a polypeptide of interest. The

polypeptide of interest can be of any length, for example, about 15 amino acid residues, about 50 residues, about 150 residues, or up to about 1000 amino acid residues or more, provided that the fluorescent protein component of the fusion protein can fluoresce or can be induced to fluoresce when exposed to electromagnetic radiation of the appropriate wavelength. The polypeptide of interest can be, for example, a peptide tag such as a polyhistidine sequence, a c-myc epitope, a FLAG epitope, and the like; can be an enzyme, which can be used to effect a function in a cell expressing a fusion protein comprising the enzyme or to identify a cell containing the fusion protein; can be a protein to be examined for an ability to interact with one or more other proteins in a cell, or any other protein as disclosed herein or otherwise desired.

As disclosed herein, the *Discosoma* (coral) red fluorescent protein, DsRed, can be used as a complement to or alternative for a GFP or spectral variant thereof. In particular, the invention encompasses fusion proteins of any of the tandem dimeric and monomeric DsRed fluorescent proteins discussed above, and variants thereof, which has altered spectral and/or fluorescent characteristics.

A fusion protein, which includes a fluorescent protein variant operatively linked to one or more polypeptides of interest also is provided. The polypeptides of the fusion protein can be linked through peptide bonds, or the fluorescent protein variant can be linked to the polypeptide of interest through a linker molecule. In one embodiment, the fusion protein is expressed from a recombinant nucleic acid molecule containing a polynucleotide encoding a fluorescent protein variant operatively linked to one or more polynucleotides encoding one or more polypeptides of interest.

A polypeptide of interest can be any polypeptide, including, for example, a peptide tag such as a polyhistidine peptide, or a cellular polypeptide such as an enzyme, a G-protein, a growth factor receptor, or a transcription factor; and can be one of two or more proteins that can associate to form a complex. In one embodiment, the fusion protein is a tandem fluorescent protein variant construct, which includes a donor fluorescent protein variant, an acceptor fluorescent protein variant, and a peptide linker moiety coupling said donor and said acceptor, wherein cyclized amino acids of the donor emit light characteristic of said donor, and wherein the donor and the acceptor exhibit fluorescence resonance energy transfer when the donor is excited, and the linker moiety does not substantially emit light to excite the donor. As such, a fusion protein of the

invention can include two or more operatively linked fluorescent protein variants, which can be linked directly or indirectly, and can further comprise one or more polypeptides of interest.

5 Preparation of DsRed Dimers and Monomers

The present invention also provides polynucleotides encoding fluorescent protein variants, where the protein can be a dimeric fluorescent protein, a tandem dimeric fluorescent protein, a monomeric protein, or a fusion protein comprising a fluorescent protein operatively linked to one or more polypeptides of interest. In the case of the
10 tandem dimer the entire dimer may be encoded by one polynucleotide molecule. If the linker is a non-peptide linker, the two subunits will be encoded by separate polynucleotide molecules, produced separately, and subsequently linked by methods known in the art.

The invention further concerns vectors containing such polynucleotides, and host
15 cell containing a polynucleotide or vector. Also provided is a recombinant nucleic acid molecule, which includes at least one polynucleotide encoding a fluorescent protein variant operatively linked to one or more other polynucleotides. The one or more other polynucleotides can be, for example, a transcription regulatory element such as a promoter or polyadenylation signal sequence, or a translation regulatory element such as
20 a ribosome binding site. Such a recombinant nucleic acid molecule can be contained in a vector, which can be an expression vector, and the nucleic acid molecule or the vector can be contained in a host cell.

The vector generally contains elements required for replication in a prokaryotic or eukaryotic host system or both, as desired. Such vectors, which include plasmid
25 vectors and viral vectors such as bacteriophage, baculovirus, retrovirus, lentivirus, adenovirus, vaccinia virus, semliki forest virus and adeno-associated virus vectors, are well known and can be purchased from a commercial source (Promega, Madison WI; Stratagene, La Jolla CA; GIBCO/BRL, Gaithersburg MD) or can be constructed by one skilled in the art (see, for example, Meth. Enzymol., Vol. 185, Goeddel, ed. (Academic
30 Press, Inc., 1990); Jolly, Canc. Gene Ther. 1:51-64, 1994; Flotte, J. Bioenerg. Biomemb. 25:37-42, 1993; Kirshenbaum et al., J. Clin. Invest. 92:381-387, 1993; each of which is incorporated herein by reference).

A vector for containing a polynucleotide encoding a fluorescent protein variant can be a cloning vector or an expression vector, and can be a plasmid vector, viral vector, and the like. Generally, the vector contains a selectable marker independent of that encoded by a polynucleotide of the invention, and further can contain transcription or translation regulatory elements, including a promoter sequence, which can provide tissue specific expression of a polynucleotide operatively linked thereto, which can, but need not, be the polynucleotide encoding the fluorescent protein variant, for example, a tandem dimer fluorescent protein, thus providing a means to select a particular cell type from among a mixed population of cells containing the introduced vector and recombinant nucleic acid molecule contained therein.

Where the vector is a viral vector, it can be selected based on its ability to infect one or few specific cell types with relatively high efficiency. For example, the viral vector also can be derived from a virus that infects particular cells of an organism of interest, for example, vertebrate host cells such as mammalian host cells. Viral vectors have been developed for use in particular host systems, particularly mammalian systems and include, for example, retroviral vectors, other lentivirus vectors such as those based on the human immunodeficiency virus (HIV), adenovirus vectors, adeno-associated virus vectors, herpesvirus vectors, vaccinia virus vectors, and the like (see Miller and Rosman, BioTechniques 7:980-990, 1992; Anderson et al., Nature 392:25-30 Suppl., 1998; Verma and Somia, Nature 389:239-242, 1997; Wilson, New Engl. J. Med. 334:1185-1187 (1996), each of which is incorporated herein by reference).

Recombinant production of a fluorescent protein variant, which can be a component of a fusion protein, involves expressing a polypeptide encoded by a polynucleotide. A polynucleotide encoding the fluorescent protein variant is a useful starting material. Polynucleotides encoding fluorescent protein are disclosed herein or otherwise known in the art, and can be obtained using routine methods, then can be modified such that the encoded fluorescent protein lacks a propensity to oligomerize. For example, a polynucleotide encoding a GFP can be isolated by PCR of cDNA from *A. victoria* using primers based on the DNA sequence of *Aequorea* GFP (SEQ ID NO: 21). A polynucleotide encoding the red fluorescent protein from *Discosoma* (DsRed) can be similarly isolated by PCR of CDNA of the *Discosoma* coral, or obtained from the commercially available DsRed2 or HcRed1 (CLONTECH). PCR methods are well

known and routine in the art (see, for example, U.S. Pat. No. 4,683,195; Mullis et al., Cold Spring Harbor Symp. Quant. Biol. 51:263, 1987; Erlich, ed., "PCR Technology" (Stockton Press, NY, 1989)). A variant form of the fluorescent protein then can be made by site-specific mutagenesis of the polynucleotide encoding the fluorescent protein.

5 Similarly, a tandem dimer fluorescent protein can be expressed from a polynucleotide prepared by PCR or obtained otherwise, using primers that can encode, for example, a peptide linker, which operatively links a first monomer and at least a second monomer of a fluorescent protein.

The construction of expression vectors and the expression of a polynucleotide in
10 transfected cells involves the use of molecular cloning techniques also well known in the art (see Sambrook et al., In "Molecular Cloning: A Laboratory Manual" (Cold Spring Harbor Laboratory Press 1989); "Current Protocols in Molecular Biology" (eds., Ausubel et al.; Greene Publishing Associates, Inc., and John Wiley & Sons, Inc. 1990 and supplements). Expression vectors contain expression control sequences operatively
15 linked to a polynucleotide sequence of interest, for example, that encodes a fluorescent protein variant, as indicated above. The expression vector can be adapted for function in prokaryotes or eukaryotes by inclusion of appropriate promoters, replication sequences, markers, and the like. An expression vector can be transfected into a recombinant host cell for expression of a fluorescent protein variant, and host cells can be selected, for
20 example, for high levels of expression in order to obtain a large amount of isolated protein. A host cell can be maintained in cell culture, or can be a cell *in vivo* in an organism. A fluorescent protein variant can be produced by expression from a polynucleotide encoding the protein in a host cell such as *E. coli*. *Aequorea* GFP-related fluorescent proteins, for example, are best expressed by cells cultured between about
25 15°C. and 30°C, although higher temperatures such as 37°C can be used. After synthesis, the fluorescent proteins are stable at higher temperatures and can be used in assays at such temperatures.

An expressed fluorescent protein variant, which can be a tandem dimer fluorescent protein or a non-oligomerizing monomer, can be operatively linked to a first
30 polypeptide of interest, further can be linked to a second polypeptide of interest, for example, a peptide tag, which can be used to facilitate isolation of the fluorescent protein variant, including any other polypeptides linked thereto. For example, a polyhistidine

tag containing, for example, six histidine residues, can be incorporated at the N-terminus or C-terminus of the fluorescent protein variant, which then can be isolated in a single step using nickel-chelate chromatography. Additional peptide tags, including a c-myc peptide, a FLAG epitope, or any ligand (or cognate receptor), including any peptide epitope (or antibody, or antigen binding fragment thereof, that specifically binds the epitope are well known in the art and similarly can be used. (see, for example, Hopp et al., Biotechnology 6:1204 (1988); U.S. Pat. No. 5,011,912, each of which is incorporated herein by reference).

10 Kits of the Invention

The present invention also provides kits to facilitate and/or standardize use of compositions provided by the present invention, as well as facilitate the methods of the present invention. Materials and reagents to carry out these various methods can be provided in kits to facilitate execution of the methods. As used herein, the term "kit" is used in reference to a combination of articles that facilitate a process, assay, analysis or manipulation.

Kits can contain chemical reagents (*e.g.*, polypeptides or polynucleotides) as well as other components. In addition, kits of the present invention can also include, for example but not limited to, apparatus and reagents for sample collection and/or purification, apparatus and reagents for product collection and/or purification, reagents for bacterial cell transformation, reagents for eukaryotic cell transfection, previously transformed or transfected host cells, sample tubes, holders, trays, racks, dishes, plates, instructions to the kit user, solutions, buffers or other chemical reagents, suitable samples to be used for standardization, normalization, and/or control samples. Kits of the present invention can also be packaged for convenient storage and safe shipping, for example, in a box having a lid.

In some embodiments, for example, kits of the present invention can provide a fluorescent protein of the invention, a polynucleotide vector (*e.g.*, a plasmid) encoding a fluorescent protein of the invention, bacterial cell strains suitable for propagating the vector, and reagents for purification of expressed fusion proteins. Alternatively, a kit of the present invention can provide the reagents necessary to conduct mutagenesis of an

Anthozoan fluorescent protein in order to generate a protein variant having a reduced propensity to oligomerize.

A kit can contain one or more compositions of the invention, for example, one or a plurality of fluorescent protein variants, which can be a portion of a fusion protein, or
5 one or a plurality of polynucleotides that encode the polypeptides. The fluorescent protein variant can be a mutated fluorescent protein having a reduced propensity to oligomerize, such as a non-oligomerizing monomer, or can be a tandem dimer fluorescent protein and, where the kit comprises a plurality of fluorescent protein variants, the plurality can be a plurality of the mutated fluorescent protein variants, or of
10 the tandem dimer fluorescent proteins, or a combination thereof.

A kit of the invention also can contain one or a plurality of recombinant nucleic acid molecules, which encode, in part, fluorescent protein variants, which can be the same or different, and can further include, for example, an operatively linked second polynucleotide containing or encoding a restriction endonuclease recognition site or a
15 recombinase recognition site, or any polypeptide of interest. In addition, the kit can contain instructions for using the components of the kit, particularly the compositions of the invention that are contained in the kit.

Such kits can be particularly useful where they provide a plurality of different fluorescent protein variants because the artisan can conveniently select one or more
20 proteins having the fluorescent properties desired for a particular application. Similarly, a kit containing a plurality of polynucleotides encoding different fluorescent protein variants provides numerous advantages. For example, the polynucleotides can be engineered to contain convenient restriction endonuclease or recombinase recognition sites, thus facilitating operative linkage of the polynucleotide to a regulatory element or
25 to a polynucleotide encoding a polypeptide of interest or, if desired, for operatively linking two or more the polynucleotides encoding the fluorescent protein variants to each other.

Uses of Fluorescent Protein Variants

30 A fluorescent protein variant having features of the invention is useful in any method that employs a fluorescent protein. Thus, the fluorescent protein variants, including the monomeric, dimeric, and tandem dimer fluorescent proteins, are useful as

fluorescent markers in the many ways fluorescent markers already are used, including, for example, coupling fluorescent protein variants to antibodies, polynucleotides or other receptors for use in detection assays such as immunoassays or hybridization assays, or to track the movement of proteins in cells. For intracellular tracking studies, a first (or
5 other) polynucleotide encoding the fluorescent protein variant is fused to a second (or other) polynucleotide encoding a protein of interest and the construct, if desired, can be inserted into an expression vector. Upon expression inside the cell, the protein of interest can be localized based on fluorescence, without concern that localization of the protein is an artifact caused by oligomerization of the fluorescent protein component of
10 the fusion protein. In one embodiment of this method, two proteins of interest independently are fused with two fluorescent protein variants that have different fluorescent characteristics.

Fluorescent protein variants having features of the invention are useful in systems to detect induction of transcription. For example, a nucleotide sequence encoding a
15 non-oligomerizing monomeric, dimeric or tandem dimeric fluorescent protein can be fused to a promoter or other expression control sequence of interest, which can be contained in an expression vector, the construct can be transfected into a cell, and induction of the promoter (or other regulatory element) can be measured by detecting the presence or amount of fluorescence, thereby allowing a means to observe the
20 responsiveness of a signaling pathway from receptor to promoter.

A fluorescent protein variant of the invention also is useful in applications involving FRET, which can detect events as a function of the movement of fluorescent donors and acceptors towards or away from each other. One or both of the donor/acceptor pair can be a fluorescent protein variant. Such a donor/acceptor pair
25 provides a wide separation between the excitation and emission peaks of the donor, and provides good overlap between the donor emission spectrum and the acceptor excitation spectrum. Variant red fluorescent proteins or red-shifted mutants as disclosed herein are specifically disclosed as the acceptor in such a pair.

FRET can be used to detect cleavage of a substrate having the donor and acceptor
30 coupled to the substrate on opposite sides of the cleavage site. Upon cleavage of the substrate, the donor/acceptor pair physically separate, eliminating FRET. Such an assay can be performed, for example, by contacting the substrate with a sample, and

determining a qualitative or quantitative change in FRET (see, for example, U.S. Pat. No. 5,741,657, which is incorporated herein by reference). A fluorescent protein variant donor/acceptor pair also can be part of a fusion protein coupled by a peptide having a proteolytic cleavage site (see, for example, U.S. Pat. No. 5,981,200, which is incorporated herein by reference). FRET also can be used to detect changes in potential across a membrane. For example, a donor and acceptor can be placed on opposite sides of a membrane such that one translates across the membrane in response to a voltage change, thereby producing a measurable FRET (see, for example, U.S. Pat. No. 5,661,035, which is incorporated herein by reference).

10 In other embodiments, a fluorescent protein of the invention is useful for making fluorescent sensors for protein kinase and phosphatase activities or indicators for small ions and molecules such as Ca^{2+} , Zn^{2+} , cyclic 3', 5'-adenosine monophosphate, and cyclic 3', 5'-guanosine monophosphate.

Fluorescence in a sample generally is measured using a fluorimeter, wherein
15 excitation radiation from an excitation source having a first wavelength, passes through excitation optics, which cause the excitation radiation to excite the sample. In response, a fluorescent protein variant in the sample emits radiation having a wavelength that is different from the excitation wavelength. Collection optics then collect the emission from the sample. The device can include a temperature controller to maintain the sample
20 at a specific temperature while it is being scanned, and can have a multi-axis translation stage, which moves a microtiter plate holding a plurality of samples in order to position different wells to be exposed. The multi-axis translation stage, temperature controller, auto-focusing feature, and electronics associated with imaging and data collection can be managed by an appropriately programmed digital computer, which also can transform
25 the data collected during the assay into another format for presentation. This process can be miniaturized and automated to enable screening many thousands of compounds in a high throughput format. These and other methods of performing assays on fluorescent materials are well known in the art (see, for example, Lakowicz, "Principles of Fluorescence Spectroscopy" (Plenum Press 1983); Herman, "Resonance energy transfer microscopy" In "Fluorescence Microscopy of Living Cells in Culture" Part B, Meth. Cell Biol. 30:219-243 (ed. Taylor and Wang; Academic Press 1989); Turro, "Modern
30

Molecular Photochemistry" (Benjamin/ Cummings Publ. Co., Inc. 1978), pp. 296-361, each of which is incorporated herein by reference).

Accordingly, the present invention provides a method for identifying the presence of a molecule in a sample. Such a method can be performed, for example, by linking a
5 fluorescent protein variant of the invention to the molecule, and detecting fluorescence due to the fluorescent protein variant in a sample suspected of containing the molecule. The molecule to be detected can be a polypeptide, a polynucleotide, or any other molecule, including, for example, an antibody, an enzyme, or a receptor, and the fluorescent protein variant can be a tandem dimer fluorescent protein.

10 The sample to be examined can be any sample, including a biological sample, an environmental sample, or any other sample for which it is desired to determine whether a particular molecule is present therein. Preferably, the sample includes a cell or an extract thereof. The cell can be obtained from a vertebrate, including a mammal such as a human, or from an invertebrate, and can be a cell from a plant or an animal. The cell can
15 be obtained from a culture of such cells, for example, a cell line, or can be isolated from an organism. As such, the cell can be contained in a tissue sample, which can be obtained from an organism by any means commonly used to obtain a tissue sample, for example, by biopsy of a human. Where the method is performed using an intact living cell or a freshly isolated tissue or organ sample, the presence of a molecule of interest in
20 living cells can be identified, thus providing a means to determine, for example, the intracellular compartmentalization of the molecule. The use of the fluorescent protein variants of the invention for such a purpose provides a substantial advantage in that the likelihood of aberrant identification or localization due to oligomerization the fluorescent protein is greatly minimized.

25 A fluorescent protein variant can be linked to the molecule directly or indirectly, using any linkage that is stable under the conditions to which the protein-molecule complex is to be exposed. Thus, the fluorescent protein and molecule can be linked via a chemical reaction between reactive groups present on the protein and molecule, or the linkage can be mediated by linker moiety, which contains reactive groups specific for the
30 fluorescent protein and the molecule. It will be recognized that the appropriate conditions for linking the fluorescent protein variant and the molecule are selected depending, for example, on the chemical nature of the molecule and the type of linkage

desired. Where the molecule of interest is a polypeptide, a convenient means for linking a fluorescent protein variant and the molecule is by expressing them as a fusion protein from a recombinant nucleic acid molecule, which comprises a polynucleotide encoding, for example, a tandem dimer fluorescent protein operatively linked to a polynucleotide encoding the polypeptide molecule.

A method of identifying an agent or condition that regulates the activity of an expression control sequence also is provided. Such a method can be performed, for example, by exposing a recombinant nucleic acid molecule, which includes a polynucleotide encoding a fluorescent protein variant operatively linked to an expression control sequence, to an agent or condition suspected of being able to regulate expression of a polynucleotide from the expression control sequence, and detecting fluorescence of the fluorescent protein variant due to such exposure. Such a method is useful, for example, for identifying chemical or biological agents, including cellular proteins, that can regulate expression from the expression control sequence, including cellular factors involved in the tissue specific expression from the regulatory element. As such, the expression control sequence can be a transcription regulatory element such as a promoter, enhancer, silencer, intron splicing recognition site, polyadenylation site, or the like; or a translation regulatory element such as a ribosome binding site.

Fluorescent protein variants having features the invention also are useful in a method of identifying a specific interaction of a first molecule and a second molecule. Such a method can be performed, for example, by contacting the first molecule, which is linked to a donor first fluorescent protein variant, and the second molecule, which is linked to an acceptor second fluorescent protein variant, under conditions that allow a specific interaction of the first molecule and second molecule; exciting the donor; and detecting fluorescence or luminescence resonance energy transfer from the donor to the acceptor, thereby identifying a specific interaction of the first molecule and the second molecule. The conditions for such an interaction can be any conditions under which is expected or suspected that the molecules can specifically interact. In particular, where the molecules to be examined are cellular molecules, the conditions generally are physiological conditions. As such, the method can be performed *in vitro* using conditions of buffer, pH, ionic strength, and the like, that mimic physiological conditions, or the method can be performed in a cell or using a cell extract.

Luminescence resonance energy transfer entails energy transfer from a chemiluminescent, bioluminescent, lanthanide, or transition metal donor to the red fluorescent protein moiety. The longer wavelengths of excitation of red fluorescent proteins permit energy transfer from a greater variety of donors and over greater distances than possible with green fluorescent protein variants. Also, the longer wavelengths of emission is more efficiently detected by solid-state photodetectors and is particularly valuable for *in vivo* applications where red light penetrates tissue far better than shorter wavelengths. Chemiluminescent donors include but are not limited to luminol derivatives and peroxyoxalate systems. Bioluminescent donors include but are not limited to aequorin, obelin, firefly luciferase, *Renilla* luciferase, bacterial luciferase, and variants thereof. Lanthanide donors include but are not limited to terbium chelates containing ultraviolet-absorbing sensitizer chromophores linked to multiple liganding groups to shield the metal ion from solvent water. Transition metal donors include but are not limited to ruthenium and osmium chelates of oligopyridine ligands. Chemiluminescent and bioluminescent donors need no excitation light but are energized by addition of substrates, whereas the metal-based systems need excitation light but offer longer excited state lifetimes, facilitating time-gated detection to discriminate against unwanted background fluorescence and scattering.

The first and second molecules can be cellular proteins that are being investigated to determine whether the proteins specifically interact, or to confirm such an interaction. Such first and second cellular proteins can be the same, where they are being examined, for example, for an ability to oligomerize, or they can be different where the proteins are being examined as specific binding partners involved, for example, in an intracellular pathway. The first and second molecules also can be a polynucleotide and a polypeptide, for example, a polynucleotide known or to be examined for transcription regulatory element activity and a polypeptide known or being tested for transcription factor activity. For example, the first molecule can comprise a plurality of nucleotide sequences, which can be random or can be variants of a known sequence, that are to be tested for transcription regulatory element activity, and the second molecule can be a transcription factor, such a method being useful for identifying novel transcription regulatory elements having desirable activities.

The present invention also provides a method for determining whether a sample contains an enzyme. Such a method can be performed, for example, by contacting a sample with a tandem fluorescent protein variant of the invention; exciting the donor, and determining a fluorescence property in the sample, wherein the presence of an enzyme in the sample results in a change in the degree of fluorescence resonance energy transfer. Similarly, the present invention relates to a method for determining the activity of an enzyme in a cell. Such a method can be performed, for example, providing a cell that expresses a tandem fluorescent protein variant construct, wherein the peptide linker moiety comprises a cleavage recognition amino acid sequence specific for the enzyme coupling the donor and the acceptor; exciting said donor, and determining the degree of fluorescence resonance energy transfer in the cell, wherein the presence of enzyme activity in the cell results in a change in the degree of fluorescence resonance energy transfer.

Also provided is a method for determining the pH of a sample. Such a method can be performed, for example, by contacting the sample with a first fluorescent protein variant, which can be a tandem dimer fluorescent protein, wherein the emission intensity of the first fluorescent protein variant changes as pH varies between pH 5 and pH 10; exciting the indicator; and determining the intensity of light emitted by the first fluorescent protein variant at a first wavelength, wherein the emission intensity of the first fluorescent protein variant indicates the pH of the sample. The first fluorescent protein variant useful in this method, or in any method of the invention, can comprise two DsRed monomers as set forth in SEQ ID NO: 8. It will be recognized that such fluorescent protein variants similarly are useful, either alone or in combination, for the variously disclosed methods of the invention.

The sample used in a method for determining the pH of a sample can be any sample, including, for example, a biological tissue sample, or a cell or a fraction thereof. In addition, the method can further include contacting the sample with a second fluorescent protein variant, wherein the emission intensity of the second fluorescent protein variant changes as pH varies from 5 to 10, and wherein the second fluorescent protein variant emits at a second wavelength that is distinct from the first wavelength; exciting the second fluorescent protein variant; determining the intensity of light emitted by the second fluorescent protein variant at the second wavelength; and comparing the

fluorescence at the second wavelength to the fluorescence at the first wavelength. The first (or second) fluorescent protein variant can include a targeting sequence, for example, a cell compartmentalization domain such a domain that targets the fluorescent protein variant in a cell to the cytosol, the endoplasmic reticulum, the mitochondrial matrix, the chloroplast lumen, the medial trans-Golgi cisternae, a lumen of a lysosome, or a lumen of an endosome. For example, the cell compartmentalization domain can include amino acid residues 1 to 81 of human type II membrane-anchored protein galactosyltransferase, or amino acid residues 1 to 12 of the presequence of subunit IV of cytochrome c oxidase.

The following Examples are provided to further illustrate certain embodiments and aspects of the present invention. It is not intended that these Examples should limit the scope of any aspect of the invention. Although specific reaction conditions and reagents are described, it is clear that one familiar with the art would recognize alternative or equivalent conditions that also find use with the invention, where the alternative or equivalent conditions do not depart from the scope of the invention.

Example 1

Construction of Dimeric and Monomeric Red Fluorescent Proteins

MATERIALS AND METHODS

DsRed Mutagenesis and Screening

The DsRed gene was amplified from vector pDsRed-N1 (CLONTECH, Palo Alto, CA) or the T1 variant (provided by B.S. Glick, University of Chicago) and subcloned into pRSET_B (Invitrogen™; see Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 97:11984-11989 [2000]) (4). The pRSET_B vector produces 6xHis tagged fusion proteins, where an N-terminal polyhistidine tag having the following sequence is coupled to the suitably subcloned sequence.

MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDP (SEQ ID NO: 22)

This resulting construct was used as the template for introduction of the I125R mutant using the QuikChange™ Site Directed Mutagenesis Kit (Stratagene®), according to the manufacturer's instructions. The complete DsRed wild-type cDNA and polypeptide sequences are provided in GenBank Accession Number AF168419. This

nucleotide sequence is also provided in FIG. 16 and SEQ ID NO: 2. A variation of this nucleotide sequence is also known (Clontech), where various nucleotide positions been amended to accommodate mammalian codon usage utilization preferences. This nucleotide sequence is provided in FIG. 25 and SEQ ID NO: 23. The corresponding polypeptide encoded by both of these nucleotide sequences is provided in FIG. 17 and SEQ ID NO: 1.

Similarly, the DsRed T1 variant cDNA nucleotide sequence is provided in FIG. 18 and SEQ ID NO: 5. The corresponding polypeptide is provided in FIG. 19 and SEQ ID NO: 4.

As used herein, the numbering of DsRed amino acids conforms to the wild-type sequence of GFP, in which residues 66-68 of wild-type DsRed (Gln-Tyr-Gly) are homologous to the chromophore-forming residues 65-67 of GFP (Ser-Tyr-Gly). The amino-terminal polyhistidine tag is numbered -33 to -1.

Error-prone PCR Mutagenesis - Error prone PCR was performed essentially as described in Griesbeck *et al.* (*J. Biol. Chem.*, 276:29188-29194 [2001]). Briefly, the cDNA encoding DsRed in the vector pRSET_B (Invitrogen™) was subjected to error-prone PCR using *Taq* DNA polymerase. The 5' primer included a *Bam*HI site and ended at the starting Met of the DsRed, and the 3' primer included an *Eco*RI site and ended at the stop codon, theoretically allowing mutagenesis of every base of DsRed open reading frame, except for the initiator methionine. The PCR reactions (38 cycles with annealing at 55°C) were run in four 100 µL batches, each containing 10 µL of 10× PCR buffer with Mg²⁺ (Roche Molecular Biochemicals), 150 µM Mn²⁺, 250 µM of three nucleotides, 50 µM of the remaining nucleotide, and 5 ng of template DNA.

Mutagenized PCR products were combined, purified by agarose gel electrophoresis, digested with *Bam*HI and *Eco*RI, and isolated by QIAGEN® QIAquick™ DNA purification spin column following the manufacturer's instructions. The resulting fragments were ligated into pRSET_B, and the crude ligation mixture was transformed into *E. coli* BL21(DE3) Gold (Stratagene®) by electroporation.

Overlap Extension PCR Mutagenesis - Semi-random mutations at multiple distant locations were introduced by overlap extension PCR with multiple fragments essentially as described in Ho *et al.*, *Gene* 77:51-59 (1989). Briefly, two to four pairs of sense and antisense oligonucleotide primers (Invitrogen™ or GenBase), with semi-

degenerate codons at positions of interest, were used for PCR amplification of the DsRed template with *Pfu* DNA polymerase (Stratagene®) in individual reactions. The resulting overlapping fragments were gel purified using QIAGEN® gel extraction kit and recombined by overlap extension PCR with *Pfu* or *Taq* DNA polymerase (Roche).

5 Full length genes were digested with *Bam*HI/*Eco*RI (New England BioLabs®) and ligated into pRSET_B with T4 ligase (New England BioLabs®). Chemically competent *E. coli* JM109(DE3) were transformed and grown on LB/agar at 37°C.

Bacterial Fluorescence Screening - Bacteria plated on LB/agar plates were screened essentially as described in Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 96:11241-10 11246 (1999). Briefly, the bacterial plates were illuminated with a 150-W Xe lamp using 470 nm (40 nm bandwidth), 540 nm (30 nm bandwidth), or 560 nm (40 nm bandwidth) excitation filters and 530 nm (40 nm bandwidth), 575 nm (long pass), or 610 nm (long pass) emission filters. Fluorescence was imaged by a cooled charge-coupled device camera (Sensys Photometrics, Tucson, AZ) and were processed using Metamorph 15 software (Universal Imaging, West Chester, PA).

Fluorescent colonies of interest were cultured overnight in 2 ml of LB supplemented with ampicillin. Bacteria were pelleted by centrifugation and imaged again to ensure that the protein was expressed well in culture. For fast maturing proteins a fraction of the cell pellet was extracted with B-per II (Pierce) and complete spectra 20 obtained. DNA was purified from the remaining pellet by QIAGEN® QIAprep® plasmid isolation spin column according to the manufacturer's instructions and submitted for DNA sequencing. To determine the oligomeric state of DsRed mutants, a single colony of *E. coli* was restreaked on LB/agar and allowed to mature at room temperature. After 2 days to 2 weeks the bacteria were scraped from the plate, extracted with B-per II, 25 analyzed (not boiled) by SDS-PAGE (BioRad), and the gel imaged with a digital camera.

Bacterial Transformations and DsRed Protein Purification

Ligation mixtures were transformed into *Escherichia coli* BL21(DE3) Gold (Stratagene) by electroporation in 10% glycerol with a ligation mixture (0.1 cm cuvette, 30 12.5 kV/cm, 200Ω, 25 μF).

Protein was expressed and purified essentially as described in Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 96:11241-11246 (1999). Briefly, when cultured for protein

expression, transformed bacteria were grown to an OD₆₀₀ of 0.6 in LB containing 100 mg/liter ampicillin, at which time they were induced with 1 mM isopropyl β -D-thiogalactoside. Bacteria were allowed to express recombinant protein for 6 hr at room temperature and then overnight at 4°C. The bacteria then were pelleted by centrifugation, resuspended in 50 mM Tris·HCl/300 mM NaCl, and lysed by a French press. The bacterial lysates were centrifuged at 30,000 $\times g$ for 30 min, and the proteins were purified from the supernatants using Ni-NTA resin (QIAGEN®).

Spectroscopy of purified protein was typically performed in 100 mM KCl, 10 mM MOPS, pH 7.25, in a fluorescence spectrometer (Fluorolog-2, Spex Industries). All DNA sequencing was performed by the Molecular Pathology Shared Resource, University of California, San Diego, Cancer Center.

Construction of DsRed Tandem Dimers and Constructs for Mammalian Cell Expression, including Chimeric Constructs

To construct tandem dimers of DsRed protein, dimer2 in pRSET_B was amplified in two separate PCR reactions. In the first reaction, the 5' *Bam*HI and a 3' *Sph*I site were introduced while in the second reaction a 5' *Sac*I and a 3' *Eco*RI site were introduced. The construct was assembled in a 4-part ligation containing the digested dimer2 genes, a synthetic linker with phosphorylated sticky ends, and digested pRSET_B. Four different linkers were used, which encoded polypeptides of various lengths. These were:

Linker	Polypeptide Sequence	SEQ ID NO
9 a.a. residue linker	RMGTGSGQL	16
12 a.a. residue linker	GHGTGSTGSGSS	17
13 a.a. residue linker	RMGSTSGSTKGQL	18
22 a.a. residue linker	RMGSTSGSGKPGSGEGSTKGQL	19

For expression in mammalian cells, DsRed variants were amplified from pRSET_B with a 5' primer that encoded a *Kpn*I restriction site and a Kozak sequence. The PCR product was digested, ligated into pcDNA3, and used to transform *E. coli* DH5 α .

A gene encoding a chimeric fusion polypeptide comprising DsRed and connexin43 (Cx43) was constructed. To produce these fusions, Cx43 was first amplified

with a 3' primer encoding a seven-residue linker ending in a *Bam*HI site. The construct was assembled in a 3-part ligation containing *Kpn*I/*Bam*HI digested Cx43, *Bam*HI/*Eco*RI digested enhanced GFP, and digested pcDNA3. For all other fusion proteins (Cx43-T1, -dimer2, -tdimer2(12) and -mRFP1) the gene for the fluorescent protein was ligated into the *Bam*HI/*Eco*RI digested Cx43-GFP vector.

DsRed Protein Variant Production and Characterization

DsRed variants were expressed essentially as described in Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 96:11241-11246 (1999). All proteins were purified by Ni-NTA chromatography (QIAGEN®) according to the manufacturer's instructions and dialyzed into 10 mM Tris, pH 7.5 or phosphate buffered saline supplemented with 1 mM EDTA. All biochemical characterization experiments were performed essentially as described in Baird *et al.*, *Proc. Natl. Acad. Sci. USA* 97:11984-11989 (2000).

The maturation time courses were determined on a Safire 96 well plate reader with monochromators (TECAN, Austria). All photobleaching measurements were performed in microdroplets under paraffin oil with a Zeiss Axiovert 35 fluorescence microscope equipped with a 40× objective and a 540 nm (25 nm bandpass) excitation filter that delivered 4.5 W/cm² of light.

Analytical Ultracentrifugation - Purified, recombinant DsRed was dialyzed extensively against PBS, pH 7.4 or 10 mM Tris, 1 mM EDTA, pH 7.5. Sedimentation equilibrium experiments were performed on a Beckman Optima XL-I analytical ultracentrifuge at 20°C measuring absorbance at 558 nm as a function of radius. Samples of DsRed were normalized to 3.57 μM (0.25 absorbance units), and from this, 125 μL aliquots were loaded into six channel cells. The data were analyzed globally at 10K, 14K, and 20K rpm by nonlinear least-squares analysis using the ORIGIN software package supplied by Beckman. The goodness of fit was evaluated on the basis of the magnitude and randomness of the residuals, expressed as the difference between the experimental data and the theoretical curve and also by checking each of the fit parameters for physical reasonability.

Absorption/Fluorescence Spectra and Extinction Coefficients - Fluorescence spectra were taken with a Fluorolog spectrofluorimeter (Spex Industries, Edison, NJ). Absorbance spectra of proteins were taken with a Cary UV-Vis spectrophotometer. For

quantum yield determination, the fluorescence of a solution of DsRed or DsRed variant in PBS was compared with equally absorbing solutions of rhodamine B and rhodamine 101 in ethanol. Corrections were included in the quantum yield calculation for the refractive index difference between ethanol and water. For extinction coefficient determination, native protein absorbance was measured with the spectrophotometer, and protein concentration was measured by the BCA method (Pierce).

Mammalian Cell Imaging and Microinjection

HeLa cells were transfected with DsRed variants or Cx43-DsRed fusions in pcDNA3 through the use of Eugene 6 transfection reagent (Roche). Transfected cells were grown for 12 hours to 2 days in DMEM at 37°C before imaging using a Zeiss Axiovert 35 fluorescence microscope with cells in glucose-supplemented HBSS at room temperature. Individual cells expressing Cx43 fused to a DsRed variant, or contacting non-transfected cells for control experiments, were microinjected with a 2.5% solution of lucifer yellow (Molecular Probes, Eugene, OR). Images were acquired and processed with the Metafluor software package (Universal Imaging, West Chester, PA).

RESULTS

Stepwise Evolution of DsRed Molecules

The present invention provides methods for the stepwise evolution of tetrameric DsRed to a dimer and then either to a genetic fusion of two copies of the protein, *i.e.*, a tandem dimer, or to a true monomer designated mRFP1. Each subunit interface was disrupted by insertion of arginines, which initially crippled the resulting protein, but red fluorescence could be rescued by random and directed mutagenesis totaling 17 substitutions in the dimer and 33 substitutions in mRFP1. Fusions of the gap junction protein connexin43 to mRFP1 formed fully functional junctions, whereas analogous fusions to the tetramer and dimer failed. Although mRFP1 has somewhat lower extinction coefficient, quantum yield, and photostability than DsRed, mRFP1 matures >10× faster, so that it shows similar brightness in living cells. In addition, the excitation and emission peaks of mRFP1, 584 and 607 nm, are ~25 nm red shifted from DsRed, which should confer greater tissue penetration and spectral separation from autofluorescence and other fluorescent proteins.

The consensus view is that a monomeric form of DsRed will be essential if it is to ever reach its full potential as a genetically encoded red fluorescent tag (Remington, *Nat. Biotechnol.*, 20:28-29 [2002]). The present invention provides a directed evolution and preliminary characterization of the first monomeric red fluorescent protein. The present invention provides an independent alternative to GFP in the construction of fluorescently tagged fusion proteins.

Directed and Random Evolution of a Dimer of DsRed

The basic strategy for decreasing the oligomeric state of DsRed was to replace key hydrophobic residues at the dimer interface by charged residues such as arginine. The high energetic cost of burying a charged residue within a nonpolar hydrophobic interface or of placing two positive charges in close proximity should disrupt the interaction. Initial attempts to break apart the DsRed AC interface (see FIG. 2A) with the single mutations T147R, H162R, and F224R, consistently gave non-fluorescent proteins. The AB interface however, proved somewhat less resilient and could be broken with the single mutation I125R to give a poorly red fluorescent dimer that suffered from an increased green component and required more than 10 days to fully mature.

To reconstitute the red fluorescence of DsRed-I125R, the protein was subjected to iterative cycles of evolution. This accelerated evolution strategy used either random mutagenesis or semi-directed mutagenesis to create a library of mutated molecules, which can be screened for desirable characteristics. The directed evolution strategy of the present invention is shown in FIG. 7. Each cycle of the mutagenesis began with random mutagenesis to identify those positions that effected either the maturation or brightness of the red fluorescent protein. Once several residues were identified, expanded libraries were constructed in which several of these key positions were simultaneously mutated to a number of substitutions (see FIGS. 10-12). These directed libraries combine the benefits of shuffling of improved mutant genes with an efficient method of overcoming the limited number of substitutions accessible during random mutagenesis by error prone PCR. Most methods of *in vitro* recombination rely on random gene fragmentation. In contrast, the methods of the present invention use PCR to generate designed fragments that can be reassembled to give the full length shuffled gene.

Libraries of mutant red fluorescent proteins were screened in colonies of *E. coli* and were evaluated on both the magnitude of their red fluorescence under direct excitation at 540 nm and the ratio of emission intensities at 540 nm over 470 nm excitation. While the former constraint selected for very bright or fast maturing mutants, the latter constraint selected for mutants with decreased 470 nm excitation or red-shifted excitation spectra. Multiple cycles of random mutagenesis were used to find sequence locations that affected the maturation and brightness of the protein, and then expanded libraries of mutations at those positions were created and recombined to find optimal permutations.

Initial random mutagenesis of DsRed-I125R identified several beneficial mutations including K163Q or M, S179T and T217S. These three positions were included in our first directed library in which a total of seven residues were simultaneously mutated to a number of reasonable substitutions. The additional positions targeted in the first directed library included N42 and V44, residues that are critical for the fast phenotype of T1 (Bevis and Glick, *Nat. Biotechnol.*, 20:83-87 [2002]). Also included were I161 and S197, positions at which specific mutations contributed to the modest improvements of DsRed2 (CLONTECH) and the very similar 'E57' (Terskikh *et al.*, *J. Biol. Chem.*, 277:7633-7636 [2002]). From this library, several clones were identified such as DsRed-I125R, S179T, T217A and DsRed-I125R, K163Q, T217A, but improvements were not dramatic.

As an alternative strategy, the DsRed variant fast tetramer T1 (Bevis and Glick, *Nat. Biotechnol.*, 20:83-87 [2002]) was also studied. Introduction of the I125R mutation into this protein (T1 DsRed-I125R polypeptide sequence provided in SEQ ID NO: 24) resulted in a dimer that matured in only a few days, which was comparable to the best DsRed dimers produced at that time. By further targeting those positions that had helped rescue DsRed-I125R, dramatic improvements in our first generation library were observed.

A similar directed mutagenesis strategy starting from T1-I125R (see FIG. 10A, library D1) was undertaken and eventually identified dimer1. Dimer1 was somewhat better than wt DsRed both in terms of brightness and rate of maturation but had a substantial green peak equivalent to that of T1. Dimer1 was also somewhat blue-shifted with an excitation maximum at 551 nm and an emission maximum at 579 nm. Error

prone PCR on dimer1 (FIG. 10A, library D2) resulted in the discovery of dimer1.02 containing the mutation V71A in the hydrophobic core of the protein and effectively no green component in the excitation spectra. A second round of random mutagenesis (FIG. 10A, library D3) identified the mutations K70R which further decreased the green excitation, S197A which red-shifted the dimer back to DsRed wavelengths and T217S which greatly improved the rate of maturation. Unfortunately, K70R and S197A matured relatively slowly and T217S had a green excitation peak equivalent to DsRed. Using dimer1.02 as the template, two more rounds of directed mutagenesis were performed; the first focusing on the three positions identified above (FIG. 11A, library D3) and the second on C117, F118, F124, and V127 (FIG. 10A, library D4).

Continuing with the directed evolution strategy for a total of 4 generations, an optimal dimeric variant was produced, which was designated dimer2 (illustrated in FIG. 2B). This variant contains 17 mutations, of which eight are internal to the β -barrel (N42Q, V44A, V71A, F118L, K163Q, S179T, S197T and T217S), three are the aggregation reducing mutations found in T1 (R2A, K5E and N6D and see Bevis and Glick, *Nat. Biotechnol.*, 20:83-87 [2002]; and Yanushevich *et al.*, *FEBS Lett.*, 511:11-14 [2002]), two are AB interface mutations (I125R and V127T), and 4 are miscellaneous surface mutations (T21S, H41T, C117T and S131P). The dimer2 nucleotide sequence is provided in SEQ ID NO: 7 and FIG. 21. The dimer2 polypeptide is provided in SEQ ID NO: 6 and FIG. 22.

Construction of a Tandem Dimer of DsRed

In an attempt to produce a still further advantageous form of DsRed, an alternative novel strategy to synthesize a more stable DsRed dimer was devised. This approach utilized covalent tethering of two engineered monomeric DsRed units to yield a dimeric form of DsRed with advantageous properties. The basic strategy was to fuse two copies of an AC dimer with a polypeptide linker such that the critical dimer interactions could be satisfied through intramolecular contacts with the tandem partner encoded within the same polypeptide.

Based on the crystal structure of the DsRed tetramer (Yarbrough *et al.*, *Proc. Natl. Acad. Sci. USA* 98:462-467 [2001]; and Wall *et al.*, *Nature Struct. Biol.*, 7:1133-1138 [2000]), it was contemplated that a 10 to 20 residue linker could extend from the C-

terminus of the A subunit to the N-terminus of the C subunit (~30 Å, see Fig. 1B), but not to the N-terminus of the B subunit (>70 Å). Using the optimized dimer2, a series of four tandem constructs were produced using linkers of varying lengths (9, 12, 13, or 22 amino acids) comprising a sequence similar to a known protease resistant linker (Whitlow *et al. Protein Eng.*, 6:989-995 [1993]).

Of the four constructions, only the tandem construct with the 9 residue linker was notable for a somewhat slower maturation. The other three constructs were practically indistinguishable in this respect, and thus, find equal use with the present invention. The tandem dimer construct with the 12 residue linker, designated tdimer2(12), was used in all subsequent experiments. As expected, dimer2 and tdimer2(12) have identical excitation and emission maximum and quantum yields (see FIG. 14). However, the extinction coefficient of tdimer2(12) is twice that of dimer2 due to the presence of two equally absorbing chromophores per polypeptide chain.

15 Evolution of a Monomeric DsRed

In an attempt to create improved dimers of DsRed would better tolerate disruption of the remaining interface, libraries were constructed where AC interface breaking mutations were incorporated into the tdimer(12). An initial dimer library was reassembled using a 3' primer that encoded the mutations H222G and F224G (FIG. 10A, library D5). These two residues form the bulk of the dimer contacts in the C-terminal tail of DsRed that hooks around the C-terminal tail of the dimer partner. From this library the best two unique clones, HF2Ga and HF2Gb, were very similar in sequence to dimer1 with the primary differences being the mutations F124L present in both clones, K163H in HF2Gb and the H222G and F224G replacements. Both HF2Ga and HF2Gb migrated as fluorescent dimers when loaded unboiled onto a 12% SDS-PAGE gel so they must maintain a stable dimer interface.

Simultaneously, a more direct approach to breaking up the AC interface through introduction of dimer-breaking mutations was undertaken. Dimer1 was the template for the first such library (FIG. 10A, library M1) in which nine different positions were targeted, including two key AC interface residues, H162 and A164, which were substituted for lysine or arginine, respectively. The brightest colonies from this library were difficult to distinguish from the background red fluorescence of the *E. coli* colonies even after prolonged imaging with a digital camera. Suspect colonies were restreaked on

LB/agar, allowed to mature at room temperature for two weeks and a crude protein preparation analyzed by SDS-PAGE. Imaging of the gel revealed a single faint band consistent with the expected mass of the monomer. Thus, this species was termed mRFP0.1 (for monomeric Red Fluorescent Protein). Sequencing of this clone revealed
5 that mRFP0.1 was equivalent to dimer1 with mutations E144A, A145R, H162K, K163M, A164R, H222G and H224G.

Random mutagenesis on mRFP0.1 (FIG. 10A, library M2) resulted in the creation of the much brighter mRFP0.2, which gave an unambiguous red fluorescent and monomeric band by SDS-PAGE, and which contained the single additional mutation
10 Y192C. Both mRFP0.1 and mRFP0.2 displayed at least 3-fold greater green fluorescence than red fluorescence, but as expected for the monomer, there was no FRET between the green and red components.

With the suspicion that mutations that were beneficial to the dimer could also benefit the monomer, a template mixture including mRFP0.2, dimer1.56, HF2Ga and
15 HG2Gb was subjected to a combination of PCR-based template shuffling and directed mutagenesis (FIG. 10A, library M3). The top clone identified in this library, mRFP0.3 was relatively bright and had a greatly diminished green fluorescent component. In addition, mRFP0.3 was approximately 10 nm red shifted from DsRed and was primarily derived from dimer1.56.

20 The goal of the next directed library (FIG. 10B, library M4) was to investigate the effect of mutations at K83, which have previously been shown to cause a red shift in DsRed (Wall *et al.*, *Nature Struct. Biol.*, 7:1133-1138 [2000]). The top two clones, designated mRFP0.4a and mRFP0.4b, contained the K83I or L mutation respectively; were 25 nm red shifted relative to DsRed and were very similar in terms of maturation
25 rate and brightness. Unlike all the previous generations of the monomer, colonies of *E. coli* transformed with mRFP0.4a were red fluorescent within 12 h after transformation when excited with 540 nm light and viewed through a red filter.

A template mixture of mRFP0.4a and mRFP0.4b was subjected to random mutagenesis (FIG. 10B, library M5) and the resulting library was thoroughly screened.
30 The 5 fastest maturing clones from this library were derived from mRFP0.4a and contained individual mutations L174P, V175A (two clones), F177C and F177S. The F177S clone or mRFP0.5a, appeared to mature slightly faster and had the smallest green

peak in the absorbance spectra. One colony isolated from this library was exceptionally bright when grown on LB/agar but expressed very poorly when grown in liquid culture. This clone, designated mRFP0.5b, was derived from mRFP0.4b and contained two new mutations; L150M inside the barrel and V156A outside.

5 The next library (FIG. 10B, library M6) was intended to optimize the region around residues V175 and F177 in both mRFP0.5a and the increasingly divergent mRFP0.5b. The top clone in this library, designated mRFP0.6, was derived from mRFP0.5b, though of three other top clones, one was derived from mRFP0.5b, one from mRFP0.5a, and one appeared to have resulted from multiple crossovers between the two
10 templates. The final library (FIG. 10B, library M7) targeted residues in the vicinity of L150 because this was the one remaining critical mutation that was derived from random mutagenesis and had not been reoptimized. Top clones had combinations of mutations at all targeted positions though the clone with the single mutation R153E was found to express slightly better in culture. This clone was further modified through deletion of the
15 unnecessary V1a insertion and replacement of the cysteine at position 222 with a serine.

This final clone, designated mRFP1, contained a total of 33 mutations (see FIG. 1C) relative to wild-type DsRed. Of these mutations, 13 are internal to the β -barrel (N42Q, V44A, V71A, K83L, F124L, L150M, K163M, V175A, F177V, S179T, V195T, S197I and T217A). Of the 20 remaining-external mutations, three are the aggregation
20 reducing mutations from T1 (R2A, K5E and N6D), three are AB interface mutations (I125R, V127T and I180T), ten are AC interface mutations (R153E, H162K, A164R, L174D, Y192A, Y194K, H222S, L223T, F224G and L225A), and four additional mutations (T21S, H41T, C117E and V156A). The mRFP1 nucleotide and polypeptide sequences are provided in SEQ ID NOS: 9 and 8, respectively.

25

Characterization of dimer2, tdimer2(12) and mRFP1

Initial evidence for the monomeric structure of mRFP1 and its precursors was based on SDS-PAGE results (see FIG. 8) and the lack of FRET between the green and red fluorescent components in early generations. Thus analytical equilibrium
30 ultracentrifugation was performed on DsRed, dimer2, and mRFP0.5a (an evolutionary precursor to mRFP1). The mRFP0.5a polypeptide sequence is illustrated in FIGS. 20A-

20D. The analytical equilibrium analysis confirmed the expected tetramer, dimer, and monomer configurations of the tested species (see FIGS. 3A-3C).

In a fluorescence and absorption spectra analysis, DsRed, T1 and dimer2 all have a fluorescent component that contributes at 475-486 nm to the excitation spectra due to FRET between oligomeric partners (see FIGS. 4A-4C). In this analysis, the T1 peak is quite pronounced (FIG. 4B), but in dimer2 (FIG. 4C), any excitation shoulder near 480 nm is almost obscured by the 5 nm blue-shifted excitation peak. The 25 nm red-shifted monomeric mRFP1 (FIG. 4D) also has a peak at 503 nm in the absorption spectra, but in contrast to the other variants, this species is non-fluorescent mutant and therefore does not show up in the excitation spectrum collected at any emission wavelength. When the 503 nm absorbing species is directly excited, negligible fluorescence emission is observed at any wavelength.

As shown in FIG. 5, the rate of maturation of dimer2, tdimer2(12) and mRFP1 is greatly accelerated over that of DsRed, though only mRFP1 matures at least as quickly as T1. Based on data collected at 37°C, the $t_{0.5}$ for maturation of mRFP1 and T1 are less than 1 hour. *E. coli* colonies expressing either dimer2 or mRFP1 display similar or brighter levels of fluorescence to those expressing T1 after overnight incubation at 37°C (see FIG. 9).

Expression of dimer2, tdimer2(12) and mRFP1 in Mammalian Cells

The fluorescence of the dimer2, tdimer2(12) and mRFP1 proteins in the context of mammalian cells was tested. Mammalian expression vectors encoding dimer2, tdimer2(12) and mRFP1 were expressed in transiently transfected HeLa cells. Within 12 hours the cells displayed strong red fluorescence evenly distributed throughout the nucleus and cytoplasm (data not shown).

In view of this result, it was tested whether an RFP-fusion polypeptide could be created, where the RFP moiety retains its fluorescence, and where the fused polypeptide partner retains a native biological activity. This experiment was conducted using the gap junction protein connexin43 (Cx43), which could demonstrate the advantage of a monomeric red fluorescent protein if the fused Cx43 polypeptide retained its biological activity. A series of constructs consisting of Cx43 fused to either GFP, T1, dimer2, tdimer2(12) or mRFP1 were expressed in HeLa cells, which do not express endogenous

connexins. Following transfection, the red fluorescence of the cells was observed with a fluorescence microscope. The results of this experiment are shown in FIGS. 6A, 6C and 6E. As previously reported (Lauf *et al.*, *FEBS Lett.* 498:11-15 [2001]), the Cx43-GFP fusion protein was properly trafficked to the membrane and was assembled into functional gap junctions (data not shown), whereas the Cx43-DsRed tetramer (*i.e.*, the T1 tetramer) consistently formed perinuclear localized red fluorescent aggregates (FIG. 6E). Both Cx43-tdimer2(12) (not shown) and Cx43-dimer2 (FIG. 6C) were properly trafficked to the membrane though neither construct formed visible gap junctions. In contrast, the Cx43-mRFP1 construct behaved identically to Cx43-GFP and many red gap junctions were observed (FIG. 6A).

In another experiment, the transfected cells were microinjected with lucifer yellow to assess the functionality of the gap junctions (see FIGS. 6B, 6D and 6F; and FIG. 13). The Cx43-mRFP1 gap junctions rapidly and reliably passed dye (FIG. 6B), while neither Cx43-T1 transfected cells (FIG. 6E) nor non-transfected cells (not shown) passed dye. Both Cx43-dimer2 and Cx43-tdimer2(12) constructs slowly passed dye to a contacting transfected neighbor about one third of the time (FIG. 6D).

DISCUSSION

The monomeric mRFP1 simultaneously overcomes the three critical problems associated with the wild-type tetrameric form of DsRed. Specifically mRFP1 is a monomer, it matures rapidly, and it has minimal emission when excited at wavelengths optimal for GFP. These features make mRFP1 a suitable red fluorescent protein for the construction of fusion proteins and multi-color labeling in combination with GFP. As demonstrated with the gap junction forming protein Cx43, mRFP1 fusion proteins are functional and trafficked in a manner identical to their GFP analogues.

Although the extinction coefficient and fluorescence quantum yield result in reduced brightness of fully mature mRFP1 compared to DsRed, this is not an obstacle to use of mRFP1 in imaging experiments, as the reduced brightness is more than compensated for by the greater than 10-fold decrease in maturation time for mRFP1. Variant RFP polypeptides of the present invention, for example tdimer2(12), also find use as FRET based sensors. This species is sufficiently bright, and displays FRET with all variants of *Aequorea* GFP.

The present invention provides methods for the generation of still further advantageous RFP species. These methods use multistep evolutionary strategies involving one or multiple rounds of evolution with few mutational steps per cycle. These methods also find use in the converting of other oligomeric fluorescent proteins into advantageous monomeric or dimeric forms.

Example 2

Preparation And Characterization Of Fluorescent Protein Variants

This example demonstrates that mutations can be introduced into GFP spectral variants that reduce or eliminate the ability of the proteins to oligomerize.

ECFP (SEQ ID NO: 14) and EYFP-V68L/Q69K (SEQ ID NO: 12) at the dimer interface were subcloned into the bacterial expression vector pRSET_B (Invitrogen Corp., La Jolla CA), creating an N-terminal His₆ tag on the of ECFP (SEQ ID NO: 14) and EYFP-V68L/Q69K (SEQ ID NO: 12), which allowed purification of the bacterially expressed proteins on a nickel-agarose (Qiagen) affinity column. All dimer-related mutations in the cDNAs were created by site-directed mutagenesis using the QuickChange mutagenesis kit (Stratagene), then expressed and purified in the same manner. All cDNAs were sequenced to ensure that only the desired mutations existed.

EYFP-V68L/Q69K (SEQ ID NO: 12) was mutagenized using the QuickChange kit (Stratagene). The overlapping mutagenic primers were designated "top" for the 5' primer and "bottom" for the 3' primer and are designated according to the particular mutation introduced (see TABLE 1). All primers had a melting temperature greater than 70°C. The mutations were made as close to the center of the primers as possible and all primers were purified by polyacrylamide gel electrophoresis. The primers are shown in a 5' to 3' orientation, with mutagenized codons underlined (TABLE 1).

TABLE 1

Primer	Sequence	SEQ ID NO:
A206K top	CAG TCC <u>AAG</u> CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC	25
A206K bottom	GTG ATC GCG CTT CTC GTT GGG GTC TTT GCT CAG <u>CTT</u> GGA CTG	26
L221K top	CAC ATG GTC CTG <u>AAG</u> GAG TTC GTG ACC GCC GCC GGG	27
L221K bottom	CCC GGC GGC GGT CAC GAA CTC <u>CTT</u> CAG GAC CAT GTG	28
F223R top	CAC ATG GTC CTG CTG GAG <u>CGC</u> GTG ACC GCC GCC GGG	29
F223R bottom	CCC GGC GGC GGT CAC <u>GCG</u> CTC CAG CAG GAC CAT GTG	30
L221K/F223 R top	CAC ATC GTC CTG <u>AAG</u> GAG <u>CGC</u> GTG ACC GCC GCC GGG	31
L221K/F223 R bottom	CCC GGC GGC GGT CAC <u>GCG</u> CTC CTT CAG GAC CAT GTG	32

For protein expression, plasmids containing cDNAs for the various EYFP-V68L/Q69K (SEQ ID NO: 12) mutants were transformed into *E. coli* strain JM109 and grown to an OD₆₀₀ of 0.6 in LB containing 100 µg/ml ampicillin at which time they were induced with 1 mM isopropyl β-D-thiogalactoside. The bacteria were allowed to express the protein at room temperature for 6 to 12 hr, then overnight at 4°C, then were pelleted by centrifugation, resuspended in phosphate buffered saline (pH 7.4), and lysed in a French press. Bacterial lysates were cleared by centrifugation at 30,000 x g for 30 min. The proteins in the cleared lysates were affinity-purified on Ni-NTA-agarose (Qiagen).

All GFPs used in these experiments were 238 amino acids in length. Subcloning the cDNAs encoding the GFPs into pRSET_B resulted in the fusion of an additional 33 amino acids to the N-terminus of the GFPs. The sequence of this tag is MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDP (SEQ ID NO: 22). Thus, the total length of the EYFP-V68L/Q69K (SEQ ID NO: 12) mutants expressed from this cDNA was 271 amino acids. The His₆ tag was removed using EKMax (Invitrogen) to determine if the associative properties measured for the GFPs were affected by the presence of the N-terminal His₆-tag. A dilution series of the enzyme and His₆-tagged GFP was made to determine the conditions necessary for complete removal of the His₆-tag. The purity of all expressed and purified proteins was analyzed by SDS-PAGE. In all cases, the expressed proteins were very pure, with no significant detectable

contaminating proteins, and all were of the proper molecular weight. In addition, removal of the His₆ tag was very efficient, as determined by the presence of a single band migrating at the lower molecular weight than the His₆-EYFP-V68L/Q69K.

Spectrophotometric analysis of the purified proteins determined that there was no significant change in either the extinction coefficient as measured by chromophore denaturation (Ward *et al.*, In *Green Fluorescent Protein: Properties, Applications and Protocols*," eds. Chalfie and Kain, Wiley-Liss [1998]) or quantum yield (the standard used for EYFP-V68L/Q69K and the mutants derived therefrom was fluorescein) of these proteins with respect to EYFP-V68L/Q69K (SEQ ID NO: 12; "wtEYFP"; Table 2). Fluorescence spectra were taken with a Fluorolog spectrofluorimeter. Absorbance spectra of proteins were taken with a Cary UV-Vis spectrophotometer. Extinction coefficients were determined by the denatured chromophore method (Ward *et al.*, In *Green Fluorescent Protein: Properties, Applications and Protocols*," eds. Chalfie and Kain, Wiley-Liss [1998]).

TABLE 2

Protein	Quantum Yield	Extinction Coefficient
WtEYFP	0.71*	62,000*
His ₆ wtEYFP	0.67	67,410
His ₆ wtEYFP L221K	0.67	64,286
His ₆ wtEYFP F223R	0.53	65,393
His ₆ wtEYFP A206K	0.62	79,183
*published data (Cubitt <i>et al.</i> , 1997)		

To determine the degree of homoaffinity of the dimers, wtEYFP and the dimer mutants derived therefrom were subjected to sedimentation equilibrium analytical ultracentrifugation. Purified, recombinant proteins were dialyzed extensively against phosphate buffered saline (pH 7.4), and 125 μ l samples of protein at concentrations ranging from 50 μ M to 700 μ M were loaded into 6-channel centrifugation cells with EPON centerpieces. Samples were blanked against the corresponding dialysis buffer. Sedimentation equilibrium experiments were performed on a Beckman Optima XL-I analytical ultracentrifuge at 20°C measuring radial absorbance at 514 nm. Each sample was examined at three or more of the following speeds: 8,000 rpm, 10,000 rpm, 14,000

rpm, and 20,000 rpm. Periodic absorbance measurements at each speed ensured that the samples had reached equilibrium at each speed.

The data were analyzed globally at all rotor speeds by nonlinear least-squares analysis using the software package (Origin) supplied by Beckman. The goodness of fit was evaluated on the basis of the magnitude and randomness of the residuals, expressed as the difference between the experimental data and the theoretical curve and also by checking each of the fit parameters for physical reasonability. The molecular weight and partial specific volume of each protein were determined using Sedenterp v 1.01, and the data were factored into the equation for the determination of homoaffinity (TABLE 3). In addition, dissociation constants (K_d) derived from the data generated by analytical ultracentrifugation are shown for some proteins (TABLE 4).

TABLE 3

Mutant	Molecular Weight	Partial Specific Volume
wtEYFP	26796.23	0.7332
His ₆ wtEYFP	30534.26	0.7273
His ₆ EYFP A206K	30593.37	0.7277
EYFP L221K	30551.29	0.7270
His ₆ EYFP L221K	30549.27	0.7271
His ₆ EYFP F223R	30543.27	0.7270
His ₆ EYFP L221K/F223R	30560.30	0.7267

TABLE 4

Protein	K_d (mM)
His ₆ wtEYFP	0.11
His ₆ wtEYFP L221K	9.7
His ₆ wtEYFP F223R	4.8
His ₆ wtEYFP A206K	74
His ₆ wtEYFP L221K/F223R	2.4

For experiments in living cells, ECFP (SEQ ID NO: 14; "wtECFP") and EYFP-V68L/Q69K (SEQ ID NO: 12; "wtEYFP") targeted to the plasma membrane

(PM) were subcloned into the mammalian expression vector, pcDNA3 (Invitrogen Corp.) and mutagenized and sequenced as described above. Targeting of the GFP variants to the PM was accomplished by making either N-terminal or C-terminal fusions of the GFP variant to short peptides containing a consensus sequence for acylation and/or prenylation (post-translational lipid modifications). The cDNAs of the PM targeted GFP variants were transfected and expressed in either HeLa cells or MDCK cells, and the expression pattern and degree of association were determined using fluorescent microscopy. FRET efficiency was measured to determine the degree of interaction of the PM-ECFP and PM-EYFP-V68L/Q69K. Analysis of the interactions by the FRET donor-dequench method (Miyawaki and Tsien, *supra*, 2000) demonstrated that the wtECFP and wtEYFP interacted in a manner that was dependent upon the association of the wtECFP and wtEYFP, and that this interaction was effectively eliminated by changing the amino acids in the hydrophobic interface to any one or a combination of the mutations A206K, L221K and F223R.

These results demonstrate that the solution oligomeric state of *Aequorea* GFP and its spectral variants, and dimer mutants derived therefrom, were accurately determined by analytical ultracentrifugation. The ECFP (SEQ ID NO: 14) and EYFP-V68L/Q69K (SEQ ID NO: 12) GFP spectral variants formed homodimers with a fairly high affinity of about 113 μ M. By using site directed mutagenesis, the amino acid composition was altered so as to effectively eliminate dimerization and the cell biological problems associated with it. Thus, the modified fluorescent proteins provide a means to use FRET to measure the associative properties of host proteins fused to the modified CFP or YFP. The ambiguity and potential for false positive FRET results associated with ECFP (SEQ ID NO: 14) and EYFP-V68L/Q69K (SEQ ID NO: 12) dimerization have been effectively eliminated, as has the possibility of misidentification of the subcellular distribution or localization of a host protein due to dimerization of GFPs.

The *Renilla* GFP and the *Discosoma* red fluorescent protein are obligate oligomers in solution. Because it was generally believed that *Aequorea* GFP could also dimerize in solution, and because GFP crystallizes as a dimer, the present investigation was designed to characterize the oligomeric state of GFP. The crystallographic interface between the two monomers included many hydrophilic contacts as well as several hydrophobic contacts (Yang et al., *supra*, 1996). It was not immediately clear, however,

to what degree each type of interaction contributed to the formation of the dimer in solution.

As disclosed herein, the extent of GFP self-association was examined using sedimentation equilibrium, analytical ultracentrifugation, which is very useful for determining the oligomeric behavior of molecules both similar (self associating homomeric complexes) and dissimilar (heteromeric complexes; see Laue and Stafford, Ann. Rev. Biophys. Biomol. Struct. 28:75-100, 1999). In contrast to X-ray crystallography, the experimental conditions used in the analytical ultracentrifugation experiments closely approximated cellular physiological conditions. Monomer contact sites identified by X-ray crystallography within a multimeric complex are not necessarily the same as those in solution. Also in contrast to analytical ultracentrifugation, X-ray crystallography alone cannot provide definitive information about the affinity of the complex. The results of this investigation demonstrate that replacement of the hydrophobic residues A206, L221 and F223 with residues containing positively charged side chains (A206K, L221K and F223R) eliminated dimerization as determined by analytical ultracentrifugation *in vitro* and by analysis of the concentration dependence of FRET in intact cells.

Example 3

20 Characterization Of The Coral Red Fluorescent Protein, DsRed, And Mutants Thereof

This example describes the initial biochemical and biological characterization of DsRed and DsRed mutants.

The coding sequence for DsRed was amplified from pDsRed-N1 (Clontech Laboratories) with PCR primers that added an N terminal BamHI recognition site upstream of the initiator Met codon and a C terminal Eco RI site downstream of the STOP codon. After restriction digestion, the PCR product was cloned between the Bam HI and Eco RI sites of pRSET_B (Invitrogen), and the resulting vector was amplified in DH5 α bacteria. The resulting plasmid was used as a template for error-prone PCR (Heim and Tsien, Curr. Biol. 6:178-182, 1996, which is incorporated herein by reference) using primers that were immediately upstream and downstream of the DsRed coding sequence, theoretically allowing mutation of every coding base, including the initiator Met. The mutagenized PCR fragment was digested with Eco RI and Bam HI

and recloned into pRSET_B. Alternatively, the Quick-Change mutagenesis kit (Stratagene) was used to make directed mutations on the pRSET_B-DsRed plasmid.

In both random and directed mutagenesis studies, the mutagenized plasmid library was electroporated into JM109 bacteria, plated on LB plates containing ampicillin, and screened on a digital imaging device (Baird et al., Proc. Natl. Acad. Sci., USA 96:11242-11246, 1999, which is incorporated herein by reference). This device illuminated plates with light from a 150 Watt xenon arc lamp, filtered through bandpass excitation filters and directed onto the plates with two fiber optic bundles. Fluorescence emission from the plates was imaged through interference filters with a cooled CCD camera. Images taken at different wavelengths could be digitally ratioed using MetaMorph software (Universal Imaging) to allow identification of spectrally shifted mutants. Once selected, the mutant colonies were picked by hand into LB/Amp medium, after which the culture was used for protein preparation or for plasmid preparations. The DsRed mutant sequences were analyzed with dye-terminator dideoxy sequencing.

DsRed and its mutants were purified using the N-terminal polyhistidine tag (SEQ ID NO: 22; see Example 1) provided by the pRSET_B expression vector (see Baird et al., *supra*, 1999). The proteins were microconcentrated and buffer exchanged into 10 mM Tris (pH 8.5) using a Microcon-30 (Amicon) for spectroscopic characterization. Alternatively, the protein was dialyzed against 10 mM Tris (pH 7.5) for oligomerization studies because microconcentration resulted in the production of large protein aggregates. To test for light sensitivity of protein maturation, the entire synthesis was repeated in the dark, with culture flasks wrapped in foil, and all purification was performed in a room that was dimly lit with red lights. There was no difference in protein yield or color when the protein was prepared in light or dark.

Numbering of amino acids conforms to the wild type sequence of drFP583 (DsRed; Matz et al., *Nature Biotechnology* 17:969-973 [1999]), in which residues 66-68, Gln-Tyr-Gly, are homologous to the chromophore-forming residues (65-67, Ser-Tyr-Gly) of GFP. The extra amino acid introduced by Clontech after the initiator Met was numbered "1a" and the residues of the N-terminal polyhistidine tag were numbered -33 to -1.

Fluorescence spectra were taken with a Fluorolog spectrofluorimeter. Absorbance spectra of proteins were taken with a Cary UV-Vis spectrophotometer. For

quantum yield determination, the fluorescence of a solution of DsRed or DsRed K83M in phosphate buffered saline was compared to equally absorbing solutions of Rhodamine B and Rhodamine 101 in ethanol. Corrections were included in the quantum yield calculation for the refractive index difference between ethanol and water. For extinction coefficient determination, native protein absorbance was measured with the spectrophotometer, and protein concentration was measured by the BCA method (Pierce).

The pH sensitivity of DsRed was determined in a 96 well format by adding 100 μ L of dilute DsRed in a weakly buffered solution to 100 μ L of strongly buffered pH solutions in triplicate (total 200 μ L per well) for pH 3 to pH 12. The fluorescence of each well was measured using a 525-555 nm bandpass excitation filter and a 575 nm long pass emission filter. After the 96 well fluorimeter measurements were taken, 100 μ L of each pH buffered DsRed solution was analyzed on the spectrofluorimeter to observe pH-dependent spectral shape changes. For time-trials of DsRed maturation, a dilute solution of freshly synthesized and purified DsRed was made in 10 mM Tris (pH 8.5), and this solution was stored at room temperature in a stoppered cuvette (not airtight) and subjected to periodic spectral analysis. For mutant maturation data, fluorescence emission spectra (excitation at 475 nm or 558 nm) were taken directly after synthesis and purification, and then after more than 2 months storage at 4°C or at room temperature.

Quantum yields for photodestruction were measured separately on a microscope stage or in a spectrofluorimeter. Microdroplets of aqueous DsRed solution were created under oil on a microscope slide and bleached with 1.2 W/cm² of light through a 525-555 nm bandpass filter. Fluorescence over time was monitored using the same filter and a 563-617 nm emission filter. For comparison, EGFP (containing mutations F64L, S65T; SEQ ID NO: 13) and EYFP-V68L/Q69K (also containing mutations S65G, S72A, T203Y; SEQ ID NO: 12) microdroplets were similarly bleached with 1.9 W/cm² at 460-490 nm while monitoring at 515-555 and 523-548 nm, respectively.

For the spectrofluorimeter bleaching experiment, a solution of DsRed was prepared in a rectangular microcuvette and overlaid with oil so that the entire 50 μ L of protein solution resided in the 0.25 cm x 0.2 cm x 1 cm illumination volume. The protein solution was illuminated with 0.02 W/cm² light from the monochromator centered at 558 nm (5 nm bandwidth). Fluorescence over time was measured at 558 nm

excitation (1.25 nm bandwidth) and 583 nm emission. Quantum yields (Φ) for photobleaching were deduced from the equation $\Phi = (\epsilon \cdot I \cdot t_{90\%})^{-1}$, where ϵ is the extinction coefficient in $\text{cm}^2\text{mol}^{-1}$, I is the intensity of incident light in einsteins $\text{cm}^{-2}\text{s}^{-1}$ and $t_{90\%}$ is the time in seconds for the fluorophore to be 90% bleached (Adams et al., J. Am. Chem. Soc. 110:3312-3320, 1988, which is incorporated herein by reference).

Polyhistidine-tagged DsRed, DsRed K83M and wild type *Aequorea* GFP (SEQ ID NO: 10) were run on a 15% polyacrylamide gel without denaturation. To prevent denaturation, protein solutions (in 10mM Tris HCl, pH 7.5) were mixed 1:1 with 2x SDS-PAGE sample buffer (containing 200 mM dithiothreitol) and loaded directly onto the gel without boiling. A broad range pre-stained molecular weight marker set (BioRad) was used as a size standard. The gel was then imaged on an Epson 1200 Perfection flatbed scanner.

Purified recombinant DsRed was dialyzed extensively against phosphate buffered saline (pH 7.4) or 10 mM Tris, 1 mM EDTA (pH 7.5). Sedimentation equilibrium experiments were performed on a Beckman Optima XL-I analytical ultracentrifuge at 20°C measuring absorbance at 558 nm as a function of radius. 125 μL samples of DsRed at 3.57 μM (0.25 absorbance units) were loaded into 6 channel cells. The data were analyzed globally at 10,000, 14,000, and 20,000 rpm by nonlinear least-squares analysis using the Origin software package (Beckman). The goodness of fit was evaluated on the basis of the magnitude and randomness of the residuals, expressed as the difference between the experimental data and the theoretical curve and also by checking each of the fit parameters for physical reasonability.

FRET between immature green and mature red DsRed was examined in mammalian cells. DsRed in the vector pcDNA3 was transfected into HeLa cells using Lipofectin, and 24 hr later the cells were imaged on a fluorescence microscope. The fluorescences of the immature green species (excitation 465-495 nm, 505 nm dichroic, emission 523-548 nm) and of mature red protein (excitation 529-552 nm, 570 nm dichroic, emission 563-618 nm) were measured with a cooled CCD camera. These measurements were repeated after selective photobleaching of the red component by illumination with light from the xenon lamp, filtered only by the 570 nm dichroic, for cumulative durations of 3, 6, 12, 24, and 49 min. By the final time, about 95% of the

initial red emission had disappeared, whereas the green emission was substantially enhanced.

Yeast two hybrid assays were also performed. The DsRed coding region was cloned in-frame downstream of the Gal4 activation domains (the "bait"; amino acid residues 768-881) and DNA binding domains (the "prey"; amino acid residues 1-147) in the pGAD GH and pGBT9 vectors, respectively (Clontech). These DsRed two hybrid plasmids were transformed into the HF7C strain of *S. cerevisiae*, which cannot synthesize histidine in the absence of interaction between the proteins fused to the Gal4 fragments. Yeast containing both DsRed-bait and DsRed-prey plasmids were streaked on medium lacking histidine and assayed for growth by visually inspecting the plates. Alternatively, the yeast were grown on filters placed on plates lacking tryptophan and leucine to select for the bait and prey plasmids. After overnight growth, the filters were removed from the plates, frozen in liquid nitrogen, thawed, and incubated in X-gal overnight at 30°C and two days at 4°C to test for β -galactosidase activity (assayed by blue color development). In both the β -galactosidase and histidine growth assays, negative controls consisted of yeast containing bait and prey plasmids, but only the bait or the prey was fused to DsRed.

Surprisingly, DsRed took days at room temperature to reach full red fluorescence. At room temperature, a sample of purified protein initially showed a major component of green fluorescence (excitation and emission maxima at 475 and 499 nm, respectively), which peaked in intensity at about 7 hr and decreased to nearly zero over two days. Meanwhile, the red fluorescence reached half its maximal fluorescence after approximately 27 hr and required more than 48 hr to reach greater than 90% of maximal fluorescence (see Baird et al., *supra*, 2000).

Fully matured DsRed had an extinction coefficient of $75,000 \text{ M}^{-1}\text{cm}^{-1}$ at its 558 nm absorbance maximum and a fluorescence quantum yield of 0.7, which is much higher than the values of $22,500 \text{ M}^{-1}\text{cm}^{-1}$ and 0.23 previously reported (Matz et al., *Nature Biotechnology* 17:969-973 [1999]). These properties make mature DsRed quite similar to rhodamine dyes in wavelength and brightness. Unlike most GFP variants, DsRed displayed negligible (<10%) pH-dependence of absorbance or fluorescence from pH 5 to 12. (see Baird et al., *supra*, 2000). However, acidification to pH 4-4.5 depressed both the absorbance and excitation at 558 nm relative to the shorter wavelength shoulder at

526 nm, whereas the emission spectrum was unchanged in shape. DsRed was also relatively resistant to photobleaching. When exposed to a beam of 1.2 W/cm^2 of approximately 540 nm light in a microscope stage, microdroplets of DsRed under oil took 1 hr to bleach 90%, whereas 20 mW/cm^2 of 558 nm light in a spectrofluorimeter microcuvette required 83 hr to bleach 90%. The microscope and fluorimeter measurements, respectively, gave photobleach quantum efficiencies of 1.06×10^{-6} and 4.8×10^{-7} (mean of 7.7×10^{-7}). Analogous microscope measurements of EGFP (S65T; SEQ ID NO: 13) and EYFP-V68L/Q69K (SEQ ID NO: 12; including Q69K) gave 3×10^{-6} and 5×10^{-5} , respectively.

10 In an effort to examine the nature of the red chromophore and to identify DsRed variants useful as biological indicators, DsRed was mutagenized randomly and at specific sites predicted by sequence alignment with GFP to be near the chromophore. Many mutants that matured more slowly or not at all were identified, but none were identified that matured faster than DsRed. Screening of random mutants identified
15 mutants that appeared green or yellow, which was found to be due to substitutions K83E, K83R, S197T, and Y120H. The green fluorescence was due to a mutant species with excitation and emission maxima at 475 and 500 nm, respectively, whereas the yellow was due to a mixture of this green species with DsRed-like material, rather than to a single species at intermediate wavelengths.

20 The DsRed K83R mutant had the lowest percentage conversion to red, and proved very useful as a stable version of the immature green-fluorescing form of DsRed (see Baird et al., *supra*, 2000). Further directed mutagenesis of K83 yielded more green and yellow mutants that were impaired in chromophore maturation. In many of the K83 mutants that matured slowly and incompletely, the red peak was at longer wavelengths
25 than DsRed. K83M was particularly interesting because its final red-fluorescing species showed a 602 nm emission maximum, with relatively little residual green fluorescence and a respectable quantum yield, 0.44. However, its maturation was slower than that of the wild type DsRed. Y120H had a red shift similar to that of K83M and appeared to produce brighter bacterial colonies, but also maintained much more residual green
30 fluorescence.

Spectroscopic data of the DsRed mutants are shown in FIG. 15. In this FIG., "maturation" of protein refers to the rate of appearance of the red fluorescence over the

two days after protein synthesis. Because some maturation occurs during the synthesis and purification (which take 1-2 days), numerical quantification is not accurate. A simple +/- rating system was used, wherein (--) means very little change, (-) means a 2-5 fold increase in red fluorescence, (+) means 5-20 fold increase, and (++) indicates the wild type increase (approximately 40 fold). The red/green ratio was determined two months after protein synthesis by dividing the peak emission fluorescence obtained at 558 nm excitation by the 499 nm fluorescence obtained at 475 nm excitation from the same sample. This does not represent a molar ratio of the two species because the ratio does not correct for differences in extinction coefficient or quantum yields between the two species, or the possibility of FRET between the two species if they are in a macromolecular complex.

To determine whether Lys70 or Arg95 can form imines with the terminal carbonyl of a GFP-like chromophore (see Tsien, *Nature Biotechnol.*, 17:956-957, 1999), DsRed mutants K70M, K70R, and R95K were produced. K70M remained entirely green with no red component, whereas K70R matured slowly to a slightly red-shifted red species. The spectral similarity of K70R to wild type DsRed argues against covalent incorporation of either amino acid into the chromophore. No fluorescence at any visible wavelength was detected from R95K, which might be expected because Arg95 is homologous to Arg96 of GFP, which is conserved in all fluorescent proteins characterized to date (Matz *et al.*, *Nature Biotechnology* 17:969-973 [1999]). The failure of R95K to form a green chromophore prevented testing whether Arg95 was also required for reddening.

In view of the propensity of *Aequorea* GFP to form dimers at high concentrations in solution and in some crystal forms, and the likelihood that *Renilla* GFP forms an obligate dimer (Ward *et al.*, In *Green Fluorescent Protein: Properties, Applications and Protocols*, eds. Chalfie and Kain, Wiley-Liss [1998]), the ability of DsRed to oligomerize was examined. Initial examination of the expressed proteins by SDS-PAGE suggested that aggregates formed, in that polyhistidine-tagged proteins DsRed and DsRed K83R migrated as red and yellow-green bands, respectively, at an apparent molecular weight of greater than 110 kDa when mixed with 200 mM DTT and not heated before loading onto the gel (see Baird *et al.*, *supra*, 2000). In comparison, *Aequorea* GFP, when treated similarly, ran as a fluorescent green band near its predicted

monomer molecular weight of 30 kDa. The high molecular weight DsRed band was not observed when the sample was briefly boiled before electrophoresis (see Gross et al., *supra*, 2000). Under these conditions, a band near the predicted monomer molecular weight of 30 kDa predominated and was colorless without Coomassie staining.

5 To determine the oligomerization status more rigorously, the DsRed protein was subjected to analytical equilibrium centrifugation (Laue and Stafford, *supra*, 1999). Global curve fitting of the absorbance data determined from the radial scans of equilibrated DsRed indicated that DsRed exists as an obligate tetramer in solution (Baird et al., *supra*, 2000), in both low salt and physiological salt concentrations. When the
10 data was modeled with a single-species tetramer, the fitted molecular weight was 119,083 Da, which is in excellent agreement with the theoretical molecular weight of 119,068 Da for the tetramer of polyHis-tagged DsRed. Attempts to fit the curves with alternative stoichiometries from monomer to pentamer failed to converge or gave unreasonable values for the floating variables and large, non-random residuals. The
15 residuals for the tetramer fit were much smaller and more randomly distributed, but were somewhat further improved by extending the model to allow the obligate tetramer to dimerize into an octamer, with a fitted dissociation constant of 39 μ M. Thus the 558-nm-absorbing species appears to be tetrameric over the range of monomer concentrations from 14 nM to 11 μ M *in vitro*. The hint of octamer formation at the highest
20 concentrations is only suggestive because the highest concentrations of tetramer achieved in the ultracentrifugation cell remained more than an order of magnitude below the fitted dissociation constant.

To confirm whether DsRed also oligomerizes in live cells, FRET analysis was performed in mammalian cells and in two hybrid assays in yeast cells. HeLa cells were
25 transfected with wild type DsRed and imaged 24 hr later, when they contained a mixture of the immature green intermediate and the final red form. The green fluorescence was monitored intermittently before and during selective photobleaching of the red species over 49 min of intense orange illumination. If the two proteins were non-associated, bleaching the red species would be expected to have no effect on the green fluorescence.
30 In fact, however, the green fluorescence increased by 2.7 to 5.8 fold in different cells, corresponding to FRET efficiencies of 63% to 83%. These values equal or surpass the highest FRET efficiencies ever observed between GFP mutants, 68% for cyan and

yellow fluorescent proteins linked by a zinc ion-saturated zinc finger domain (Miyawaki and Tsien, *supra*, 2000).

Additional evidence of *in vivo* oligomerization was provided by the directed yeast two hybrid screen. When DsRed fusions to the Gal4 DNA binding domain and activation domain were expressed in HF7C yeast, the yeast demonstrated a his⁺ phenotype and were able to grow without supplemental histidine, indicating a two hybrid interaction had occurred. Neither fusion construct alone (DsRed-DNA binding domain or DsRed-activation domain) produced the his⁺ phenotype, indicating that a DsRed-DsRed interaction, and not a non-specific DsRed-Gal4 interaction, was responsible for the positive result. In addition, the his⁺ yeast turned blue when lysed and incubated with X-gal, suggesting that the DsRed-DsRed interaction also drove transcription of the β -galactosidase gene. Thus, two separate transcriptional measurements of the yeast two hybrid assay confirmed that DsRed associates *in vivo*.

This investigation of DsRed revealed that DsRed has many desirable properties, as well as some nonoptimal properties, with respect to its being useful to complement or as an alternative to GFPs. One of the most important favorable properties identified was that DsRed has a much higher extinction coefficient and fluorescence quantum yield (0.7) than was previously reported, such that the fluorescence brightness of the mature well-folded protein is comparable to rhodamine dyes and to the best GFPs.

DsRed also is quite resistant to photobleaching by intensities typical of spectrofluorimeters (mW/cm²) or microscopes with arc lamp illumination and interference filters (W/cm²), showing a photobleaching quantum yield on the order of 7×10^{-7} in both regimes. This value is significantly better than those for two of the most popular green and yellow GFP mutants, EGFP (3×10^{-6}) and EYFP-V68L/Q69K (5×10^{-5}). The mean number of photons that a single molecule can emit before photobleaching is the ratio of the fluorescence and photobleaching quantum yields, or 1×10^6 , 2×10^5 , and 1.5×10^4 for DsRed, EGFP, and EYFP-V68L/Q69K, respectively. A caveat is that the apparent photobleaching quantum yield might well increase at higher light intensities and shorter times if the molecule can be driven into dark states such as triplets or tautomers from which it can recover its fluorescence. GFPs usually show a range of such dark states (Dickson et al., *Nature* 388:355-358, 1997; Schwille et al., *Proc. Natl. Acad. Sci., USA* 97:151-156, 2000), and there is no reason to expect that DsRed will be

any simpler. The photobleaching measurements described herein were made over minutes to hours, and include ample time for such recovery. In contrast, fluorescence correlation spectroscopy and flow cytometry monitor single passages of molecules through a focused laser beam within microseconds to milliseconds, such that temporary
5 dark states that last longer than the transit time count as photobleaching, raising the apparent quantum yield for bleaching. Techniques such as laser scanning confocal microscopy, in which identified molecules are repetitively scanned, will show intermediate degrees of photobleaching depending on the time scale of illumination and recovery.

10 Another desirable feature of DsRed is its negligible sensitivity to pH changes over the wide range (pH 4.5 to 12). The currently available brighter GFP mutants are more readily quenched than DsRed by acidic pH. Such pH sensitivity can be exploited under controlled conditions to sense pH changes, especially inside organelles or other specific compartments (see Llopis et al., Proc. Natl. Acad. Sci., USA 95:6803-6808,
15 1998), although this feature can cause artifacts in some applications.

DsRed mutants such as K83M demonstrate that DsRed can be pushed to longer wavelengths (564 and 602 nm excitation and emission maxima), while retaining adequate quantum efficiency (0.44). The 6 nm and 19 nm bathochromic shifts correspond to 191 cm^{-1} and 541 cm^{-1} in energy, which are of respectable magnitude for a
20 single amino acid change that does not modify the chromophore. A homolog of DsRed recently cloned from a sea anemone has an absorbance maximum at 572 nm and extremely weak emission at 595 nm with quantum yield <0.001 ; one mutant had an emission peak at 610 nm but was very dim and slow to mature (Lukyanov et al., J. Biol. Chem. 275:25879-25882, 2000, which is incorporated herein by reference).

25 Less desirable features of DsRed include its slow and incomplete maturation, and its capacity to oligomerize. A maturation time on the order of days precludes a use of DsRed as a reporter for short term gene expression studies and for applications directed to tracking fusion proteins in organisms that have short generation times or fast development. Since maturation of GFPs was considerably accelerated by mutagenesis
30 (Heim et al., Nature 373:663-664, 1995, which is incorporated herein by reference), DsRed similarly can be mutagenized and variants having faster maturation times can be isolated.

Because the Lys83 mutants all permitted at least some maturation, it is unlikely that the primary amine plays a direct catalytic role for this residue, a suggestion supported by the observation that the most chemically conservative replacement, Lys to Arg, impeded red development to the greatest extent. Ser197 provided a similar result, in that the most conservative possible substitution, Ser to Thr, also significantly slowed maturation. Mutations at the Lys83 and Ser197 sites appeared several times independently in separate random mutagenesis experiments and, interestingly, Lys83 and Ser197 are replaced by Leu and Thr, respectively, in the highly homologous cyan fluorescent protein dsFP483 from the same *Discosoma* species. Either of the latter two mutations could explain why dsFP483 never turns red. Residues other than Lys83 and Ser197 also affected maturation to the red.

The multimeric nature of DsRed was demonstrated by four separate lines of evidence, including slow migration on SDS-PAGE unless pre-boiled, analytical ultracentrifugation, strong FRET from the immature green to the final red form in mammalian cells, and directed two hybrid assays in yeast using HIS3 and LacZ reporter genes. Analytical ultracentrifugation provided the clearest evidence for an obligate stoichiometry of four over the entire range of monomer concentrations assayed (10^{-8} to 10^{-5} M), with a hint that octamer formation can occur at yet higher concentrations. In addition, the tests in live cells confirmed that aggregation occurs under typical conditions of use, including the reducing environment of the cytosol and the presence of native proteins.

While oligomerization of DsRed does not preclude its use as a reporter of gene expression, it can result in artifactual results in applications where DsRed is fused to a host protein, for example, to report on the trafficking or interactions of the host protein in a cell. For a host protein of mass M without its own aggregation tendencies, fusion with DsRed can result in the formation of a complex of at least $4(M+26 \text{ kDa})$. Furthermore, since many proteins in signal transduction are activated by oligomerization, fusion to DsRed and consequent association can result in constitutive signaling. For host proteins that are oligomeric, fusion to DsRed can cause clashes of stoichiometry, steric conflicts of quaternary structures, or crosslinking into massive aggregates. In fact, red cameleons, i.e., fusions of cyan fluorescent protein, calmodulin, and calmodulin-binding peptide, and DsRed, are far more prone to form visible punctae in mammalian cells than the

corresponding yellow cameleons with yellow fluorescent protein in place of DsRed (Miyawaki et al., Proc. Natl. Acad. Sci., USA 96:2135-2140, 1999).

The results disclosed above indicate that variants of DsRed, like those of the GFPs, can be produced such that the propensity of the fluorescent protein to oligomerize is reduced or eliminated. DsRed variants can be constructed and examined, for example, using a yeast two hybrid or other similar assay to identify and isolate non-aggregating mutants. In addition, the X-ray crystallographic structure of DsRed can be examined to confirm that optimal amino acid residues are modified to produce a form of DsRed having a reduced propensity to oligomerize.

Example 4

DsRed Variants Having Reduced Propensity To Oligomerize

This example demonstrates that mutations corresponding to those introduced into GFP variants to reduce or eliminate oligomerization also can be made in DsRed to reduce the propensity of DsRed to form tetramers.

In view of the results described in Example 1 and guided by the DsRed crystal structure, amino acid residues were identified as potentially being involved in DsRed oligomerization. One of these amino acids, isoleucine-125 (I125), was selected because, in the oligomer, the I125 residues of the subunits were close to each other in a pairwise fashion; i.e., the side chain of I125 of the A subunit was about 4 Angstroms from the side chain of I125 of the C subunit, and the I125 residues in the B and D subunits were similarly positioned. In addition, the area in which the I125 side chains reside exhibited hydrophobicity, analogous to that identified in *Aequorea* GFP variants, which was demonstrated to be involved in the inter-subunit interaction. Based on these observations, DsRed mutants containing substitutions of positively charged amino acids, Lys (K) and Arg (R), for I125 were generated.

DsRed I125K and I125R were prepared with the QuickChange Mutagenesis Kit using the DsRed cDNA (SEQ ID NO: 23; Clontech) subcloned into the expression vector pRSETB (Invitrogen) as the template for mutagenesis. The primers for mutagenesis, with the mutated codons underlined, were as follows:

TABLE 5

Primer	Sequence	SEQ ID NO
I125K (forward)	5'-TAC AAG GTG AAG TTC <u>AAG</u> GGC GTG AAC TTC CCC-3'	33
I125K (reverse)	5'-GGG GAA GTT CAC GCC <u>CTT</u> GAA CTT CAC CTT GTA-3'	34
I125R (forward)	5'-TAC AAG GTG AAG TTC <u>CGC</u> GGC GTG AAC TTC CCC-3'	35
I125R (reverse)	5'-GGG GAA GTT CAC GCC <u>GCG</u> GAA CTT CAC CTT GTA-3'	36

The mutant proteins were prepared following standard methodology and analyzed with polyacrylamide gel electrophoresis as described (Baird et al., *supra*, 2000). For further analysis, DsRed I125R was dialyzed extensively in PBS, then diluted in PBS until the absorbance of the solution at 558nm was 0.1. This solution was centrifuged in a Beckman XL-1 analytical ultracentrifuge in PBS at 10,000 rpm, 12,000 rpm, 14,000 rpm, and 20,000 rpm. Absorbance at 558nm versus radius was determined and compared to a wild type tetrameric DsRed control (Baird et al., *supra*, 2000).

The DsRed I125K yielded a protein that became red fluorescent and was a mixture of dimer and tetramer as analyzed by non-denaturing polyacrylamide gel electrophoresis of the native protein. The same analysis of Ds Red I125R revealed that the protein was entirely dimeric. The dimeric status of DsRed I125R was confirmed by analytical ultracentrifugation; no residual tetramer was detected. These results demonstrate that the interaction between the A:C subunits and the B:D subunits can be disrupted, thereby reducing the propensity of the DsRed variant to oligomerize. No attempt was made to disrupt the A:B and C:D interfaces. These results demonstrate that the method of reducing or eliminating oligomerization of the GFP variants as described in Example 1 is generally applicable to other fluorescent proteins that have a propensity to oligomerize.

Example 5

Preparation And Characterization Of Tandem DsRed Dimers

This example demonstrates that a tandem DsRed protein can be formed by linking two DsRed monomers, and that such tandem DsRed proteins maintain emission and excitation spectra characteristic of DsRed, but do not oligomerize.

To construct tDsRed, a 3' primer, 5'-CCGGATCCCCCTTGGTGCTGCCCTCTCCGCTGCCAGGCTTGCCGCTGCCGC TGGTGCTGCCAAGGAACAGATGGTGGCGTCCCTCG-3' (SEQ ID NO: 37), was designed that overlapped the last 25 bp of DsRed (derived from the Clontech vector pDsRed-N1) and encoded for the linker sequence GSTSGSGKPGSGEGSTKG (SEQ ID NO: 38), followed by a Bam HI restriction site in frame with the Bam HI site of pRSET_B (Invitrogen). It was later determined that the above primer sequence contains three mismatches in the overlap region and contained several codons that were not optimal for mammalian expression. Accordingly, a new 3' primer, 5'-CCGGATCCCCCTTGGTGCTGCCCTCCCCGCTGCCGGGCTTCCCGCTCCCGC TGGTGCTGCCAAGGAACAGGTGGTGGCGGCCCTCG-3' (SEQ ID NO: 39), also was used. The 5' primer, 5'-GTACGACGATGACGATAAGGATCC-3' (SEQ ID NO: 40) also contained a Bam HI restriction site in frame with the Bam HI site of pRSET_B.

PCR amplification of DsRed and of DsRed-I125R with the new linker was accomplished with Taq DNA polymerase (Roche) and an annealing protocol that included 2 cycles at 40°C, 5 cycles at 43°C, 5 cycles at 45°C, and 15 cycles at 52°C. The resulting PCR product was purified by agarose gel-electrophoresis and digested with Bam HI (New England Biolabs). Bam HI and calf intestinal phosphatase (New England Biolabs) treated vector was prepared from pRSET_B with DsRed or DsRed-I125R inserted in frame with the His-6 tag and between the 5' Bam HI and 3' Eco RI restriction sites.

Following ligation of the digested PCR products and vector with T4 DNA ligase (NEB), the mixture was used to transform competent *E. coli* DH5 α by heat shock. Transformed colonies were grown on LB agar plates supplemented with the antibiotic ampicillin. Colonies were picked at random, and plasmid DNA was isolated through standard miniprep procedures (Qiagen). DNA sequencing was used to confirm the correct orientation of the inserted sequence.

In order to express protein, the isolated and sequenced vectors were used to transform competent *E. coli* JM109(DE3). Single colonies grown on LB agar/ampicillin were used to inoculate 1 liter cultures of LB/ampicillin, then were grown with shaking at 225 rpm and 37°C until the broth reached an OD₆₀₀ of 0.5-1.0. IPTG was added to a final concentration of 100 mg/l and the culture was grown for either 5 hr at 37°C

(tDsRed) or 24 hr at room temperature (RT; tDsRed-I125R). Cells were harvested by centrifugation (10 min, 5000 rpm), the pellet was resuspended in 50 mM Tris pH 7.5, and the cells were lysed by a single pass through a French press. Protein was purified by Ni-NTA (Qiagen) chromatography as described by the manufacturer and was stored in the elution buffer or was dialyzed into 50 mM Tris, pH 7.5.

With respect to the excitation and emission spectra as well as the maturation time of tDsRed and tDsRed-I125R, the proteins behaved identically to their untethered counterparts. As expected, tDsRed developed visible fluorescence within approximately 12 hr at room temperature, while tDsRed-I125R required several days before significant red color developed. The maturation of tDsRed-I125R continued for up to approximately 10 days. The excitation and emission maxima were unchanged at 558 nm and 583 nm, respectively.

The differences in the tandem dimer became apparent when the proteins were analyzed by SDS-polyacrylamide electrophoresis. Due to the high stability of the tetramer, DsRed that was not subjected to boiling migrated with an apparent molecular mass of about 110 kDa. In addition, the band on the gel, which corresponded to a DsRed tetramer, retained its red fluorescence, indicating that the rigid barrel structure of each monomer was intact. When the sample was boiled before loading, DsRed was non-fluorescent and presumably denatured, and ran as a monomer of approximately 32 kDa.

SDS-PAGE analysis confirmed the tandem structure of the expressed red fluorescent proteins, tDsRed and tDsRed-I125R. The unboiled tDsRed migrated at the same apparent molecular mass (about 110 kDa) as unboiled normal DsRed. The difference in their molecular structures only was apparent when the samples were boiled (denatured) before they were loaded onto the gel. Boiled tDsRed migrated with an apparent molecular mass of about 65 kDa, which is approximately the mass of two DsRed monomers, whereas boiled DsRed migrated at the monomer molecular mass of 32 kDa.

A similar comparison was made for DsRed-I125R and tDsRed-I125R. When they were not boiled prior to SDS-PAGE, tDsRed-I125R and DsRed-I125R both migrated as dimers with an apparent molecular mass of about 50 kDa. DsRed-I125R that was not boiled also had a large component that appeared to be denatured, though the fluorescent band for the dimer (50 kDa) was clearly visible. tDsRed-I125R also had a

denatured component that migrated slower (65 kDa vs. 50 kDa) than the intact fluorescent species. However, when boiled, tDsRed-I125R migrated at approximately the same mass as two monomers (65 kDa), while DsRed-I125R migrated at the monomer molecular mass of 32 kDa.

5 These results demonstrate that linking two DsRed monomers to form an intramolecularly bound tandem dimer prevented formation of intermolecular oligomers, without affecting the emission or excitation spectra of the red fluorescent proteins.

Example 6

10 Red Fluorescent Proteins with Improvement Efficiency of Maturation

Wild-type DsRed and Q66M DsRed maturation

In an attempt to improve the speed and efficacy of maturation, Q66 of dsRed was converted by site-directed mutagenesis to every other naturally occurring amino acid.
15 Only picking fluorescent colonies, it was determined that almost all single-mutations at this position (F, N, G, T, H, E, K, D, R, L, C) were deleterious, leading to loss of fluorescence, or inability to mature to a red fluorescent species. One substitution, however, Q66M, yielded a protein that had significantly improved properties.

First, wild-type DsRed and Q66M DsRed were both produced in bacteria (*E.*
20 *coli*) quickly purified, and allowed to mature in a cuvette sealed with parafilm. Parafilm was chosen to allow oxygen to diffuse into the protein solution, and to prevent the loss of water from the solution. The maturation was monitored by taking absorbance scans over time. Figure 26 plots maturation as peak absorbance of the red chromophore versus time. Since the proteins were not expressed instantaneously or with the exact same
25 efficiency, the two different curves did not both start at the same value, and they reached slightly different end values. To allow comparison, both curve amplitudes were first normalized to the same final absorbance. Then, the curves were fit to a three component kinetic model, and the time base for each scan was adjusted so that the curves intersected at zero time.

30

Wild-type DsRed and Q66M DsRed Fluorescence

Fluorescence emission and excitation spectra of wild-type DsRed and the Q66M DsRed variant were taken using 558 nm excitation or monitoring 583 nm emission for DsRed, and by using 566 nm excitation or monitoring 590 nm emission for Q66M DsRed. The results are shown in Figure 27. Of note is the prominent red-shift of the entire Q66M DsRed fluorescence spectrum, as well as the marked depression of the excitation shoulder at 480 nm for Q66M DsRed relative to wild-type.

Q66M DsRed Completeness of Maturation

Wild-type DsRed, Q66M DsRed, and another DsRed variant, K83R DsRed were subjected to brief boiling in pH 1 HCl, and then run on an SDS polyacrylamide gel. Since red chromophore formation makes the protein acid labile at residue 66, the relative amount of hydrolysis products versus full-length protein is indicative of the completeness of maturation. The gel was Coomassie stained and imaged with a flat-bed scanner, and the relative intensity of all of the bands was then quantified using the software NIH Image. After normalization for molecular weights (since the darkness of a Coomassie-stained band is related to the mass of protein in the band, not the molarity), the maturation completeness was calculated by dividing the normalized intensity of the split fragments' bands by the normalized intensity of the sum of all the bands. The results are shown in Figure 28. As expected for K83R DsRed, which contains only a trace amount of red protein, only full-length protein is visible. However, wild-type DsRed is degraded roughly 2/3 into split fragments, and Q66M DsRed is almost completely degraded into split fragments.

In conclusion, when Q66M DsRed was expressed in bacteria, the bacteria appeared to become fluorescent slightly faster than bacteria expressing wild-type DsRed. Furthermore, the Q66M DsRed protein appeared to be a deeper pink color than wild-type DsRed, which has an orange tinge. Finally, the excitation spectrum of Q66M DsRed has a significantly smaller hump at 480 nm than wild-type DsRed, suggesting that the species absorbing at 480 nm (the immature green form of the protein) was less abundant. These data together show that Q66M DsRed has significantly improved properties over the wild-type DsRed protein.

Example 7Preparation of a Further Improved Variant of the Monomeric Red Fluorescent Protein,
mRFP1

5 The engineering of the monomeric DsRed, mRFP1 (SEQ ID NO: 8), as described in the previous examples, has overcome at least three problems associated with the use of unmodified DsRed as a genetically encoded red fluorescent fusion label. Specifically, (1) mRFP1 is monomeric, (2) it matures rapidly, and (3) is not efficiently excited at wavelengths suitable for imaging of GFP. However mRFP1 is relatively dim (extinction
10 coefficient (EC) of 44,000 M⁻¹ and quantum yield (QY) of 0.25) and therefore limited in certain applications. In an effort to improve the brightness of mRFP1 the strategy of directed evolution by randomizing specific residues has been continued, in the hope of finding variants with improved spectral properties.

 In the first such library to improve the properties of mRFP1 the following codon
15 substitutions were made in the mRFP1 cDNA:

 N42Q to NNK = all 20 amino acids

 V44A to NNK = all 20 amino acids

 L46 to MTC = I or L

 Q66 to NNK = all 20 amino acids

20 K70 to ARG = K or R

 V71A to GYC = V or A

 This library contains a genetic diversity of 262,144 cDNAs which encode for 64,000 different amino acid sequences. This library was transformed into *E. coli* JM109(DE3) and bacterial colonies were manually screened (~50,000 independent
25 colonies) as described in the previous examples. Colonies that exhibited improved brightness or were a different color were picked and the gene was sequenced to determine the amino acid substitution. Top clones identified from this library fell into several different categories including:

30 Red-shifted variants:

 Q66M + T147S; x588m610, EC ~58,000 M⁻¹, QY ~0.25

 Q66M; x588m610, EC ~52,000 M⁻¹, QY ~0.25

Blue-shifted variants:

Q66T + Q213L; x574m595, EC $\sim 34,000 \text{ M}^{-1}$, QY ~ 0.25

Q66T; x564m581, EC $\sim 23,000 \text{ M}^{-1}$, QY ~ 0.25

Q66S; x558m578, dimmer than Q66T

5 Other interesting variants:

N42H + Q66G; x504m516, dim

V44M + Q66G; x504m516, dim

Q66L; absorbance maximum at 502 nm, practically non-fluorescent

10 The top mutant isolated from this library is mRFP1 + Q66M/T147S, which has been designated mRFP1.1. Although this variant does not improve the quantum yield relative to mRFP1, mRFP1.1 is $\sim 30\%$ brighter than mRFP1 due to an improved EC. This improvement is due to an apparent increase in the fraction of the protein that forms the mature red chromophore at the expense of the non-fluorescent species that absorbs at
15 502 nm (see Figure 29, presenting the absorption and emission spectrum of mRFP1.1). The beneficial T147S mutant arose from an error during PCR amplification of the cDNA due to the use of Taq polymerase. The Q66M mutation has previously been shown to improve the fluorescence of the dimeric I125R variant of DsRed (Baird, G. S. (2001) *Ph.D. Thesis*, University of California, San Diego). The amino acid sequence of
20 mRFP1.1 is shown in Figure 30 (SEQ ID NO: 79), while the nucleotide sequence of mRFP1.1 is provided in Figure 31 (SEQ ID NO: 80).

All publications, GenBank Accession Number sequence submissions, patents and published patent applications mentioned in the above specification are herein
25 incorporated by reference in their entirety. Various modifications and variations of the described compositions and methods of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with various specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific
30 embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in protein chemistry or molecular biological arts or related fields are intended to be within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A polynucleotide sequence encoding a *Discosoma* red fluorescent protein (DsRed) variant having a reduced propensity to oligomerize, comprising one or more
5 amino acid substitutions at the AB interface, at the AC interface, or at the AB and AC interfaces of the wild-type DsRed amino acid sequence of SEQ ID NO: 1, where the substitutions result in reduced propensity of the DsRed variant to form tetramers, wherein said variant displays detectable fluorescence of at least one red wavelength.

10 2. The polynucleotide sequence of claim 1, wherein said variant has at least about 80% sequence identity with the amino acid sequence of SEQ ID NO: 1.

3. The polynucleotide sequence of claim 1, wherein said detectable fluorescence matures at a rate at least about 80% as fast as the rate of fluorescence maturation of wild-
15 type DsRed of SEQ ID NO: 1.

4. The polynucleotide sequence of claim 1 having improved fluorescence maturation relative to DsRed of SEQ ID NO: 1.

20 5. The polynucleotide sequence of claim 1 substantially retaining the fluorescing properties of DsRed of SEQ ID NO: 1.

6. The polynucleotide sequence of claim 1, which has a propensity to form a dimer.

25 7. The polynucleotide sequence of claim 6, which has substitutions in the AB interface and forms an AC dimer.

8. The polynucleotide sequence of claim 6 comprising at least nine amino acid
30 substitutions that are at residues 2, 5, 6, 21, 41, 42, 44, 117, and 217, and additionally at least one more substitution including substitution at residue 125 of SEQ ID NO: 1.

9. The polynucleotide sequence of claim 8, optionally further comprising at least one additional amino acid substitution that is at residue 71, 118, 163, 179, 197, 127, or
35 131 of SEQ ID NO: 1.

10. The polynucleotide sequence of claim 9, wherein any one or more of said substitutions is optionally selected from R2A, K5E, N6D, T21S, H41T, N42Q, V44A, V71A, C117T, F118L, I125R, V127T, S131P, K163Q/M, S179T, S197T, and T217A/S.

11. The polynucleotide sequence of claim 1, wherein said variant is selected from the group of variants consisting of dimer1, dimer1.02, dimer1.25, dimer1.26, dimer 1.28, dimer1.34, dimer1.56, dimer1.61, dimer1.76, provided in FIG. 20.

12. The polynucleotide sequence of claim 1 that is dimer2 (SEQ ID NO: 6).

13. The polynucleotide sequence of claim 6, having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.

14. The polynucleotide sequence of claim 6, having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO: 1.

15. The polynucleotide sequence of claim 1, which is a monomer.

16. The polynucleotide sequence of claim 15, which has substitutions in the AB interface and the AC interface.

17. The polynucleotide sequence of claim 15 comprising at least 14 amino acid substitutions that are at residues 2, 5, 6, 21, 41, 42, 44, 71, 117, 127, 163, 179, 197, and 217, and additionally at least one more substitution that is at residue 125 of SEQ ID NO: 1.

18. The polynucleotide sequence of claim 17, optionally further comprising at least one additional amino acid substitution at residue 83, 124, 125, 150, 153, 156, 162, 164, 174, 175, 177, 180, 192, 194, 195, 222, 223, 224, and 225 of SEQ ID NO: 1.

19. The polynucleotide sequence of claim 18, wherein any one or more of said substitutions is optionally selected from R2A, K5E, N6D, T21S, H41T, N42Q, V44A, V71A, K83L, C117E/T, F124L, I125R, V127T, L150M, R153E, V156A, H162K, K163Q/M, L174D, V175A, F177V, S179T, I180T, Y192A, Y194K, V195T, S197A/T/I, T217A/S, H222S, L223T, F224G, L225A

20. The polynucleotide sequence of claim 15, wherein said variant is selected from the group of variants consisting of mRFP0.1, mRFP0.2, mRFP0.3, mRFP0.4a, mRFP0.4b, mP11, mP17, m1.01, m1.02, mRFP0.5a, m1.12, mRFP0.5b, m1.15, m1.19, mRFP0.6, m124, m131, m141, m163, m173, m187, m193, m200, m205 and m220, provided in FIG. 20.

21. The polynucleotide sequence of claim 15 that is mRFP1 (SEQ ID NO: 8).

22. The polynucleotide sequence of claim 15, having at least about 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.

23. The polynucleotide sequence of claim 15, having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO: 1.

24. A polynucleotide sequence encoding a tandem dimer comprising two DsRed protein variants encoded by the polynucleotide sequence of claim 1, operatively linked by a peptide linker.

25. The polynucleotide sequence of claim 24, wherein said peptide linker is about 10 to about 25 amino acids long.

26. The polynucleotide sequence of claim 25, wherein said peptide linker is about 12 to about 22 amino acids long.

27. The polynucleotide sequence of claim 24, wherein said peptide linker is selected from the group consisting of GHGTGSTGSGSS (SEQ ID NO: 17), RMGSTSGSTKGQL (SEQ ID NO: 18), and RMGSTSGSGKPGSGEGSTKGQL (SEQ ID NO: 19).

28. The polynucleotide sequence of claim 24 wherein at least one of said DsRed subunits is selected from the group consisting of dimer1, dimer1.02, dimer1.25, dimer1.26, dimer 1.28, dimer1.34, dimer1.56, dimer1.61, dimer1.76, and dimer2, provided in FIG. 20.

29. The polynucleotide sequence of claim 24 wherein said tandem dimer is a homodimer.

30. The polynucleotide sequence of claim 24 wherein said tandem dimer is a
5 heterodimer.

31. The polynucleotide sequence of claim 24 wherein at least one of said DsRed variants is dimer2 (SEQ ID NO: 6).

10 32. A polynucleotide sequence encoding a fusion protein, comprising at least one DsRed protein variant encoded by the polynucleotide sequence of claim 1 or 15 operatively joined to at least one polypeptide of interest.

15 33. The polynucleotide sequence of claim 32, wherein said fusion protein comprises a peptide tag.

34. The polynucleotide sequence of claim 33, wherein the peptide tag is a polyhistidine peptide tag.

20 35. The DsRed protein variant encoded by the polynucleotide sequence selected from the group of sequences consisting of the polynucleotide sequences of claim 1, claim 6, claim 15, and claim 24.

25 36. A kit, comprising at least one polynucleotide sequence of claim 1.

37. A kit, comprising at least one polypeptide encoded by the polynucleotide sequence of claim 1.

30 38. A vector comprising a polynucleotide sequence selected from the polynucleotide sequences of claim 1, claim 6, claim 15, and claim 24.

39. The vector of claim 38, wherein the vector is an expression vector.

35 40. A host cell comprising the vector of claim 38.

41. A method for the generation of a dimeric or monomeric variant of a fluorescent protein which has propensity to tetramerize or dimerize, comprising:

- (a) mutagenizing at least one amino acid residue in said fluorescent protein to produce a dimeric variant, if the protein had the propensity to tetramerize, and a monomeric variant, if the protein had the propensity to dimerize; and
- (b) mutagenizing at least one additional amino acid residue to yield a dimeric or monomeric variant, which retains the qualitative ability to fluoresce in the same wavelength region as the non-mutagenized fluorescent protein.

42. The method of claim 41, further comprising the step of introducing a further mutation into a dimeric variant produced from a fluorescent protein that had the propensity to form tetramers to produce a monomeric variant.

43. The method of claim 42, wherein said further step follows (a).

44. The method of claim 41, wherein said dimeric or monomeric variant has improved fluorescence intensity or fluorescence maturation relative to the non-mutagenized fluorescent protein.

45. The method of claim 41, wherein said mutagenizing is by multiple overlap extension with semidegenerate primers.

46. The method of claim 41, wherein said mutagenizing is by error-prone PCR.

47. The method of claim 41, wherein said mutagenizing is by site directed mutagenesis.

48. The method of claim 41, wherein said mutagenizing is by a combination of at least two of multiple overlap extension, error-prone PCR and site directed mutagenesis.

49. The method of claim 41, wherein said fluorescent protein is an Anthozoan fluorescent protein.

50. The method of claim 49 wherein said Anthozoan fluorescent protein fluoresces at a red wavelength.

51. The method of claim 49 wherein said Anthozoan fluorescent protein is
5 *Discosoma* DsRed.

52. The method of claim 41, wherein said variant fluorescent protein has a propensity to form dimers.

10 53. The method of claim 41, wherein said variant fluorescent protein has a propensity to form monomers.

54. A method for the detection transcriptional activity, comprising:

- 15 (a) providing a host cell comprising a vector, wherein said vector comprises nucleotide sequence encoding a variant DsRed fluorescent protein of claim 1 operably linked to at least one expression control sequence, and a means to assay said variant fluorescent protein fluorescence, and
- 20 (b) assaying fluorescence of said variant fluorescent protein produced by said host cell, where variant fluorescent protein fluorescence is indicative of transcriptional activity.

55. A polynucleotide sequence encoding a polypeptide probe suitable for use in fluorescence resonance energy transfer (FRET), comprising at least one polynucleotide
25 of claim 1.

56. A method for the analysis of *in vivo* localization or trafficking of a polypeptide of interest, comprising the steps of:

- 30 (a) providing a polynucleotide sequence of claim 32 and a host cell or tissue, and
- (b) visualizing said fusion protein that is expressed in said host cell or tissue.

57. A polynucleotide encoding a variant of a red fluorescent protein (RFP) having a propensity to form tetrameric structures, comprising at least one amino acid alteration resulting in increased efficiency of maturation, and at least one further amino acid alteration resulting in a reduced propensity to tetramerize.

5

58. The polynucleotide of claim 57 wherein said amino acid alteration is substitution.

59. The polynucleotide of claim 58 encoding a *Discosoma* red fluorescent protein (DsRed) variant.

10

60. The polynucleotide of claim 59 wherein the amino acid substitution resulting in higher fluorescence intensity at red wavelength is at position 66 of wild-type DsRed of SEQ ID NO: 1.

15

61. The polynucleotide of 60 encoding a DsRed variant comprising a Q66M substitution within SEQ ID NO: 1.

62. The polynucleotide of claim 59 wherein the amino acid substitution resulting in higher fluorescence intensity at red wavelength is at position 147 of wild-type DsRed of SEQ ID NO: 1.

20

63. The polynucleotide of claim 61 encoding a DsRed variant further comprising a substitution at position 147 within SEQ ID NO: 1.

25

64. The polynucleotide of claim 62 or 63 encoding a DsRed variant comprising a T147S substitution within SEQ ID NO: 1.

65. The polynucleotide of claim 61 encoding a DsRed variant further comprising one or more substitutions at the AB interface, at the AC interface, or at the AB and AC interfaces of the wild-type DsRed amino acid sequence of SEQ ID NO: 1,

30

where at least one of said substitutions result in reduced propensity of the DsRed variant to form tetramers.

66. The polynucleotide of claim 64 encoding a DsRed variant further comprising one or more substitutions at the AB interface, at the AC interface, or at the AB and AC interfaces of the wild-type DsRed amino acid sequence of SEQ ID NO: 1, where at least one of said substitutions result in reduced propensity of the DsRed variant to form tetramers.

67. The polynucleotide of claim 66 encoding a DsRed variant comprising one or more substitutions at an amino acid position selected from the group consisting of 42, 44, 71, 83, 124, 150, 163, 175, 177, 179, 195, 197, 217, 2, 5, 6, 125, 127, 180, 153, 162, 164, 174, 192, 194, 222, 223, 224, 225, 21, 41, 117, and 156 within the wild-type DsRed amino acid sequence of SEQ ID NO: 1.

68. The polynucleotide of claim 66 encoding a DsRed variant comprising one or more substitutions selected from the group consisting of N42Q, V44A, V71A, K83L, F124L, L150M, K163M, V175A, F177V, S179T, V195T, S197I, T217A, R2A, K5E, N6D, I125R, V127T, I180T, R153E, H162K, A164R, L174D, Y192A, Y194K, H222S, L223T, F224G, L225A, T21S, H41T, C117E, and V156A within the wild-type DsRed amino acid sequence of SEQ ID NO: 1.

69. The polynucleotide of claim 68 encoding a DsRed variant comprising the following substitutions: N42Q, V44A, V71A, K83L, F124L, L150M, K163M, V175A, F177V, S179T, V195T, S197I, T217A, R2A, K5E, N6D, I125R, V127T, I180T, R153E, H162K, A164R, L174D, Y192A, Y194K, H222S, L223T, F224G, L225A, T21S, H41T, C117E, and V156A within the wild-type DsRed amino acid sequence of SEQ ID NO: 1.

70. The polynucleotide of claim 69 encoding a mRFP1.1 shown in Figure 30 (SEQ ID NO: 79).

71. A polynucleotide encoding a DsRed variant comprising a Q66M substitution within the amino acid sequence of wild-type DsRed of SEQ ID NO: 1.

72. The polynucleotide of claim 71 encoding a DsRed variant that is
5 tetrameric.

73. The polynucleotide of claim 71 encoding a DsRed variant that is monomeric.

10 74. A polynucleotide encoding a fusion protein, comprising at least one DsRed protein variant encoded by the polynucleotide of claim 59, 61, 64, 70, 71, or 72 operatively joined to at least one polypeptide of interest.

75. A polynucleotide encoding a tandem dimer of DsRed, comprising two
15 DsRed protein variants, at least one of which comprises an amino acid alteration resulting in increasing efficiency of maturation, operatively linked by a peptide linker.

76. The polynucleotide of claim 75 encoding a tandem dimer of DsRed, in which at least one of said DsRed variants comprises a Q66M mutation within the wild-
20 type DsRed sequence of SEQ ID NO: 1.

77. The polynucleotide of claim 75 encoding a tandem dimer of DsRed, in which at least one of said DsRed variants comprises a T147S mutations within the wild-
25 type DsRed sequence of SEQ ID NO: 1.

78. The polynucleotide of claim 75 wherein said peptide linker is about 10 to about 25 amino acids long.

79. The polynucleotide of claim 75 wherein said peptide linker is about 12 to
30 about 22 amino acids long.

80. The polynucleotide of claim 75 wherein said peptide linker is selected from GHGTGSTGSGSS (SEQ ID NO: 17), RMGSTSGSTKGQL (SEQ ID NO: 18), and RMGSTSGSGKPGSGEGSTKGQL (SEQ ID NO: 19).

5 81. A polypeptide comprising an amino acid sequence encoded by the polynucleotide of claim 57.

82. A DsRed variant comprising an amino acid sequence encoded by the polynucleotide of claim 59, 61, or 64.

10 83. A DsRed variant encoded by the polynucleotide of claim 70 or 71.

84. A tandem dimer of DsRed encoded by a polynucleotide of claim 75, 76, 77, or 80.

15 85. A kit, comprising a polynucleotide of claim 59.

86. A kit, comprising a polypeptide encoded by the polynucleotide of claim 59.

20 87. A vector comprising a polynucleotide of claim 59, 61, 64, 70, or 71.

88. A host cell comprising the vector of claim 87.

25 89. A method for the detection transcriptional activity, comprising providing a host cell comprising a vector, wherein said vector comprises nucleotide sequence encoding a DsRed fluorescent protein variant of claim 59 operably linked to at least one expression control sequence, and a means to assay said variant fluorescent protein fluorescence, and assaying fluorescence of said variant fluorescent protein produced by
30 said host cell, where variant fluorescent protein fluorescence is indicative of transcriptional activity.

90. A method for the detection of protein-protein interactions, comprising detection of energy transfer from a fluorescent or bioluminescent protein fusion, acting as a donor, to a fusion protein encoded by a polynucleotide of claim 64, acting as an acceptor.


5

91. A method for the analysis of *in vivo* localization or trafficking of a polypeptide of interest, comprising the steps of:

- (a) providing a polynucleotide of claim 64 and a host cell or tissue, and
- (b) visualizing said fusion protein that is expressed in said host cell or tissue.

10

1/40

*FIG. 1*

2/40

FIG. 2A




FIG. 2B





FIG. 2C



3/40

FIG. 3A




FIG. 3B





FIG. 3C



4/40

FIG. 4A





FIG. 4C



5/40

FIG. 4B







FIG. 4D



6/40

FIG. 5



*FIG. 6*

8/40

FIG. 7




FIG. 8B





FIG. 8A



10/40




FIG. 9

11/40

FIG. 10A

Library*	Template	Method [†]	Targeted positions	Top clone [‡]	Name
D1	T1 [§] + I125R	MOE	I161/K163/S179/ S197	T1 + S117C _{rev} /I125R/ K163Q/S179T/S197T	dimer1
D2	dimer1	EPM	n/a	dimer1 + V71A/S131P	dimer1.02
D3	dimer1.02	MOE	K70/S197/T217	dimer1.02 + K70R/ F118L/T217S	dimer1.56
D4	dimer1.56	MOE	C117/F118/F124/ V127T	dimer1.56 + R70K _{rev} / C117T/F118L/V127T	dimer2
D5	T1 + I125R	MOE	I161/K163/S179/ S197/H222G/F224G	a. T1 + S117C _{rev} /F124L/ I125R/K163Q/S179T/ S197T/H222G/F224G b. As in a with K163H	a. HF2Ga b. HF2Gb
M1	dimer1	MOE	E144/A145/S146/ I161/H162/K163/ A164/H222G/F224G	dimer1 + E144A/ A145R/H162K/K163M/ A164R/H222G/F224G	mRFP0.1
M2	mRFP0.1	EPM	n/a	mRFP0.1 + Y192C	mRFP0.2
M3	dimer1.56 & HF2Ga & HF2Gb & mRFP0.2	MOE	C117/F124/V127T/ S131/H162/K163/ A164/Y192A/Y194A/ H222G/F224G	mRFP0.2 + K70R/ C117E/F124L/V127T/ A144E _{rev} /R145A _{rev} / Y192A/Y194A/T217S	mRFP0.3

*Libraries are labeled either 'M' or 'D' if they are composed of monomers or dimers respectively. †In each round libraries were constructed by either multiple overlap extension (MOE) or error-prone PCR mutagenesis (EPM). ‡Unless otherwise indicated, the top clone contains all mutations present in the starting template. All mutations are relative to wild type. DsRed except reversions, which are identified with the subscript 'rev'. § The T1 construct used in this work differs from the original T1 construct(7) by the absence of the P(-4)L mutation and the inserted valine residue (V1a) which is present in all constructs except mRFP1.

12/40

Library*	Template	Method [†]	Targeted positions	Top clone [‡]	Name
M4	mRFP0.3	MOE	K70/V71/K83/ Y192/Y194/V195/ S197/T217/L223/ L225	a. mRFP0.3 + K83/ L223E/L225A	a. mRFP0.4a
				b. mRFP0.3 + R70K _{rev} / V71A/ K83L/Y194K/ V195T/S197I/T217A/ H222C/L223T/L225A	b. mRFP0.4b
M5	mRFP0.4a & mRFP0.4b	EPM	n/a	a. mRFP0.4a + F177S b. mRFP0.4b + L150M/ V156A	a. mRFP0.5a b. mRFP0.5b
M6	mRFP0.5a & mRFP0.5b	MOE	L174/V175/F177/ F180	mRFP0.5b + L174D/ V175A/F177V/I180T	mRFP0.6
M7	mRFP0.6	MOE	V1a _{del} /A145/R149/L150/ R153/V156/H222S	mRFP0.6 + V1a _{del} / R153E/H222S	mRFP1

*Libraries are labeled either 'M' or 'D' if they are composed of monomers or dimers respectively. †In each round libraries were constructed by either multiple overlap extension (MOE) or error-prone PCR mutagenesis (EPM). ‡Unless otherwise indicated, the top clone contains all mutations present in the starting template. All mutations are relative to wild type DsRed except reversions, which are identified with the subscript 'rev'. § The T1 construct used in this work differs from the original T1 construct(7) by the absence of the P(-4)L mutation and the inserted valine residue (V1a) which is present in all constructs except mRFP1.

FIG. 10B




FIG. 10


*FIG. 11*

FIG. 11A

Library	Primer pairs for fragment amplification	Positions	Codon *	Possible substitutions
D1	1. PRSET_BamH1_FW/I161X_K163X_RV	I161	VYC	T/A/V/P/L
	2. I161X_K163X_FW/S179X_RV	K163	MWS	Q/H/L/K/N/M/I
	3. S179X_FW/S197X_A_RV	S179	NCC	A/S/T/P
	4. S197X_A_FW/PRSET_EcoR1_RV	S197	NCC	A/S/T/P
D3	1. PRSET_BamH1_FW/S197X_B_RV	K70 [†]	ARG	K/R
	2. S197X_B_FW/T217X_RV	S197	NNK	All 20 a.a.
	3. T217X_FW/PRSET_EcoR1_RV	T217	DYC	A/T/S/V/I/F
D4	1. PRSET_BamH1_FW/C117X_V127T_RV	C117	RVS	T/K/S/N/R/A/E/G/D
	2. C117X_V127T_FW/PRSET_EcoR1_RV	F118	NTS	L/M/V/I/F
		F124	NTS	L/M/V/I/F
		V127	ACC	T
D5	1. PRSET_BamH1_FW/I161X_K163X_RV	I161	VYC	T/A/V/P/L
	2. I161X_K163X_FW/S179X_RV	K163	MWS	Q/H/L/K/N/M/I
	3. S179X_FW/S197X_RV	S179	NCC	A/S/T/P
	4. S197X_FW/H222G_F224G_RV	S197	NCC	A/S/T/P
		H222	GGC	G
		F224	GGC	G

*The standard mixed base definitions are R = A/G, Y = C/T, M = A/C, K = G/T, S = C/G, W = A/T, H = A/C/T, B = C/G/T, V = A/C/G, D = A/G/T, N = A/C/G/T. Multiple templates were used to introduce these K70 substitutions.

FIG. 11B

Library	Primer pairs for fragment amplification	Positions	Codon *	Possible substitutions
M1	1. PRSET_BamH1_FW/E144X_A164X_RV	E144	VVS	G/R/A/P/T/E/Q/K/S/D/H/N
	2. E144X_A164X_FW/H222G_F224G_RV	A145	VVS	G/R/A/P/T/E/Q/K/S/D/H/N
		S146	ASC	S/T
		I161	NHC	N/D/H/Y/T/A/P/S/I/L/V/F
		H162	ARG	K/R
		K163	NWS	K/E/Q/M/V/L/N/D/H/Y/V/F
		A164	ARG	K/R
		H222	GGC	G
		F224	GGC	G
				T/K/S/N/R/A/E/G/D
M3	1. PRSET_BamH1_FW/C117X_S131X_RV	C117	RVS	L/M/V/I/F
	2. C117X_S131X_FW/H162X_A164X_RV	F124	NTS	T
	3. H162X_A164X_FW/Y192A_Y194A_RV	V127	ACC	S/P
	4. Y192A_Y194A_FW/H222G_F224G_RV	S131	YCC	K/R
		H162	ARG	Q/H/L/K/N/M/I
		K163	MWS	K/R
		A164	ARG	A
		Y192	GCC	A
		Y194	GCC	G
		H222	GGC	G
		F224	GGC	G

*The standard mixed base definitions are R = A/G, Y = C/T, M = A/C, K = G/T, S = C/G, W = A/T, H = A/C/T, B = C/G/T, V = A/C/G, D = A/G/T, N = A/C/G/T. Multiple templates were used to introduce these K70 substitutions.

16/40

FIG. 11C

Library	Primer pairs for fragment amplification	Positions	Codon *	Possible substitutions
M4	1. PRSET_BamH1_FW/K70X_K83X_RV	K70	ARG	K/R
	2. K70X_K83X_FW/Y192X_S197X_RV	V71	GYC	V/A
	3. Y192X_S197X_FW/T217X_L225X_RV	K83	WWK	N/K/I/M/Y/F/L
		Y192	RMS	E/D/A/K/N/T
		Y194	RMS	E/D/A/K/N/T
		V195	RYC	T/I/A/V
		S197	RYC	T/I/A/V
		T217	DCC	S/T/A
		L223	RMS	E/D/A/K/N/T
		L225	RMS	E/D/A/K/N/T
M6	1. PRSET_BamH1_FW/L174X_I180X_RV	L174	VVC	A/D/G/H/N/P/R/S/T
	2. L174X_I180X_FW/PRSET_EcoR1_RV	V175	NYC	P/T/S/A/L/I/F/V
		F177	NYC	P/T/S/A/L/I/F/V
		I180	AYC	I/T
M7	1. PRSET_BamH1_FW/A145X_V156X_RV	V1a	deletion	deletion
	2. A145X_V156X_FW/PRSET_EcoR1_RV	A145	SCC	A/P
	3. V1a_del_FW/H222S_REV	R149	CRS	Q/H/R/R
		L150	NTS	L/M/V/I/F
		R153	VAS	E/Q/D/H/K/N
		V156	RBC	V/A/T/I/S/G
		H222	TCC	S

*The standard mixed base definitions are R = A/G, Y = C/T, M = A/C, K = G/T, S = C/G, W = A/T, H = A/C/T, B = C/G/T, V = A/C/G, D = A/G/T, N = A/C/G/T. Multiple templates were used to introduce these K70 substitutions.

17/40

FIG. 12A

Primer Name	Sequence	SEQ ID No.
Primers for General Use		
PRSET_BamH1_FW	GTA CGA CGA TGA CGA TAA GGA TCC	41
PRSET_EcoR1_RV	GCA GCC GGA TCA AGC TTC GAA TTC	42
Primers Used to Construct Libraries for DsRed Dimer Evolution		
N42X_V44X_FW	CGC CCC TAC GAG GGC CAC MWS ACC VYC AAG CTG AAG GTG ACC AAGG	43
N42X_V44X_RV	CCT TGG TCA CCT TCA GCT TGR BGG TSW KGT GGC CCT CGT AGG GGC G	44
K70X_V71X_FW	CAG TTC CAG TAC GGC TCC NNK NYC TAC GTG AAG CAC CCC GCC	45
K70X_V71X_RV	GGC GGG GTG CTT CAC GTA GRN MNN GGA GCC GTA CTG GAA CTG	46
C117X_V127T_FW	CAG GAC GGC RVS NTS ATC TAC AAG GTG AAG NTS CGC GGC ACC AAC TTC	47
C117X_V127T_RV	GAA GTT GGT GCC GCG SAN CTT CAC CTT GTA GAT SAN SBY GCC GTC CTG	48
I161X_K163X_FW	GGC GTG CTG AAG GGC GAG VYC CAC MWS GCC CTG AAG CTG AAG GACG	49
I161X_K163X_RV	CGT CCT TCA GCT TCA GGG CSW KGT GGR BCT CGC CCT TCA GCA CGC C	50
S179X_FW	GGT GGA GTT CAA GNC CAT CTA CAT GGC CAA G	51
S179X_RV	CTT GGC CAT GTA GAT GGN CTT GAA CTC CAC C	52
S197X_A_FW	CTA CTA CTA CGT GGA CNC CAA GCT GGA CAT CAC C	53
S197X_A_RV	P-GGT GAT GTC CAG CTT GKN GTC CAC GTA GTA GTA G	54
S197_B_FW	C TAC TAC TAC GTG GAC NNK AAG CTG GAC ATC ACC	55
S197_B_RV	GGT GAT GTC CAG CTT MNN GTC CAC GTA GTA GTA G	56
T217X_FW	CAG TAC GAG CGC NCC GAG GGC CGC CAC	57
T217X_RV	GTG GCG GCC CTC GGN GCG CTC GTA CTG	58

The standard mixed base definitions are R = A/G, Y = C/T, M = A/C, K = G/T, S = C/G, W = A/T, H = A/C/T, B = C/G/T, V = A/C/G, D = A/G/T, N = A/C/G/T.

FIG. 12B

Primer Name	Sequence	SEQ ID No.
Primers used for DsRed Monomer Evolution		
K70X_K83X_FW	AAG CAC CCC GCC GAC ATC CCC GAC TAC WWK AAG CTG TCC	59
K70X_K83X_RV	GAT GTC GGC GGG GTG CTT CAC GTA GRC CYT GGA GCC GTA CTG	60
C117X_S131X_FW	GTG AAG NTS CGC GGC ACC AAC TTC CCC YCC GAC GGC CCC	61
C117X_S131X_RV	GAA GTT GGT GCC GCG SAN CTT CAC CTT GTA GAT GAA SBY GCC GTC CTG	62
E144X_A164X_FW	CTG TAC CCC CGC GAC GGC GTG CTG AAG GGC GAG NHC ARG NWS ARG	63
	CTG AAG CTG AAG GAC GGC GGC	
E144X_A164X_RV	CTT CAG CAC GCC GTC GCG GGG GTA CAG GCG CTC GGT GST SBB SBB	64
	CCA GCC CAT RGT CTT CTT CTG	
A145X_V156X_FW	TCC ACC GAG CRS NTS TAC CCC VAS GAC GGC RBC CTG AAG GGC	65
A145X_V156X_RV	GCC GTC STB GGG GTA SAN SYG CTC GGT GGA GGS CTC CCA GCC	66
H162X_A164X_FW	CTG AAG GGC GAG ATC ARG MWS ARG CTG AAG CTG AAG GAC	67
H162X_A164X_RV	GTC CTT CAG CTT CAG CYT SWK CYT GAT CTC GCC CTT CAG	68
L174X_180X_FW	GGC CAC TAC VVC NYC GAG NYC AAG ACC AYC TAC ATG GCC	69
L174X_180X_RV	GGC CAT GTA GRT GGT CTT GRN CTC GRN GBB GTA GTG GCC	70
Y192A_Y194A_FW	GTG CAG CTG CCC GGC GCC TAC GCC GTG GAC ACC AAG CTG	71
Y192A_Y194A_RV	CAG CTT GGT GTC CAC GGC GTA GGC GCC GGG CAG CTG CAC	72
Y192X_S197X_FW	GGC RMS TAC RMS RYC GAC RYC AAG CTG GAC ATC ACC	73
Y192X_S197X_RV	CTT GRY GTC GRY SKY GTA SKY GCC GGG CAG CTG CAC	74
T217X_L225X_RV	C GAA TTC TTA SKY GCC SKY GCC GTG GCG GCC CTC GGH GCG CTC	75
H222G_F224G_RV	P-GCT TCG AAT TCT TAC AGG CCC AGG CCG TGG CCG CCC TCG G	76
V1a_del_FW	AAG GAT CCG ATG GCC TCC TCC GAG GAC GTC	77
H222S_REV	TTC GAA TTC TTA GGC GCC GGT GGA GTG GCG GCC	78
The standard mixed base definitions are R = A/G, Y = C/T, M = A/C, K = G/T, S = C/G, W = A/T, H = A/C/T, B = C/G/T, V = A/C/G, D = A/G/T, N = A/C/G/T.		

19/40

FIG. 13

Construct/Injection	Number of Cells (and %) Showing Lucifer Yellow Passage	Did not pass Lucifer yellow
Cx43-mRFP1	8 (100%)	0
Cx43-mRFP0.5a	36 (100%)	0
Cx43-tdimer2(12)*	13 (33.5%)	27
Cx43-dimer2	16 (35%)	29
Cx43-T1	1 (2.5%)	38
Injected untransfected cells	0 (0%)	22
Injected transfected cell in contact with an untransfected cell.	0 (0%)	76
* Found one obvious gap junction with Cx43-tdimer2(12)		

20/40

FIG. 14

	Excitation maximum (nm)	Emission maximum (nm)	ϵ ($M^{-1}cm^{-1}$)	Quantum Yield (QY)	QY of photobleach	pK _a	t _{0.5} for maturation at 37°C
DsRed*	558	583	57×10^3	0.79	2.7×10^{-7}	4.7	~10 h
T1	555	584	35×10^3	0.51	2.1×10^{-7}	4.8	<1 h
dimer2	552	579	60×10^3	0.69	2.5×10^{-7}	4.9	~2 h
tdimer2(12)	552	579	120×10^3	0.68	2.0×10^{-7}	4.8	~2 h
mRFP1	584	607	44×10^3	0.25	2.9×10^{-6}	4.5	<1 h
*Published values for the ϵ and QY of photobleach of DsRed are highly variable, suggesting that these values depend critically on the conditions of the purification or handling. All values were determined in parallel on identically treated							

FIG. 15

Mutation	Red Species Exc (nm)	Red Species Em (nm)	Green Exc (nm)	Species Em (nm)	Maturation Speed	Red/Green Ratio
None	558	583	475	499	++	840
K83R	558	582	480	499	--	0.05
K83E	550	584	474	497	--	0.43
K83N	558	592	474	497	-	9.8
K83P	558	594	474	497	-	3.3
K83F	560	594	474	499	--	0.29
K83W	562	594	478	501	-	0.44
K83M	564	602	474	499	--	49
Y120H	562	600	478	499	-	0.4
S197T	558	584	478	499	+	53
K70R	562	585	480	503	-	13.8
K70M	N/a	n/a	480	499	n/a	0

FIG. 16

nucleotide sequence of the *Discosoma* wild-type red fluorescent protein open reading frame

```
atgaggtcttccaagaatggttatcaaggaggttcattgaggtttaaggttcgcatacgaagga  
acggtcaatgggcacgagtttgaaatagaaggcgaaggagagagggaggccatacgaaggg  
cacaataccgtaaaagcttaaggtaaccaaggggggacctttgccatttgcttgggatatt  
ttgtcaccacaatttcagtatggaagcaaggatataatgtcaagcacccctgccgacatacca  
gactataaaaagctgtcatttcctgaaggatttaaatgggaagggtcatgaactttgaa  
gacggtggcgtcgttactgtaccaggattccagtttgcaggatggctgtttcatctac  
aaggtcaagttcattggcgtgaactttcctccgatggacctgttatgcaaaaagaagaca  
atgggctgggaagccagcactgagcgtttgtatcctcgtgatggcgtgttgaaaggagag  
attcataaggctctgaagctgaaagacggtggtcattacctagttgaattcaaaagtatt  
tacaatggcaaaagacgtgtgcagctaccagggtactactatgttgactccaaactggat  
ataacaagccacaacgaagactatacaaatcgttgagcagtatgaaagaaccgaggacgc  
caccatctgttcctttaa
```

FIG. 17

amino acid sequence of the *Discosoma* wild-type red fluorescent protein

M R S S K N V I K E F M R F K V R M E G
T V N G H E E F E I E G E G E G R P Y E G
H N T V K L K V T K G G P L P F A W D I
L S P Q F Q Y G S K V Y V K H P A D I P
D Y K K L S F P E G F K W E R V M N F E
D G G V V T V T Q D S S L Q D G C F I Y
K V K F I G V N F P S D G P V M Q K K T
M G W E A S T E R L Y P R D G V L K G E
I H K A L K L K D G G H Y L V E F K S I
Y M A K K P V Q L P G Y Y V D S K L D
I T S H N E D Y T I V E Q Y E R T E G R
H H L F L

FIG. 18

nucleotide sequence of the *Discosoma* variant fast T1 red fluorescent protein open reading frame

```
atggcctcctccgaggacgtcatcaaggaggttcattcgcttcaagggtgcgcattggagggc  
tccgtgaacggccacgagttcgagatcgaggcgaggcgaggcgccccctacgagggc  
accagaccgccaagctgaagtgaccgaaggcgccccctgcccttcgctgggacatc  
ctgtccccccagttccagtagcgtcccaagggtacgtgaagcaccgccgacatcccc  
gactacaagaagctgtccttccccgagggttcaagtgaggcgctgatgaacttcgag  
gacggcggtgtgtgacctgacctgacctcctccctgaggacggtccttcatctac  
aaggagaagttcatcggcgtgaactccccctccgacggccccgtaatgcagaagaagact  
atgggtgggagcctccaccgagcgcctgtacccccgacggcgtgctgaaggcgag  
atccacaaggccctgaagctgaaggacggcgccactacctggtggagttcaagtcctc  
tacatggccaagaagccgtgcagctgcccggtactactacgtggactccaagctggac  
atcacctcccacaacgaggactacaccatcgtggagcagtagcagcgccgagggccgc  
caccacctgttcctgttag
```

FIG. 19

amino acid sequence of the *Discosoma* variant fast T1 red fluorescent protein

M	A	S	S	E	D	V	I	K	E	F	M	R	F	K	V	R	M	E	G
S	V	N	G	H	E	F	E	I	E	G	E	G	E	G	R	P	Y	E	G
T	Q	T	A	K	L	K	V	T	K	G	G	P	L	P	F	A	W	D	I
L	S	P	Q	F	Q	Y	G	S	K	V	Y	V	K	H	P	A	D	I	P
D	Y	K	K	L	S	F	P	E	G	F	K	W	E	R	V	M	N	F	E
D	G	G	V	V	T	V	T	Q	D	S	S	L	Q	D	G	S	F	I	Y
K	V	K	F	I	G	V	N	E	P	S	D	G	P	V	M	Q	K	T	
M	G	W	E	A	S	T	E	R	L	Y	P	R	D	G	V	L	K	G	E
I	H	K	A	L	K	L	K	D	G	G	H	Y	L	V	E	F	K	S	I
Y	M	A	K	K	P	V	Q	L	P	G	Y	Y	Y	V	D	S	K	L	D
I	T	S	H	N	E	D	Y	T	I	V	E	Q	Y	E	R	A	E	G	R
H	H	L	F	L															

26/40

FIG. 20A

T1 (as received from B. Glick)	P-4L	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			
T1 + I125R (after subcloning into our preferred vector)	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			
dimer1	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			
dimer1.02	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
1.26	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
1.28	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A	K47R		V71A
1.34	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	V71A
dimer1.56	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	V71A
1.61	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
1.76	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
dimer2	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
non-aggregating mutations		X	X	X								
AB interface												
AC interface												
external to barrel	X					X	X					
internal to barrel								X	X			X
mRFP0.1	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			
mRFP0.2	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			
mRFP0.3	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
mRFP0.4a	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
mRFP0.4b	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
mP11	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
mP17	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
m1.01	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
m1.02	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
mRFP0.5a	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
m1.12	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
mRFP0.5b	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m1.15	V1a	R2A	K5E	N6D	F11S	T21S	H41T	N42Q	V44A		K70R	
m1.19	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A		K70R	
mRFP0.6	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m124	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m131	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m141	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m163	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m173	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m187	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m193	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m200	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m205	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
m220	V1a	R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
mRFP1		R2A	K5E	N6D		T21S	H41T	N42Q	V44A			V71A
non-aggregating mutations		X	X	X								
AB interface												
AC interface												
external to barrel						X	X					
internal to barrel								X	X			X

FIG. 20C

BNSDOCID: <WO_____03086446A1_I_>

FIG. 20D

FIG. 20

FIG. 20A

FIG. 20C

FIG. 20B

FIG. 20D

FIG. 21

nucleotide sequence of the *Discosoma* variant red fluorescent protein dimer2 open reading frame

```
atggtggcctcctccgaggacgtcatcaaagagttcatcgcttcaaggcgcatggag
ggctccgtgaacggccacgagttcgagatcgagggcgagggcgagggcccccctacgag
ggcaccagaccgccaagctgaaggtagccaaggcgccccctgcccttgcctgggac
atcctgtccccccagttccagtagggctccaaggcgtagtgagcaccgcgcgacatc
ccgactacaagaagctgtccttccccgagggcttcaagtgggagcgctgatgaacttc
gaggacggcggtggtgacctgacccaggactcctccctgcaggacggcacgctgac
tacaaggtaggttccgggcaccaacttccccccgagggccccgtaatgcagaagaag
accatgggtgggagcctccaccgagcgctgtacccccgcgacggcgctgaagggc
gagatccaccaggccctgaagctgaaggacggcgccactacctggtggagttcaagacc
atctacatggccaagaagcccgtgcagctgccccggctactactacgtggacaccaagctg
gacatcacctcccacaacgaggactacaccatcgtggaaacagtagcgcgtcccgagggc
cgccaccacctgttctctgtag
```

FIG. 22

amino acid sequence of the *Discosoma* variant red fluorescent protein dimer2

M	V	A	S	S	E	D	V	I	K	E	F	M	R	F	K	V	R	M	E
G	S	V	N	G	H	E	F	E	I	E	G	E	G	E	G	R	P	Y	E
G	T	Q	T	A	K	L	K	V	T	K	G	G	P	L	P	F	A	W	D
I	L	S	P	Q	F	Q	Y	G	S	K	A	Y	V	K	H	P	A	D	I
P	D	Y	K	K	L	S	F	P	E	G	F	K	W	E	R	V	M	N	F
E	D	G	G	V	V	T	V	T	Q	D	S	S	L	Q	D	G	T	L	I
Y	K	V	K	F	R	G	T	N	F	P	P	D	G	P	V	M	Q	K	K
T	M	G	W	E	A	S	T	E	R	L	Y	P	R	D	G	V	L	K	G
E	I	H	Q	A	L	K	L	K	D	G	G	H	Y	L	V	E	F	K	T
I	Y	M	A	K	K	P	V	Q	L	P	G	Y	Y	Y	V	D	T	K	L
D	I	T	S	H	N	E	D	Y	T	I	V	E	Q	Y	E	R	S	E	G
R	H	L	F	L															

32/40

FIG. 23

nucleotide sequence of the *Discosoma* variant red fluorescent protein mRFP1 open reading frame

atggcctcctcggaggacgtcatcaaggaggttcatgcgcttcaagggtgcgcgtggagggc
tccgtgaacggccacgagttcagagatcgaggcgagggcgagggcccccctacgagggc
accagaccgccaagctgaagtgaccaaggcgccccctgcccttcgacctgggacatc
ctgtccctcagttccagtaaggctccaaggcctacgtgaagcaccccgccgacatcccc
gactactgaagctgtccttccccgagggttcaagtgggagcggtgatgaacttcgag
gacggcggtggtgacctgacctgacctcctccctgcaggacggcgagttcatctac
aagtgaaagtgcgcgccaccaacttccccctccgacggccccgtaatgcagaagaagacc
atgggctgggaggcctccaccgagcggtgtacctccgaggaaggcgccctgaaggcgag
atcaagatgaggctgaagctgaaggacggcgccactacgacgccgaggtcaagaccacc
tacatggccaagaagcccgctgcagctgcccgccgacctacaagaccgacatcaagctggac
atcacctcccacaacgaggactacaccatcgtggaacagtagcagcgccgagggccgc
cactccaccggcgccctaa

FIG. 24

amino acid sequence of the *Discosoma* variant red fluorescent protein mRFP1


M	A	S	S	E	D	V	I	K	E	F	M	R	F	K	V	R	P	Y	W	D	I	F	E	Y	T	E	T	D	R	
S	V	N	G	H	E	F	E	I	E	G	E	G	E	G	R	P	A	A	A	A	N	F	K	K	G	T	L	G		
T	Q	T	A	K	L	K	V	T	K	G	G	P	L	P	H	P	A	A	A	M	E	Q	L	V	I	K	E			
L	S	P	Q	F	Q	Y	G	S	K	A	Y	K	W	E	R	V	G	M	A	E	D	I	K	K	E					
D	Y	L	K	L	S	F	P	E	G	F	S	S	L	Q	D	V	G	M	A	E	D	I	K	K	E					
D	G	V	L	V	T	V	T	Q	D	S	S	P	E	P	D	V	G	M	A	E	D	I	K	K	E					
K	V	K	L	R	G	T	N	F	P	M	Y	G	H	Y	D	A	E	D	I	K	K	E								
M	G	W	R	A	S	T	E	R	D	G	P	H	Y	D	A	E	D	I	K	K	E									
I	K	M	R	L	K	P	K	Q	L	P	A	Y	Y	K	T	E	D	I	K	K	E									
Y	M	A	K	K	P	V	Q	L	P	A	Y	Y	K	T	E	D	I	K	K	E										
I	T	S	H	N	E	D	Y	T	I	V	E	Q	Y	E	R	A	E													
H	S	T	G	A																										

FIG. 25


nucleotide sequence of a modified *Discosoma* wild-type red fluorescent protein open reading frame with humanized codon usage

atggtgcgctcctccaagaacgtcatcaaggagttcatgcgcttcaagggtgcgcattggag
ggcaccgtgaacggccacgagttcgagatcgagggcgaggggcgcccccctacgag
ggccacaacaccgtgaagctgaaggtgaccaaggcgccccctgcccttcgcctgggac
atcctgtccccccagttccagtaagggtccaaaggtgtacgtgaagcaccgccgacatc
cccgaactacaagaagctgtccttccccgagggttcaagtgggagcgctgatgaacttc
gaggacggcggtgtgacctgacctgacctcctcctgcaggacggctgcttcac
tacaagggtgaagttcatcggcgtgaacttccccctccgacggcccccgtaatgcagaagaag
accatgggtgggagcctccaccgagcgctgtacccccgcgacggcgctgctgaagggc
gagatccacaaggccctgaagctgaaggacggcgccactacctggtggagttcaagtcc
atctacatggccaagaagcccggtgcagctgccccggctactactacgtggactccaagctg
gacatcacctcccacaacgaggactacaccatcgtggagcagtacgagcgaccgagggc
cgccaccacctgttctctgtag

35/40

*FIG. 26*

36/40

dsRed w.t. vs. Q66M Fluorescence*FIG. 27*

37/40





FIG. 28

38/40

*FIG. 29*

39/40

FIG. 30

mRFP1.1 amino acid sequence

G G I P E Y T E T D R
 E E D I F I K G T L G
 M Y W D N F K K K K E
 R P A A M E Q L V I A
 V R F P V G M A E D R
 K G P H R D V G A T E
 F E L K E Q P D D K Y
 R G P V W L G E Y Y Q
 M E G Y K S S D P H A E
 F G G A F S S Y G G V
 E E K K G D P M G P I
 K I T S E Q F R D L T
 I E V G P T N E K Q Y
 V F K Y F V T S L V D
 D E L M S T G S K P E -
 E H K F L V R A L K N A
 S G A Q K V L E R K H G
 S N T P L G K W M A S T
 A V Q S Y G V G K M T S
 M S T L D D K M I Y I H

40/40

FIG. 31

mRFP1.1 DNA sequence

```
atggcctcctccgaggacgtcatcaaggagttcatgcgcttcaaggtgcgcattggagggc
tccgtgaacggccacgagttcgagatcgagggcgagggcgagggcccccctacgagggc
accagaccgccaagctgaagtgaccaaggcgggcccccctgccttcgctgggacatc
ctgtccctcagttcatgtacggctccaaggcctacgtgaagcaccccgacatcccc
gactactgaagctgtccttcccggaggcttcaagtgaggcgctgatgaacttcgag
gacggcggtggtgacogtgacccaggactcctccctgcaggacggcagttcatctac
aagtgaaagtgcgcggcaccaacttcccctccgacggccccgtaatgcagaagaagacc
atgggctgggagggcctcctccgagcggatgtaccccgaggacggcgccctgaaggcgag
atcaagatgaggctgaagctgaaggacggcgccactacgacgccgaggtcaagaccacc
tacctggccaagaagcccgtgcagctgccggcgccctacaagaccgacatcaagctggac
atcacctcccacaacgaggactacaccatcgttggaacagtacgagcgccgagggccgc
cactccaccggcgccctaa
```

39754-0831 PCT.TXT

SEQUENCE LISTING

<110> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
 Tsien, Roger
 Campbell, Robert
 Geoffrey, Baird

<120> MONOMERIC AND DIMERIC FLUORESCENT PROTEIN VARIANTS AND METHODS
 FOR MAKING SAME

<130> 39754-0831 PCT

<140> 10/209,208
 <141> 2002-07-29

<150> 10/121,258
 <151> 2002-04-10

<150> 09/866,538
 <151> 2001-05-24

<150> 09/794,308
 <151> 2001-02-26

<160> 80

<170> FastSEQ for windows Version 4.0

<210> 1
 <211> 225
 <212> PRT
 <213> Discosoma sp.

<220>
 <221> misc_feature
 <222> (1)...(225)
 <223> wild-type DsRed

<400> 1
 Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1 5 10 15
 Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
 20 25 30
 Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val
 35 40 45
 Thr Lys Gly Gly Pro Leu pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
 50 55 60
 Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
 65 70 75 80
 Asp Tyr Lys Lys Leu Ser Phe pro Glu Gly Phe Lys Trp Glu Arg Val
 85 90 95
 Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
 100 105 110
 Leu Gln Asp Gly Cys Phe Ile Tyr Lys Val Lys Phe Ile Gly Val Asn
 115 120 125
 Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
 130 135 140
 Ala Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
 145 150 155 160
 Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
 165 170 175
 Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr
 180 185 190
 Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
 195 200 205
 Thr Ile Val Glu Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe
 210 215 220

39754-0831 PCT.TXT

Leu
225

<210> 2
 <211> 678
 <212> DNA
 <213> Discosoma sp.

<220>
 <221> misc_feature
 <222> (1)...(678)
 <223> wild-type DsRed

<400> 2
 atgaggtcctt ccaagaatgt tatcaaggag ttcattgaggt ttaagggttcg catggaagga 60
 acggtcaatg ggcacgaggt tgaaatagaa ggcgaaggag aggggaggcc atacgaaggc 120
 cacaataaccg taaagcttaa ggtaaccaag gggggacctt tgccatttgc ttgggatatt 180
 ttgtcaccac aatttcagta tggaagcaag gtatatgtca agcaccctgc cgacatacca 240
 gactataaaa agctgtcatt tcctgaagga tttaaatggg aaaggggtcat gaactttgaa 300
 gacggtggcg tcgttactgt aacccaggat tccagtttgc aggatggctg tttcatctac 360
 aaggtcaagt tcattggcgt gaactttcct tccgatggac ctgttatgca aaagaagaca 420
 atgggctggg aagccagcac tgagcgtttg tatcctcgtg atggcgtgtt gaaaggagag 480
 attcataagg ctctgaagct gaaagacggg ggtcattacc tagttgaatt caaaagtatt 540
 tacatggcaa agaagcctgt gcagctacca gggctactact atgttgactc caaactggat 600
 ataacaagcc acaacgaaga ctataacaatc gttgagcagt atgaaagaac cgaggggacgc 660
 caccatctgt tcctttaa 678

<210> 3
 <211> 681
 <212> DNA
 <213> Artificial Sequence

<220>

<223> nucleotide sequence encoding DsRed with mammalian
 codon usage

<400> 3
 atgggtgcgct cctccaagaa cgtcatcaag gagttcatgc gcttcaaggt gcgcatggag 60
 ggcaccgtga acggccacga gttcgagatc gagggcgagg gcgagggccg cccctacgag 120
 ggccacaaca ccgtgaagct gaaggtgacc aaggggcgcc ccctgccctt cgcctgggac 180
 atcctgtccc cccagttcca gtacggctcc aaggtgtacg tgaagcacc cgccgacatc 240
 cccgactaca agaagctgtc cttccccgag ggcttcaagt gggagcgcgt gatgaacttc 300
 gaggacggcg gcgtgggtgac cgtgaccacg gactcctccc tgcaggacgg ctgcttcac 360
 tacaaggtga agttcatcgg cgtgaacttc cctccgacg gccccgtaat gcagaagaag 420
 accatgggct gggaggcctc caccgagcgc ctgtaccccc gcgacggcgt gctgaaggcg 480
 gagatccaca aggccctgaa gctgaaggac ggcggccact acctgggtga gttcaagtcc 540
 atctacatgg ccaagaagcc cgtgcagctg cccggctact actacgtgga ctccaagctg 600
 gacatcacct cccacaacga ggactacacc atcgtggagc agtacgagcg caccgagggc 660
 cgccaccacc tgttcctgta g 681

<210> 4
 <211> 225
 <212> PRT
 <213> Artificial Sequence

<220>

<223> DsRed polypeptide variant "T1"

<400> 4
 Met Ala Ser Ser Glu Asp Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1 5 10 15
 Arg Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
 20 25 30
 Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val
 35 40 45
 Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln

Page 2

39754-0831 PCT.TXT

```

50      55      60
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
65      70      75      80
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
85      90      95
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
100      105      110
Leu Gln Asp Gly Ser Phe Ile Tyr Lys Val Lys Phe Ile Gly Val Asn
115      120      125
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
130      135      140
Ala Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
145      150      155      160
Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
165      170      175
Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr
180      185      190
Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
195      200      205
Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His His Leu Phe
210      215      220
Leu
225

```

<210> 5
 <211> 678
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Polynucleotide encoding DsRed polypeptide variant
 "T1"

```

<400> 5
atggcctcct ccgaggacgt catcaaggag ttcattgcgt tcaagggtgcg catggagggc 60
tccgtgaacg gccacgagtt cgagatcgag ggcgagggcg agggccgccc ctacgagggc 120
accagaccg ccaagctgaa ggtgaccaag ggcggccccc tgcccttcgc ctgggacatc 180
ctgtccccc agttccagta cggctccaag gtgtacgtga agcaccgccg cgacatcccc 240
gactacaaga agctgtcctt ccccgagggc ttcaagtggg agcgcgtgat gaacttcgag 300
gacggcggcg tggtagaccgt gacccaggac tcctccctgc aggacggctc cttcatctac 360
aaggtgaagt tcatcggcgt gaacttcccc tccgacggcc ccgtaatgca gaagaagact 420
atgggcttgg aggcctccac cgagcgcctg taccccgcg acggcgtgct gaaggcgag 480
atccacaagg ccctgaagct gaaggacggc ggccactacc tggtaggagt caagtccatc 540
tacatggcca agaagcccgt gcagctgccc ggctactact acgtggactc caagctggac 600
atcacctccc acaacgagga ctacaccatc gtggagcagt acgagcgcgc cgagggccgc 660
caccacctgt tcctgtag
678

```

<210> 6
 <211> 226
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> DsRed polypeptide variant "dimer2"

```

<400> 6
Met Val Ala Ser Ser Glu Asp Val Ile Lys Glu Phe Met Arg Phe Lys
1      5      10      15
Val Arg Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly
20      25      30
Glu Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys
35      40      45
Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro
50      55      60
Gln Phe Gln Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile
65      70      75      80
Pro Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg

```


39754-0831 PCT.TXT

```

      85      90      95
Val Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser
      100      105      110
Ser Leu Gln Asp Gly Thr Leu Ile Tyr Lys Val Lys Phe Arg Gly Thr
      115      120      125
Asn Phe Pro Pro Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp
      130      135      140
Glu Ala Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly
      145      150      155
Glu Ile His Gln Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val
      165      170      175
Glu Phe Lys Thr Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly
      180      185      190
Tyr Tyr Tyr Val Asp Thr Lys Leu Asp Ile Thr Ser His Asn Glu Asp
      195      200      205
Tyr Thr Ile Val Glu Gln Tyr Glu Arg Ser Glu Gly Arg His His Leu
      210      215      220
Phe Leu
      225

```

<210> 7
 <211> 681
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Polynucleotide encoding DsRed polypeptide variant
 "dimer2"

```

<400> 7
atggtggcct cctccgagga cgtcatcaaa gagttcatgc gcttcaaggt gcgcatggag 60
ggctccgtga acggccacga gtccgagatc gagggcgagg gcgagggccg cccctacgag 120
ggcaccacaga ccgccaagct gaaggtgacc aagggcggcc cctgcccctt cgcctgggac 180
atcctgtccc cccagttcca gtacggctcc aaggcgtagc tgaagcacc cgcgcacatc 240
cccgactaca agaagctgtc cttccccgag ggcttcaagt gggagcgcgt gatgaacttc 300
gaggacggcg gcgtggtgac cgtgacccag gactcctccc tgcaggacgg cacgctgatc 360
tacaaggtga agttccgcgg caccaacttc ccccccgcag gccccgtaat gcagaagaag 420
accatgggct gggaggcctc caccgagcgc ctgtaccccc gcgacggcgt gctgaagggc 480
gagatccacc aggccttgaa gctgaaggac ggcggccact acctggtgga gttcaagacc 540
atctacatgg ccaagaagcc cgtgcagctg cccggctact actacgtgga caccaagctg 600
gacatcacct cccacaacga ggactacacc atcgtggaac agtacgagcg ctccgagggc 660
cgccaccacc tgttctgta g

```

<210> 8
 <211> 225
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> DsRed polypeptide variant "mRFP1"

```

<400> 8
Met Ala Ser Ser Glu Asp Val Ile Lys Glu Phe Met Arg Phe Lys Val
1      5      10      15
Arg Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
      20      25      30
Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val
      35      40      45
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
      50      55      60
Phe Gln Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro
      65      70      75      80
Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
      85      90      95
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
      100      105      110
Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn

```

39754-0831 PCT.TXT

```

      115      120      125
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
      130      135      140
Ala Ser Thr Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu
145      150      155      160
Ile Lys Met Arg Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu
      165      170      175
Val Lys Thr Thr Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Ala
      180      185      190
Tyr Lys Thr Asp Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
      195      200      205
Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly
210      215      220
Ala
225

```

<210> 9
 <211> 678
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Polynucleotide encoding DsRed polypeptide variant
 "mRFP1"

```

<400> 9
atggcctcct ccgaggacgt catcaaggag ttcattgcgct tcaaggtgcg catggagggc 60
tccgtgaacg gccacgagtt cgagatcgag ggcgagggcg agggccgccc ctacgagggc 120
accagaccg ccaagctgaa ggtgaccaag ggcggccccc tgcccttcgc ctgggacatc 180
ctgtccctc agttccagta cggctccaag gcctacgtga agcaccgccg cgacatcccc 240
gactacttga agctgtcctt ccccgagggc ttcaagtggg agcgcgtgat gaacttcgag 300
gacggcgggc tggtgaccgt gacccaggac tcctccctgc aggacggcga gttcatctac 360
aaggtgaagc tgcgcggcac caacttcccc tccgacggcc ccgtaatgca gaagaagacc 420
atgggctggg aggcctccac cgagcggatg taccccgagg acggcgccct gaagggcgag 480
atcaagatga ggctgaagct gaaggacggc ggccactacg acgccgaggt caagaccacc 540
tacatggcca agaagccgt gcagctgcc ggcgctaca agaccgacat caagctggac 600
atcacctccc acaacgagga ctacaccatc gtggaacagt acgagcgcgc cgagggccgc 660
cactccaccg ggcgctaa
678

```

<210> 10
 <211> 238
 <212> PRT
 <213> Aequorea victoria

```

<400> 10
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1      5      10      15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20      25      30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35      40      45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50      55      60
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln
65      70      75      80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85      90      95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100      105      110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115      120      125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130      135      140
Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145      150      155      160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165      170      175

```

39754-0831 PCT.TXT

Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
 180 185 190
 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
 195 200 205
 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
 210 215 220
 Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
 225 230 235

<210> 11

<211> 239

<212> PRT

<213> Artificial Sequence

<220>

<223> Enhanced Cyan Fluorescent Protein (ECFP)

<400> 11

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1 5 10 15
 Val Glu Leu Asp Gly Asp Val Asn Gly His Arg Phe Ser Val Ser Gly
 20 25 30
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 35 40 45
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 50 55 60
 Leu Thr Trp Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
 65 70 75 80
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
 85 90 95
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
 100 105 110
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
 115 120 125
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
 130 135 140
 Asn Tyr Ile Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln Lys Asn
 145 150 155 160
 Gly Ile Lys Ala His Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
 165 170 175
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
 180 185 190
 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
 195 200 205
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
 210 215 220
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
 225 230 235

<210> 12

<211> 239

<212> PRT

<213> Artificial Sequence

<220>

<223> Enhanced Yellow Fluorescent Protein (EYFP) Variant
V68L/Q69K

<400> 12

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1 5 10 15
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
 20 25 30
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 35 40 45
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr

39754-0831 PCT.TXT

```

50      55      60
Phe Gly Tyr Gly Leu Lys Cys Phe Ala Arg Tyr Pro Asp His Met Lys
65      70      75      80
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
85      90      95
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
100      105      110
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
115      120      125
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
130      135      140
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
145      150      155      160
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
165      170      175
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
180      185      190
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Tyr Gln Ser Ala Leu
195      200      205
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
210      215      220
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
225      230      235

```

<210> 13
 <211> 239
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Enhanced Green Fluorescent Protein (EGFP)

```

<400> 13
Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
1      5      10      15
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
20      25      30
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
35      40      45
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
50      55      60
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
65      70      75      80
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
85      90      95
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
100      105      110
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
115      120      125
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
130      135      140
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
145      150      155      160
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
165      170      175
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
180      185      190
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
195      200      205
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
210      215      220
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
225      230      235

```

<210> 14
 <211> 239

39754-0831 PCT.TXT

<212> PRT

<213> Artificial Sequence

<220>

<223> Enhanced Cyan Fluorescent Protein (ECFP)

<400> 14

```

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1      5      10      15
Val Glu Leu Asp Gly Asp Val Asn Gly His Arg Phe Ser Val Ser Gly
 20      25      30
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 35      40      45
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 50      55      60
Leu Thr Trp Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
 65      70      75      80
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
 85      90      95
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
100      105      110
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
115      120      125
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
130      135      140
Asn Tyr Ile Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln Lys Asn
145      150      155      160
Gly Ile Lys Ala His Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
165      170      175
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
180      185      190
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
195      200      205
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
210      215      220
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
225      230      235

```

<210> 15

<211> 239

<212> PRT

<213> Artificial Sequence

<220>

<223> Enhanced Yellow Fluorescent Protein (EYFP)

<400> 15

```

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1      5      10      15
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
 20      25      30
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 35      40      45
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 50      55      60
Phe Gly Tyr Gly Val Gln Cys Phe Ala Arg Tyr Pro Asp His Met Lys
 65      70      75      80
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
 85      90      95
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
100      105      110
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
115      120      125
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
130      135      140
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
145      150      155      160

```

39754-0831 PCT.TXT

Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
 165 170 175
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
 180 185 190
 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Tyr Gln Ser Ala Leu
 195 200 205
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
 210 215 220
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
 225 230 235

<210> 16
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker Polypeptide

<400> 16
 Arg Met Gly Thr Gly Ser Gly Gln Leu
 1 5

<210> 17
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker Polypeptide

<400> 17
 Gly His Gly Thr Gly Ser Thr Gly Ser Gly Ser Ser
 1 5 10

<210> 18
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker Polypeptide

<400> 18
 Arg Met Gly Ser Thr Ser Gly Ser Thr Lys Gly Gln Leu
 1 5 10

<210> 19
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Linker Polypeptide

<400> 19
 Arg Met Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Gly Gly
 1 5 10 15
 Ser Thr Lys Gly Gln Leu
 20

<210> 20
 <211> 225

39754-0831 PCT.TXT

<212> PRT

<213> Artificial Sequence

<220>

<223> DsRed with IL25R

<400> 20

```

Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
1      5      10      15
Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
20      25      30
Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val
35      40      45
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
50      55      60
Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
65      70      75      80
Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
85      90      95
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
100     105     110
Leu Gln Asp Gly Cys Phe Ile Tyr Lys Val Lys Phe Arg Gly Val Asn
115     120     125
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
130     135     140
Ala Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
145     150     155     160
Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
165     170     175
Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr
180     185     190
Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
195     200     205
Thr Ile Val Glu Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe
210     215     220
Leu
225

```

<210> 21

<211> 716

<212> DNA

<213> Aequorea victoria

<220>

<221> misc_feature

<222> (1)...(716)

<223> polynucleotide encoding wild type Green
Fluorescent Protein (GFP)

<400> 21

```

atgagtaaag gagaagaact tttcactgga gttgtcccaa ttcttggtga attagatggt 60
gatgttaatg ggcacaaatt ttctgtcagt ggagagggtg aaggtgatgc aacatacggg 120
aaacttaccc ttaaatttat ttgcactact ggaaaactac ctgttccatg gccaacactt 180
gtcactactt tctcttatgg tgttcaatgc ttttcaagat acccagatca tatgaaacag 240
catgactttt tcaagagtgc catgcccgaag ggttatgtac aggaaagaac tatatttttc 300
aaagatgacg ggaactacaa gacacgtgct gaagtcaagt ttgaaggtga tacccttggt 360
aatagaatcg agttaaaagg tattgatttt aaagaagatg gaaacattct tggacacaaa 420
ttggaataca actataactc acacaatgta tacatcatgg cagacaaaaca aaagaatgga 480
atcaaagtta acttcaaaat tagacacaac attgaagatg gaagcgttca actagcagac 540
cattatcaac aaaatactcc aattggcgat ggccctgtcc tttaccaga caaccattac 600
ctgtccacac aatctgccct ttcgaaagat cccaacgaaa agagagacca catggtcctt 660
cttgagtttg taacagctgc tgggattaca catggcatgg atgaactata caaata 716

```

<210> 22

<211> 33

<212> PRT

<213> Artificial Sequence

39754-0831 PCT.TXT

<220>

<223> 6xHis Tag

<400> 22

Met Arg Gly Ser His His His His His Gly Met Ala Ser Met Thr
 1 5 10 15
 Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp Asp Asp Asp Lys Asp
 20 25 30
 Pro

<210> 23

<211> 681

<212> DNA

<213> Artificial Sequence

<220>

<223> nucleotide sequence encoding DsRed with mammalian codon usage

<400> 23

atggtgctgct cctccaagaa cgtcatcaag gagttcatgc gcttcaaggt gcgcatggag 60
 ggcaccgtga acggccacga gttcgagatc gagggcgagg gcgagggccg cccctacgag 120
 ggccacaaca ccgtgaagct gaaggtgacc aagggcgggc ccctgccctt cgcctgggac 180
 atcctgtccc cccagttcca gtacggctcc aaggtgtacg tgaagcaccg cgcctgggac 240
 cccgactaca agaagctgtc ctcccccgag ggcttcaagt gggagcgcgt gatgaacttc 300
 gaggacggcg gcgtgggtgac cgtgacccag gactcctccc tgcaggacgg ctgcttcacg 360
 tacaaggtga agttcatcgg cgtgaacttc ccctccgacg gccccgtaat gcagaagaag 420
 accatgggct gggaggcctc caccgagcgc ctgtaccccc gcgacggcgt gctgaagggc 480
 gagatccaca aggcctgaa gctgaaggac ggcggccact acctgggtgga gttcaagtcc 540
 atctacatgg ccaagaagcc cgtgcagctg cccggctact actacgtgga ctccaagctg 600
 gacatcacct cccacaacga ggactacacc atcgtggagc agtacgagcg caccgagggc 660
 cgccaccacc tgttcctgta g 681

<210> 24

<211> 225

<212> PRT

<213> Artificial Sequence

<220>

<223> DsRed polypeptide variant "T1" with I125R mutation

<400> 24

Met Ala Ser Ser Glu Asp Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1 5 10 15
 Arg Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
 20 25 30
 Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val
 35 40 45
 Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
 50 55 60
 Phe Gln Tyr Gly Ser Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
 65 70 75 80
 Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
 85 90 95
 Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
 100 105 110
 Leu Gln Asp Gly Ser Phe Ile Tyr Lys Val Lys Phe Arg Gly Val Asn
 115 120 125
 Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
 130 135 140
 Ala Ser Thr Glu Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
 145 150 155 160
 Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
 165 170 175
 Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr

Page 11

39754-0831 PCT.TXT

Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
 180 185 190
 Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His His Leu Phe
 195 200 205
 210 215 220
 Leu
 225

<210> 25
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic primer

<400> 25
 cagtccaagc tgagcaaaga cccaacgag aagcgcgatc ac

42

<210> 26
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic primer

<400> 26
 gtgatcgcgc ttctcggttg ggtctttgct cagcttggac tg

42

<210> 27
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic primer

<400> 27
 cacatggtcc tgaaggagtt cgtgaccgcc gccggg

36

<210> 28
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic primer

<400> 28
 cccggcggcg gtcacgaact ccttcaggac catgtg

36

<210> 29
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic primer

<400> 29
 cacatggtcc tgctggagcg cgtgaccgcc gccggg

36

<210> 30
 <211> 36
 <212> DNA
 <213> Artificial Sequence

39754-0831 PCT.TXT

<220>
<223> Mutagenic primer

<400> 30
cccggcggcg gtcacgcgct ccagcaggac catgtg 36

<210> 31
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic primer

<400> 31
cacatcgtcc tgaaggagcg cgtgaccgcc gccggg 36

<210> 32
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic primer

<400> 32
cccggcggcg gtcacgcgct ccttcaggac catgtg 36

<210> 33
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic primer

<400> 33
tacaaggtga agttcaaggg cgtgaacttc ccc 33

<210> 34
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic primer

<400> 34
ggggaagttc acgcccttga acttcacctt gta 33

<210> 35
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic primer

<400> 35
tacaaggtga agttccgcgg cgtgaacttc ccc 33

<210> 36
<211> 33
<212> DNA
<213> Artificial Sequence

<220>

39754-0831 PCT.TXT

<223> Mutagenic primer

<400> 36

ggggaagttc acgccgcgga acttcacctt gta

33

<210> 37

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<223> chimeric primer encoding polypeptide linker sequence.

<400> 37

ccggatcccc tttggtgctg ccctctccgc tgccaggctt gccgctgccg ctggtgctgc 60
caaggaacag atggtggcgt ccctcg 86

<210> 38

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Linker Sequence

<400> 38

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
1 5 10 15
Lys Gly

<210> 39

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<223> Chimeric primer with altered codon usage.

<400> 39

ccggatcccc cttggtgctg ccctccccgc tgccgggctt cccgctcccc ctggtgctgc 60
ccaggaacag gtggtggcgg ccctcg 86

<210> 40

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer containing engineered restriction site.

<400> 40

gtacgacgat gacgataagg atcc

24

<210> 41

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Vector backbone primer

<400> 41

gtacgacgat gacgataagg atcc

24

<210> 42

39754-0831 PCT.TXT

<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Vector backbone primer

<400> 42
gcagccggat caagcttcga attc

24

<210> 43
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 43
cgcccctacg agggccacmw saccvyaag ctgaagggtga ccaagg

46

<210> 44
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 44
ccttggtcac cttcagcttg rbggtswkgt ggccctcgta ggggcg

46

<210> 45
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 19, 20, 22
<223> n = A,T,C or G

<400> 45
cagttccagt acggctccnn knyctacgtg aagcaccgccg cc

42

<210> 46
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 21, 23, 24
<223> n = A,T,C or G

<400> 46
ggcgggggtgc ttcacgtagr nmnnaggagcc gtactggaac tg

42

<210> 47
<211> 48
<212> DNA
<213> Artificial Sequence

<220>

39754-0831 PCT.TXT

<223> Mutagenic Primer
 <221> misc_feature
 <222> 13, 31
 <223> n = A,T,C or G
 <400> 47
 caggacggcr vsntsactta caaggtgaag ntscgcggca ccaacttc 48
 <210> 48
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Mutagenic Primer
 <221> misc_feature
 <222> 18, 36
 <223> n = A,T,C or G
 <400> 48
 gaagttggtg ccgcgsanct tcaccttgta gatsansbyg ccgtcctg 48
 <210> 49
 <211> 46
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Mutagenic Primer
 <400> 49
 ggcgtgctga agggcgagvy ccacmwsgcc ctgaagctga aggacg 46
 <210> 50
 <211> 46
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Mutagenic Primer
 <400> 50
 cgtccttcag cttcagggcs wkggtggrbct cgcccttcag cacgcc 46
 <210> 51
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Mutagenic Primer
 <221> misc_feature
 <222> 14
 <223> n = A,T,C or G
 <400> 51
 ggtggagttc aagnccatct acatggccaa g 31
 <210> 52
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Mutagenic Primer

39754-0831 PCT.TXT

<221> misc_feature
<222> 18
<223> n = A,T,C or G

<400> 52
cttggccatg tagatggnc tgaactccac c

31

<210> 53
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 17
<223> n = A,T,C or G

<400> 53
ctactactac gtggacncca agctggacat cacc

34

<210> 54
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 18
<223> n = A,T,C or G

<400> 54
ggtgatgtcc agcttgkngt ccacgtagta gtag

34

<210> 55
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 17, 18
<223> n = A,T,C or G

<400> 55
ctactactac gtggacnka agctggacat cacc

34

<210> 56
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 17, 18
<223> n = A,T,C or G

<400> 56
ggtgatgtcc agcttmngt ccacgtagta gtag

34

39754-0831 PCT.TXT

<210> 57
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 13
<223> n = A,T,C or G

<400> 57
cagtacgagc gcnccgaggg ccgccac 27

<210> 58
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 15
<223> n = A,T,C or G

<400> 58
gtggcgcccc tcggn gcgct cgtactg 27

<210> 59
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 59
aagcaccg ccgacatccc cgactacwwk aagctgtcc 39

<210> 60
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 60
gatgtcggcg ggggtgcttca cgtagrccyt ggagccgtac tg 42

<210> 61
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<221> misc_feature
<222> 7
<223> n = A,T,C or G

<400> 61
gtgaagntsc gcggcaccaa cttccccycc gacggcccc 39

<210> 62

WO 03/086446

39754-0831 PCT.TXT

<211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic Primer

<221> misc_feature
 <222> 18
 <223> n = A,T,C or G

<400> 62
 gaagttggtg ccgcgsanct tcaccttgta gatgaasbyg ccgtcctg

48

<210> 63
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic Primer

<221> misc_feature
 <222> 34, 40
 <223> n = A,T,C or G

<400> 63
 ctgtaccccc gcgacggcgt gctgaagggc gaghncargn wsargctgaa gctgaaggac 60
 ggcggc 66

<210> 64
 <211> 66
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic Primer

<400> 64
 cttcagcacg ccgtcgcggg ggtacaggcg ctcggtgsts bbsbbccagc ccatrgtctt 60
 cttctg 66

<210> 65
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic Primer

<221> misc_feature
 <222> 13
 <223> n = A,T,C or G

<400> 65
 tccaccgagc rsntstaccc cvasgacggc rbcctgaagg gc

42

<210> 66
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutagenic Primer

<221> misc_feature
 <222> 18
 <223> n = A,T,C or G

39754-0831 PCT.TXT

<400> 66
gccgtcstbg gggatasansy gctcgggtgga ggscctcccag cc 42
<210> 67
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Mutagenic Primer
<400> 67
ctgaagggcg agatcargmw sargctgaag ctgaaggac 39
<210> 68
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Mutagenic Primer
<400> 68
gtccttcagc ttcagcytsw kcytgatctc gcccttcag 39
<210> 69
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Mutagenic Primer
<221> misc_feature
<222> 13, 19
<223> n = A,T,C or G
<400> 69
ggccactacv vcnycgagny caagaccayc tacatggcc 39
<210> 70
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Mutagenic Primer
<221> misc_feature
<222> 21, 27
<223> n = A,T,C or G
<400> 70
ggccatgtag rtggtcttgr nctcgrngbb gtagtggcc 39
<210> 71
<211> 39
<212> DNA
<213> Artificial Sequence
<220>
<223> Mutagenic Primer
<400> 71
gtgcagctgc ccggcgcccta cgccgtggac accaagctg 39
<210> 72

39754-0831 PCT.TXT

<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 72 39
cagcttggtg tccacggcgt aggcgccggg cagctgcac

<210> 73
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 73 36
ggcrmstacr msrycgacry caagctggac atcacc

<210> 74
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 74 36
cttgrygtcg ryskygtask ygccgggcag ctgcac

<210> 75
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 75 43
cgaattctta skygccskyg ccgtggcggc cctcgghgcg ctc

<210> 76
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 76 40
gcttcgaatt cttacaggcc caggccgtgg cggccctcgg

<210> 77
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutagenic Primer

<400> 77 30
aaggatccga tggcctcctc cgaggacgtc

<210> 78
<211> 33
<212> DNA

39754-0831 PCT.TXT

<213> Artificial Sequence

<220>

<223> Mutagenic Primer

<400> 78

ttcgaattct taggcgccg tggagtggcg gcc

33

<210> 79

<211> 225

<212> PRT

<213> Artificial Sequence

<220>

<223> DsRed polypeptide variant "mRFP1.1"

<400> 79

```

Met Ala Ser Ser Glu Asp Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1      5      10      15
Arg Met Glu Gly Ser Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
 20     25     30
Gly Glu Gly Arg Pro Tyr Glu Gly Thr Gln Thr Ala Lys Leu Lys Val
 35     40     45
Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
 50     55     60
Phe Met Tyr Gly Ser Lys Ala Tyr Val Lys His Pro Ala Asp Ile Pro
 65     70     75     80
Asp Tyr Leu Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Val
 85     90     95
Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
100    105    110
Leu Gln Asp Gly Glu Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn
115    120    125
Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
130    135    140
Ala Ser Ser Glu Arg Met Tyr Pro Glu Asp Gly Ala Leu Lys Gly Glu
145    150    155    160
Ile Lys Met Arg Leu Lys Leu Lys Asp Gly Gly His Tyr Asp Ala Glu
165    170    175
Val Lys Thr Thr Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Ala
180    185    190
Tyr Lys Thr Asp Ile Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
195    200    205
Thr Ile Val Glu Gln Tyr Glu Arg Ala Glu Gly Arg His Ser Thr Gly
210    215    220
Ala
225

```

<210> 80

<211> 678

<212> DNA

<213> Artificial Sequence

<220>

<223> polynucleotide encoding DsRed polypeptide variant "mRFP1.1"

<400> 80

```

atggcctcct ccgaggacgt catcaaggag ttcatgcgct tcaaggtgcg catggagggc 60
tccgtgaacg gccacgagtt cgagatcgag ggcgagggcg agggccgccc ctacgagggc 120
accagagacc ccaagctgaa ggtgaccaag ggcggccccc tgcccttcgc ctgggacatc 180
ctgtccccctc agttcatgta cggctccaag gcctacgtga agcaccgccg cgacatcccc 240
gactacttga agctgtcctt ccccgagggc ttcaagtggg agcgcgtgat gaacttcgag 300
gacggcgggc tggtgacagt gaccaggac tcctccctgc aggacggcga gttcatctac 360
aaggtgaagc tgcgcggcac caacttcccc tccgacggcc ccgtaatgca gaagaagacc 420
atgggctggg aggcctcctc cgagcggatg taccccagg acggcgccct gaagggcgag 480
atcaagatga ggctgaagct gaaggacggc ggccactacg acgccgaggt caagaccacc 540

```

Page 22

39754-0831 PCT.TXT

```
tacatggcca agaagcccgt gcagctgccc ggcgcctaca agaccgacat caagctggac 600
atcacctccc acaacgagga ctacaccatc gtggaacagt acgagcgcgc cgagggccgc 660
cactccaccg ggcctaa                                     678
```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/10879

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00; G01N 21/64, 33/566; C07H 21/04; C12N 15/64, 65, 66
 US CL : 514/2; 530/350; 536/23.1, 23.4; 435/69.1, 320.1; 422/82.07; 424/9.6; 436/546
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 514/2; 530/350; 536/23.1, 23.4; 435/69.1, 320.1; 422/82.07; 424/9.6; 436/546

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	WO 00/34526 A1 (CLONTECH LABORATORIES, INC.) 15 June 2000, SEQ ID NO:60, claims 3, 6 and 10, Example 1, Table 7, Figures 2B and 8, and pages 2-3 and 10-12.	1-3, 15, 21, 32-35, 38-40, 49-51, 55, 74 and 87-88 1-4, 15, 21, 32-35, 38-40, 49-56, 74 and 87-91
X — Y	WO 0034326 A1 (CLONTECH LABORATORIES, INC.) 15 June 2000, SEQ ID NOs:56 and 57, claims 7, 9-14, 20-21 and 22, Examples, 8, 10, 11 and 13-16, Table 7, and pages, 4-5, 11-12, 23-24 and 26-27.	1-5, 8-11, 13-15, 17-19, 21-23, 31-35, 38-40, 42, 49-53, 55-59, 67-69, 73-75, 83 and 87-88 1-5, 8-11, 13-15, 17-19, 21-23, 29-35, 38-59, 65-69, 73-75, 83 and 87-91



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

10 July 2003 (10.07.2003)

Date of mailing of the international search report

01 AUG 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Valerie Belt Harris
 Samuel W. Liu

Telephone No. 703-308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	WO 0162919 A1 (AURORA BIOSCIENCES CORPORATION) 30 August 2001, SEQ ID NOs: 5 and 7, claims 9-76, 78-79 and 83-84, Tables 1 and 2, and pages 5, 13, 15, 18-19, 29, 32-35, 39-57 and 56-57.	1-5, 9-10, 13-15, 17-23, 28, 32-35, 38-64, 67-69, 71-77 and 81-91 ----- 1-26, 28-30, 32-69, 71-79 and 81-91
X — Y	WO 0196373 A2 (CLONTECH LABORATORIES, INC.) 20 December 2001, SEQ ID NOs: 1 and 2, claims 5-28, Figures 1, 4A and 4C, and pages 9-14, 19-29 and 33-42.	1-5, 8-10, 13-15, 17, 19, 21-23, 36-59, 67-69, 81-82 and 85-91 ----- 1-10, 13-15, 17, 19, 21-24, 29-30, 32-56, 57-57, 67-69, 74-75 and 81-91
X	TSIEN, R. Y. Rosy dawn for fluorescent proteins. Nat. Biotechnol. 17 October 1999, Vol. 17, pages 956-957. Entire document, and see also the attachment labeled "A1" wherein the document indicates the polynucleotide (Accession No. AF168419) and the polypeptide encoded by the polynucleotide for drFP538 protein.	1-5, 13-15, 21-23 and 49-51
X, P — Y, P	CAMPBELL, R. E. et al. A monomeric red fluorescent protein. Proc. Natl. Acad. Sci. U S A. 11 June 2002, Vol. 99, pages 7877-7882. Entire document.	1-11, 13-30, 32, 38-53, 55, 57-84 and 87-88 ----- 1-91